ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
1
1.0 Title Page
Clinical Study Protocol M06 -873
A Phase 1/2a Study Evaluating the Safety, 
Pharmacokinetics, and Efficacy of ABT -263 in 
Subjects with Relapsed or Refractory Chronic 
Lymphocytic Leukemia
Incorporating Administrative Changes 1, 2, 3, 4, 5, 
and 6 and Amendments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, and 1 4
AbbVie Number/
  Investigational Product: ABT -263 (navitoclax)
Date: 03September 2020
Development Phase: 1/2a
Study  Design: This is an open -label study  designed to determine the 
maximum tolerated dose (MTD), safet y, pharmacokinetics 
and preliminary  efficacy  profile of ABT -263 in subjects 
with relapsed or refractory chronic l ymphocy tic leukemia.
Investigator: Investigator information on file at AbbVie.
Sponsor: AbbVie Inc. (AbbVie) and AbbVie GmbH & Co. KG
Sponsor/Emergency
  Contact: 
Executive Medical Director 
1 North Waukegan Rd
North Chicago, IL 60064Phone:
EMAIL : 
This study will be conducted in compliance with the protocol, Good Clinical Practice and all other 
applicable regulatory requirements, including the archiving of essential documents.
Confidential Information
No use or disclosure outside AbbVie is permitted without prior written authorization from  AbbVie. 
[STUDY_ID_REMOVED]

ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
2
1.1 Protocol A mendment:  Summary  of Changes
Previous Protocol Versions 
Protocol Date 
Original 03 January 2007
Amendment 1 18 September 2007
Amendment 2 31 March 2008
Amendment 3 25 November 2008
Amendment 4 17 December 2008
Administrative Change 1 03 March 2009
Administrative Change 2 30 June 2009
Amendment 5 08 October 2009
Amendment 6 21 May 2010
Amendment 7 01 December 2010
Administrative Change 3 09 December 2010
Amendment 8 11 May 2011
Amendment 9 19 October 2011
Administrative Change 4 22 October 2012
Amendment 10 18 September 2014
Administrative Change 5 16 November 2015
Amendment 11 08 August 2016
Administrative Change 6 02 March 2018
Amendment 12 26 July 2018
Amendment 13 16 January 2020
The primary  purpose of this amendment is to incorporate necessary  protocol 
modifications due to the COVID- 19 (Coronavirus 2019) pandemic as follows:
●Section 3.0–Included information on the re -evaluation of the benefit and risk 
to subjects participating in the study .
●Section 5.4.1–Added that the investigator should contact the sponsor medical 
contact before discontinuing a subject from the study  for a reason other than 
"planned per protocol ." 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
3
●Section 5.5.1 –Added delay s in study  drug dosing due to the above 
COVID- 19 testing guidance .
●Section 5.5.4 –Included instructions that in the event the subject cannot pick 
up study  drug onsite, DTP (Direct To Patient) shipment can be made, as 
permitted by  local regulations.
●Section 7.0 –clarified that protocol deviations may include modifications due 
to COVI D-19.
●Section 9.1–Added that AbbVie will modify  the study  protocol as necessary  
due to the pandemic. Investigators must also notify AbbVie if an y urgent 
safet y measures are taken.
●Section 10.1 –Added that remote monitor ing may  be employ ed as needed .
●Appendix A– Addition of COVID- 19 and DTP to list of abbreviations .
●In addition, sponsor contact information updates have been made.
An itemized list of all changes made to the protocol under this amendment can be found 
in Appendix H. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
4
2.0 Table of Contents
1.0 Title Page .................................................................................. 1
1.1 Protocol Amendment:  Summary  of Changes ........................................... 2
2.0 Table of Contents ..................................................................... 4
3.0 Introduction ................................................................
............. 9
4.0 Study Objectives .................................................................... 15
5.0 Investigational Plan ............................................................... 16
5.1 Overall Study  Design and Plan:  Description .......................................... 16
5.2 Selection of Study Population ................................................................
..27
5.2.1 Phase 1 Inclusion Criteria ........................................................................ 28
5.2.2 Phase 1 Exclusion Criteria ....................................................................... 29
5.2.3 Phase 2a Inclusion Criteria ...................................................................... 31
5.2.4 Phase 2a Exclusion Criteria ..................................................................... 33
5.2.5 Extension Study  Inclusion Criteria .......................................................... 35
5.2.6 Prior and Concomitant Therap y............................................................... 36
5.3 Efficacy , Pharmacokinetic, Pharmacod ynamic, Pharmacogenetic 
and Safet y Assessments/Variables ........................................................... 38
5.3.1 Efficacy  and Safet y Measurements Assessed and Flow Chart ................ 38
5.3.1.1 Study  Procedures ..................................................................................... 50
5.3.1.2 Meals and Dietary  Requirements ............................................................. 70
5.3.1.3 Blood Samples for Pharmacogenetic Anal yses....................................... 71
5.3.1.4 Specimens for Pharmacody namic Anal yses............................................ 72
5.3.1.5 Disposition of Sam ples for Pharmacogenetic/Pharmacod ynamic 
Analy ses................................................................................................... 77
5.3.2 Drug Concentration Measurements ......................................................... 78
5.3.2.1 Collection of Samples for Anal ysis......................................................... 78
5.3.2.2 Handling/Processing of Samples ............................................................. 80
5.3.2.3 Disposition of Samples for ABT -263 Assay ........................................... 80
5.3.2.4 Measurement Methods ............................................................................. 81
5.3.3 Efficacy  Variables .................................................................................... 81
5.3.3.1 NCI-WG Criteria for Tumor Response .................................................... 81
5.3.3.1.1 NCI-WG Criteria - 1996 .......................................................................... 82 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
5
5.3.3.1.2 IWCLL Updated NCI -WG Criteria – 2008 ............................................. 87
5.3.3.1.3 Definition of Clinical Disease Progression (Phase 2a) ............................ 91
5.3.4 Safety  Variabl es....................................................................................... 92
5.3.5 Pharmacokinetic Variables ...................................................................... 92
5.3.6 Pharmacogenetic Variables ...................................................................... 92
5.3.7 Pharmacod ynamic Variables .................................................................... 93
5.4 Removal of Subjects from Therap y or Assessment ................................ .94
5.4.1 Discontinuation of I ndividual Subjects .................................................... 94
5.4.2 Discontinuation of Entire Study............................................................... 96
5.5 Treatments ................................................................................................ 96
5.5.1 Treatments Administered ......................................................................... 96
5.5.2 Identity  of Investigational Product ........................................................... 97
5.5.2.1 Packaging and Labeling ........................................................................... 99
5.5.2.2 Storage and Disposition of Study  Drug ................................................... 99
5.5.2.3 Preparation/Reconstitution of Dosage Form.......................................... 100
5.5.3 Method of Assigning Subjects to Treatment Groups ............................. 100
5.5.4 Selection and Timing of Dose for Each Subject.................................... 101
5.5.5 Blinding .................................................................................................. 101
5.5.6 Treatment Compliance........................................................................... 102
5.5.7 Drug Accountability ............................................................................... 102
5.6 Discussion and Justification of Study  Design ........................................ 103
5.6.1 Discussion of Study  Design and Choice of Control Groups .................. 103
5.6.2 Appropriateness of Measurements ......................................................... 104
5.6.3 Suitability  of Subject Population ........................................................... 104
5.6.4 Selection of Doses in the Study ............................................................. 104
6.0 Adverse Events ..................................................................... 106
6.1 Definitions ................................................................
.............................. 107
6.1.1 Adverse Event ................................................................
........................ 107
6.1.2 Serious Adverse Events ......................................................................... 108
6.2 Adverse Event Severit y.......................................................................... 109
6.3 Relationship to Study  Drug .................................................................... 110
6.4 Adverse Event Collection Period ........................................................... 111
6.5 Adverse Event Reporting ....................................................................... 111 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
6
6.6 Pregnancy ............................................................................................... 113
6.7 Toxicity  Management ............................................................................ 113
6.7.1 Definition - Dose Limiting Toxicity ...................................................... 113
6.7.2 Management of Thrombocy topenia ....................................................... 115
6.7.3 Management of Lymphopenia ............................................................... 116
6.7.4 Management of Tumor Ly sis Sy ndrome ............................................... 116
6.7.5 Determination of the MTD .................................................................... 117
7.0 Protocol Deviations .............................................................. 117
8.0 Statistical Methods and Determinatio n of Sample 
Size ........................................................................................ 119
8.1 Statistical and Analy tical Plans ................................
.............................. 119
8.1.1 Demographics and Treatment Allocation .............................................. 119
8.1.2 Pharmacokinetics ................................................................
................... 120
8.1.2.1 Tabulations and Summary Statistics ...................................................... 120
8.1.2.2 Model and Tests ..................................................................................... 120
8.1.2.3 Missing Values and Model Violations ................................................... 121
8.1.3 Exploratory  Efficacy .............................................................................. 121
8.1.3.1 Progression -Free Survival ...................................................................... 121
8.1.3.2 Objective Response Rate ....................................................................... 122
8.1.3.3 Time to Tumor Progression ................................................................... 122
8.1.3.4 Overall Survival ..................................................................................... 123
8.1.3.5 Duration of Overall Response ................................................................ 123
8.1.3.6 ECOG Performance Status .................................................................... 124
8.1.3.7 Reporting of Results .............................................................................. 124
8.1.4 Safety ..................................................................................................... 124
8.2 Determination of Sample Size ............................................................... 126
9.0 Ethics ..................................................................................... 126
9.1 Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB) ................................
........................................................... 126
9.2 Ethical Conduct of the Study ................................
................................ .127
9.3 Subject I nformation and Consent ........................................................... 128
10.0 Source Documents and Case Report Form 
Completion ........................................................................... 128 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
7
10.1 Source Documents ................................................................................. 128
10.2 Case Report Forms ................................................................................. 129
10.3 Extension Study  Case Report Forms ..................................................... 130
11.0 Data Quality Assurance ...................................................... 130
12.0 Use of Information ............................................................... 131
13.0 Completion of the Study ..................................................... 132
14.0 Investigator's Agreement ................................
.................... 134
15.0 Reference List ...................................................................... 135
List of Tables
Table 1. Schedule of Assessments –14/21 Day  Dosing (Phase 1) ........................ 39
Table 2. Schedule of Assessments –21/21 Day  Dosing with L ead-in 
Period (Phase 1) ....................................................................................... 42
Table 3. Schedul e of Assessments (Phase 2a) –21/21 Day  Continuous 
Dosing Schedule with Lead
-in Period ..................................................... 45
Table 4. Schedule of Blood Collection for ABT -263 Assay 
(Pharmacokinetic Sam pling) – Phase 1, Cy cle 1 ..................................... 48
Table 5. Schedule of Blood Collection for ABT -263 Assay 
(Pharmacokinetic Sampling) – Phase 1, Cy cle 2 and Bey ond................. 48
Table 6. Schedule of Blood Collection for ABT -263 Assay 
(Pharmacokinetic Sampling) – Phase 2a, 21/21 Day  Continuous 
Dosing Schedule ...................................................................................... 49
Table 7. Clinical L aboratory  Tests ......................................................................... 69
Table 8. Schedule of Biomarker Sample Collection (Phase 1) .............................. 76
Table 9. Schedule of Biomarker Sample Collection (Phase 2a) ............................ 77
Table 10. NCI-WG Criteria for Tumor Response (1996) ........................................ 86
Table 11. IWCLL Updated NCI -WG Criteria for Tumor Response (2008) ............ 91
Table 12. Identity  of Investigational Products ......................................................... 98
List of Figures
Figure 1. Phase 1 and Phase 2a Study  Design ......................................................... 17
Figure 2. Adaptive CRM Design ............................................................................. 20 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
8
Figure 3. ABT -263 Dosing Schematic – Phase 1 .................................................... 22
Figure 4. 21/21 Day  Continuous Dosing Schedule for ABT -263........................... 24
Figure 5. Adverse Event Collection ...................................................................... 111
List of A ppendices
Appendix A. List of Abbreviations and Definitions of Terms .................................... 139
Appendix B. List of Protocol Signatories................................................................
....143
Appendix C. Documents Required Prior to I nitiation of the Study ............................ 144
Appendix D. Responsibilities of the Clinical I nvestigator .......................................... 146
Appendix E. Sample L ist of Excluded and Cautionary  Medications .......................... 148
Appendix F. Simulations Comparing Fixed 3+3 Design Versus CRM -based 
Design .................................................................................................... 150
Appendix G. Extension Study  -Assessments ............................................................. 161
Appendix H. Protocol Amendment:  List of Changes................................................. 163 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
9
3.0 Introduction
Bcl-2 Family Proteins
The Bcl- 2 famil y proteins are important regulators of the intrinsic apoptosis pathway .  
The Bcl- 2 oncogene was first identified in follicular lymphoma where the t(14;18) 
chromosomal translocation results in significant over -expression of this protein in B -cells.  
In contra st to other known oncogenes, Bcl -2 does not stimulate cellular proliferation, but 
rather inhibits programmed cell death by  protecting cells from a wide variety  of 
pro-apoptotic stimuli, including cy tokine withdrawal, irradiation, cy totoxic drugs, heat 
and deregulated oncogenes.1  The Bcl -2 family  of genes encodes a family  of closel y 
related proteins that possess either pro -apoptotic or anti -apoptotic activit y and sh are up to 
four Bcl -2 Homology  (BH) domains.2,3,4,5  The anti -apoptotic family  members Bcl -XL, 
Bcl-2, Bcl -w, Bcl -B, A1 and Mcl -1 are characterize d by four BH domains that are 
designated BH1- 4.  The pro- apoptotic famil y members can be further subdivided into 
multidomain proteins (Bax, Bak) and the BH3 -only proteins (Bad, Bik, Bid, Bim, Hrk, 
Bmf, Noxa, and Puma).  The interplay  between these three gr oups of proteins serves as 
the gateway  to the intrinsic apoptosis pathway .
The multidomain pro -apoptotic proteins Bax and Bak are direct mediators of apoptosis 
and are absolutely required for the initiation of the mitochondrial apoptosis pathway.6,7,8  
Anti-apoptotic Bcl -2 family  proteins (e.g., Bcl -2 and Bcl -
XL) inhibit cy tochrome 
Crelease b y blocking Bax/Bak activation.9The exact mechanism of action of Bcl -2 and 
Bcl-XLhas not been completely  elucidated, however it is known that it requires the ability  
to bind the pro- apoptotic Bcl -2 family  members and that the ratio of pro -apoptotic to anti -
apoptotic proteins is associated with cell survival.10
,11,12
ABT -263 Activity and Pharmacokinetic Profile
ABT -263 (navitoclax) is a small molecule Bcl -2 family  protein inhibitor that binds with 
high affinity  (K i1 nM) to multiple anti -apoptotic Bcl -2 family  proteins including 
Bcl-XL, Bcl -2, Bcl -
w, and Bcl- B.  ABT- 263 display s potent mechanism -based  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
10
cytotoxicity  (EC 501 M) against human tumor cell lines derived from small cell lung 
carcinomas and l ymphoid malignancies.  ABT -263 exhib its potent single agent activity 
against 10 of 22 leukemia and l ymphoma cell lines spanning both B -cell and T -cell 
malignancies.
Pre-clinical experiments have been performed on primary  patient derived chronic 
lymphocy tic leukemia (CLL) samples with ABT -737, a first generation Bcl -2 family  
protein inhibitor.  Treatment with ABT -737 induced robust, concentration -dependent 
apoptosis in 47 of 50 patient -derived CLL specimens regardless of the presence of feeder 
cells.  These cells were highl y sensitive w ith EC 50values of < 0.25 M.  Forty -two of the 
47 lines had EC 50values of < 0.01 M.  ABT -263, which has similar potency  as 
ABT -737, would be expected to have similar efficacy .
The pharmacokinetic profile of ABT -263 was evaluated in multiple animal model s 
including:  CD -1 mouse, Sprague -Dawley  rat, beagle dog and cy nomolgus monkey .  The 
pharmacokinetic profile of ABT -263 is characterized by  very  low plasma clearance and 
low volumes of distribution in all species studied, with terminal half -lives in the ra nge of 
4.6 to 8.4 hours.  The oral bioavailability  of the compound is formulation dependent, with 
values of 30% to 50% obtained from protot ype solid dispersion and lipid -based 
formulations in dog.  In rat, [14C] ABT -263 is slowly  absorbed, with clearance o f the 
metabolites primarily in the bile.  Elimination of total radioactivity  is rapid, with 90% of 
the dose recovered within 24- hours post -dose.  Parent drug is the major component in 
systemic circulation.
Based on preclinical evidence, potential treatment -related side effects may  include drug 
interactions, ly mphopenia, testicular effects and thrombocy topenia.  At the expected 
biologicall y effective plasma concentration in humans of 6.5 g/mL (C max), ABT -263 is 
likely  to inhibit the metabolism of drugs that are substrates for CYP2C8 and CYP2C9 by  
greater than 50%.  Simulation of 350 mg q.d. dosing in humans describes an AUC of 
92g•hr/mL at stead y state, with a C maxof ~6.5 g/mL.  Under these conditions, platelet 
values in patients with normal platelet val ues (~300 K/ L) at baseline are expected to be 
~25 K/ L at stead y state.  At the lower end of the predicted efficacious range, an AUC of  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
11
53 g•hr/mL (predicted 200 mg q.d. dosing in humans) is expected to be attainable while 
still maintaining platelet values above 50 K/ L at steady  state.
ABT -263 induces apoptosis, rather than l ysis of circulating platelets, which differs from 
typical chemotherapy  induced thrombocy topenia related to my elosuppression.  L imited 
human clinical data are available to understand the response to infusion of exogenous 
platelets in the presence of circulating drug levels.  Platelet transfusion studies conducted 
in beagle dogs demonstrated that transfusion of one -day old platelets administered near 
the time of ABT- 263 C max, resulted i n higher platelet levels than dogs not receiving 
supplemental platelets.  Platelet concentrations remained higher after 24 hours with 
declining ABT- 263 concentrations.  This study  suggests that infusion of platelets may  
have beneficial effects in treating acute thrombocy topenia following oral dosing with 
ABT -263.
From the pre -clinical models, there may  be an opportunity  in the monotherapy  setting to 
increase efficacy  without additional platelet toxicity  in the setting of continuous dosing.  
In murine xenogr aft models of SCL C, 21 day s of continuous dosing achieves superior 
tumor growth inhibition, greater increase in life span, and greater incidence of complete 
and overall response rates compared to the intermittent dosing schedules or 14 days of 
dosing and 7 days off drug.  In a dog toxicology  study , ABT -263 was delivered once dail y 
for 28 day s.  At doses that achieve plasma concentrations within the targeted efficacious 
exposure range, circulating platelet counts recovered to baseline within 14 days of dosin g 
and remained at baseline for the subsequent 14 days of dosing.
This observation of platelet recovery  during continued ABT -263 dosing has also been 
observed in the Phase 1 clinical studies.  Given that platelet nadirs typically occur in the 
first few day sof dosing and circulating platelet counts recover during continued dosing, a 
lead-in period may  help reduce the depth of platelet nadir. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
12
ABT -263 Toxicology
The safet y of ABT -263 has been evaluated in single -and repeat -dose (up to 6 and 
9months in durati on in rats and dogs, respectively), reproductive (male and female 
fertility  and embry o fetal development), safety pharmacology (cardiovascular, 
neurofunctional, and pulmonary), genetic (Ames, in vitro cytogenetics, and in vivo 
micronucleus), and special st udies (guinea pig sensitization; ly mphocy te 
immunophenoty ping; and single -dose oral toxicity  in male rats).  The primary  effects of 
ABT -263 were on the hematopoietic sy stem (platelets and ly mphocy tes) and the male 
reproductive s ystem (germ cell depletion), and are believed to be based on inhibition of 
one or more members of the Bcl -2 family  of antiapoptotic proteins.  Other findings 
included ovarian atroph y (rats onl y), and generally minimal and reversible liver changes 
(single -cell hepatocellular necrosis, increased mitotic index, and hy pertrophy /hyperplasia 
and pigmentation of Kupffer cells) and single -cell necrosis in various tissues.  ABT- 263 
was neither genotoxic, nor did it affect male or female fertility  in rats or embry o-fetal 
development in rats and rabbits.  ABT- 263-related effects were observed on brain, testes, 
and circulating platelets in juvenile rats.  Effects on the brain (cerebellar h ypoplasia), 
which were not observed in adult rats, were the likely result of incomplete maturation of 
the blood
-brain -barrier at the time dosing was initiated in the rat pups (post natal Day  7).
ABT -263 caused increases in pulmonary  and peripheral vascular resistance and decreases 
in cardiac output in the dog following acute or multiple daily dosing.  Despite the 
increases in vascular resistance, there were no increases in blood pressure.  On Day 28 of 
the oral dosing stud y, these cardiovascular effects were associated with a mean C maxvalue 
of 16.6 g/mL, whereas no statistically  significant hemody namic changes we re associated 
with a mean C maxof 11.4 g/mL .13  Similar sy stemic exposures induced these effects in 
the acute cardiovascular study .
Chronic Lympho cytic Leukemia (CLL)
Chronic ly mphocy tic leukemia (CLL) is a monoclonal disorder characterized by  a 
progressive accumulation of functionall y incompetent lymphocytes.  It is the most  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
13
common form of leukemia in adults in the Western World, accounting for nearl y 25% of 
all leukemias.15  CLL primarily affects elderl y individuals however approximately 
one-third of patients are less than sixty  years of a ge at diagnosis.16  It is currently  
estimated that annuall y over 10,000 people will be diagnosed with CLL in the United 
States, and that almost 4,700 individuals will die of the disease.17  The approximate 5 -year 
survival rate for patients with CLL is 73%.18
CLL presents with a variable clinical course.  Approximately  one third of patients do not 
require treatment as they  experience long survival and die of causes unrelated to disease.  
Another third have an initial indolent phase that is followed b y rapid progression of the 
disease requiring therap y.  The remaining third have aggressive disease and require 
treatment at the time of diagnosis.  CLL patients will often have compromised bone 
marrow reserve due to their underl ying disease.  The principal complication of CLL is 
immunodeficiency  related to my elosuppression and as a result, infection is the major 
cause of death in patients with CLL.19
Treatment decisions for patients with CLL are made based upon considerations such as 
age, clinical staging, expected survival, and anticipated toxicities.  First line treatment 
options include al kylating agents, alky lator/anthracy cline combination therapies and 
purine analogues such as fludarabine.  Improvement in treatment response rates occurred 
with the switch from historical single -agent usage to combination therap y, such as 
fludarabine and cy clophosphamide, with some combinations y ielding overall response 
rates (ORR) in excess of 90%.  An alternative to combination therapy is sequential 
therap y.  The sequential regimen of fludarabine, cyclophosphamide, and rituximab (FCR) 
induced ORR of 88 -95% with a high incidence of complete responses (53 -70%).20-22
In previousl y treated/relapsed patients, fludarabine is the most active single -agent, with 
ORR ranging from 50 -60%, and complete remission (CR) rates from 3 -13%.23  
Many  
patients treated previously with fludarabine can be retreated and will respond again to the 
same regimen.24  However, almost all CLL patients who are treated with single agent 
fludarabine or in combination will ultimately  become fludarabine -refractory .25 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
14
The treatment options for patients with fludarabine -refractory  disease are limited.  
Campath, a fully  humanized monoclonal antibody directed against CD52, is the only  
approved therap y for CLL patients who have been treated with alk ylating agents and who 
have failed fludarabine therap y.  Clinical trials in patients treated with Campath have 
demonstrated ORRs ranging from 21 -33%.  Progression- free survival rates ranged 
between 4 and 7 months.26
Current chemotherapeutic agents elicit their anti- tumor response by  inducing apoptosis 
through a variet y of mechanisms.  However, many tumors ultim ately  become resistant to 
these agents.  Bcl -2 and Bcl -XLhave been shown to confer chemotherapy  resistance in 
both short -term survival assay s in vitro and more recentl y, in vivo.  This suggests that 
therapies aimed at suppressing the function of Bcl -2 and Bcl-XLmight potentially  
overcome this mechanism of chemotherap y resistance.27  Preclinical studies suggest that 
the Bcl -2 family  protein inhibito r has single agent anti -tumor activity .
Based upon the preclinical profile of ABT -263, the role of Bcl -2 family  proteins in 
hematological malignancies, and the lack of an existing therap y that provides a survival 
benefit in relapsed or refractory CLL patie nts, clinical investigation of ABT -263 is 
warranted.
ABT -263 Clinical Data
Preliminary  aggregate clinical data from the 3 ongoing Phase 1 studies support that 
ABT -263 is tolerable at doses up to 250 mg in a 21/21 day  continuous dosing schedule, 
which achie ves exposures consistent with preclinical efficacy .  Anti -tumor activity  has 
been noted in study  subjects with CLL at doses 200 mg, suggesting that ABT -263 may  
provide a clinical benefit to subjects with CLL.
The cumulative preclinical toxicology , safet ypharmacology , metabolism, 
pharmacokinetic, and preliminary  clinical data indicate that ABT -263 has been adequatel y 
characterized and that treatment with ABT -263 represents an acceptable risk to adult 
subjects with cancer.  Consistent with the toxicologica l finding of a concentration  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
15
dependent decrease in circulating platelets in animal models, thrombocytopenia appears to 
be a DLT for ABT -263 in humans.  The ongoing clinical studies with ABT -263 will 
continue to evaluate its safety profile, DLT, MTD, bioava ilability , pharmacokinetics, and 
efficacy .
This study  will determine the dose limiting toxicity (DLT), the maximum -tolerated dose 
(MTD), and will assess the safety, pharmacokinetics, and preliminary efficacy of 
ABT -263 in subjects with relapsed or refracto ry CLL.  ABT -263 will be administered 
orally  under two different dosing schedules (14/21 day  dosing schedule and 21/21 day  
continuous dosing schedule).  The following 14/21 dose levels have been completed to 
date:  10 mg, 110 mg, 200 mg, and 250 mg.  The f ollowing 21/21 dose levels have been 
completed to date:  125 mg, 200 mg, 250 mg and 300 mg.
Considering the coronavirus (COVID -19) pandemic, the benefit and risk to subjects 
participating in this study has been re -evaluated.  Subjects receiving ABT -263may be at 
an increased risk for COVID- 19 infection or experience serious illness if infected.  
Management of these adverse events will be made on a case -by-case basis with 
consideration of benefit/risk.  However, based on the population and disease being 
studied, and the anticipation that COVI D-19 related risks are not expected to differ 
substantially  between study  subjects and the broader population of subjects receiving 
treatment for CLL ,no change to the benefit/risk balance for subjects in this study  is
expected.
A detailed discussion of the preclinical toxicology , metabolism, and pharmacology  can be 
found in the Investigator's Brochure.14
4.0 Study  Objectives
The objectives of the Phase 1 portion of the study include:
●Safety  assessment
●Dose limiting toxicity  (DLT) determination
●Maximum tolerated dose (MTD) determination 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
16
●Recommended Phase 2 Dose (RPTD) and schedule determi nation
●Pharmacokinetic profile evaluation
The objectives of the Phase 2a portion of the stud y include:
●Safety  assessment at the recommended Phase 2 dose (RPTD) and schedule
●Preliminary  efficacy  assessment including biomarker assessment
●Pharmacokinetic profile evaluation
The objectives of the Extension Study  portion of the study  include:
●Safety  assessment
●Evaluation of data regarding progression free survival (PFS) and overall 
survival (OS)
5.0 Investigational Plan
5.1 Overall Study Design and Plan:  Descripti on
This is a Phase 1/2a study evaluating the safet y, PK, and preliminary efficacy of the orally 
administered Bcl -2 family  protein inhibitor, ABT -263, in approximately  72 subjects with 
relapsed or refractory  chronic ly mphocy tic leukemia.
The study  will cons ist of three distinct portions.  The Phase 1 portion of the study  will 
evaluate the pharmacokinetic profile and safet y of ABT -263 administered under 
twodifferent dosing schedules (14/21 day  and 21/21 day ) in up to 40 subjects with 
relapsed or refractory  CLL following a dose escalation scheme in order to define the DLT 
and the MTD.  Subjects will be enrolled at approximately  eight research sites for the 
Phase 1 portion of the study .  A continual reassessment methodology will be employ ed 
during Phase 1 to ob tain a more precise estimate of the MTD and determine the 
recommended Phase 2 dose (RPTD). 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
17
The Phase 2a portion of the study will evaluate ABT -263 in approximately 32 subjects 
with CLL who have relapsed following an y (but no more than 5) prior 
myelosuppres sive/chemotherap y treatment regimen(s) at the defined RPTD and dosing 
schedule to obtain additional safet y information and a preliminary assessment of efficacy 
as defined in Section 5.3.3 .  Subjects in the Phase 2a portion of the study will be enrolled 
at approximately  twelve research sites.
The Extension portion of the study  will continue to evaluate the safet y of ABT -263 
administered under two different dosing sch edules (14/21 day  and 21/21 day ) in 
approximately  13 subjects with relapsed or refractory  CLL.  Eligible subjects will be 
active subjects from the Phase 1 or Phase 2a portions of the study.
Figure 1depicts the Phase 1 and Phase 2a study  design.
Figure 1. Phase 1 and Phase 2a Study Design
Dose Escalation:
14/21 day dosing
schedule14/21 day dosing 
schedule: either
MTD or 
completion of 4th
dose level,
(whichever occurs
first)Dose Escalation: continuous
dosing schedule
with dose titration lead -in
periodMTD and/or 
RPTD 
determined:
continuous
dosing
scheduleRPTD and 
schedule
definedPhase 1 Phase 2a 
 
 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
18
Continual Reassessment Method
The experimental design for the Phase 1 portion of the study  is an adaptation of a 
continual reassessment method (CRM), which is based on the concept of maximizing the 
number of subjects at the best current estimation of the MTD given the previous 
observations.28,29  The CRM attempts to estimate the target MTD from a continuum of 
doses, whereas a f ixed design merely  selects a dose from a discrete set.  If the true target 
dose is not among the choices set out in advance by  fixed designs, they  can only  
approximate it.  A CRM based design uses a statistical model for dose and toxicity  by 
including the accumulating data to guide selection of the next dose.  Simulations and 
literature have shown that compared to the conventional fixed 3+3 design, the CRM 
typicall y requires fewer subjects to find the MTD, does not greatl y overshoot the MTD 
(that is, subjec ts are less likely  to be treated with dangerousl y high doses), and does not 
greatl y underestimate the MTD.  This design also minimizes the exposure of Phase 1 
subjects to lower, potentially inefficacious doses.
Escalation will continue to the estimated MTD .  The dose will be escalated by  no more 
than an incremental increase of 100 mg or a 40% increase from the current dose level, 
whichever is greater.  A minimum of 3 subjects will be enrolled in each cohort.  
Additional eligible subjects may  be enrolled at the current dose level at the discretion of 
the investigator and the AbbVie Medical Monitor.  If a cohort has enrolled more than 
3subjects, dose escalation decisions may be made following the completion of Cycle 1 
for subjects in the intended cohort size of three.  However, available data from all subjects 
receiving stud y drug will be used in dose escalation decisions.  Predicted efficacious 
concentrations of ABT -263 are expected to occur in the dose range of 200 mg to 350 mg 
based on preclinical studies.
Subsequent dose levels will be selected based on an estimate from a statistical anal ysis.  
The statistical anal ysis will be a logistic regression model for the dose -toxicity  
relationship (i.e., the relationship between dose and the probability of DLT) and will 
incorporate data from the M06 -814 study  in lymphoid malignancies (with inclusion of 
CLL subjects) for initial modeling.  The first step will be to fit the logistic regression  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
19
model and obtain the estimate of the MTD.  Three subjects will be dosed at t his estimated 
MTD.  After all three subjects complete C ycle 1, a logistic regression model will be fitted 
using all of the data cumulatively  from this study , and an updated estimate of the MTD 
will be obtained.  Three more subjects will be dosed at the new estimated MTD, and the 
design will continue in this fashion, assigning subjects to the MTD as estimated from 
current results, until the estimated MTD changes by less than 10% or the predetermined 
sample size of 40 subjects is reached, whichever comes firs t.  Complete details on the 
CRM design for the Phase 1 portion of the study are provided in Section 8.1.1 .  The 
following flowchart depicts the CRM design: 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
21
A minimum of 3 subjects will be enrolled in each cohort.  Additional eligible subjects 
may be enrolled at the current dose level at the discretion of the investigator and the 
AbbVie Medical Monitor.  If a c ohort has enrolled more than 3 subjects, dose escalation 
decisions may  be made following the completion of Cy cle 1 for subjects in the intended 
cohort size of three.  Dose adjustment decisions will be informed by subject tolerability 
and safet y.  However, adverse events occurring after the first cy cle and ongoing 
pharmacokinetic assessment may  also be considered in dose escalation decisions.  I f 
pharmacokinetic results indicate more than 25% of intersubject variability can be 
attributed to differences in bo dy weight or body  surface area (BSA), escalation will 
proceed with dosing normalized to body  weight or BSA; therefore subsequent dose levels 
will be determined using average subject BSA or average subject weight.
If, in the opinion of the investigators and the AbbVie Medical Monitor, the observed dose 
limiting toxicities are likely  to have resulted from a cumulative and continuous exposure 
to the study  drug, an alternative dosing schedule for ABT -263 may  be explored.  The 
alternative schedule will be jointl y determined b y the sponsor and investigator, based on 
pharmacokinetic data and the required recovery periods for the observed DLTs.  For 
example, an extended recovery  period may  be instituted or an every  other day  dosing 
schedule could be implemented.
Adjustments to the dose escalation schedule may  also be made based upon preliminary  
pharmacokinetic and safety  data obtained from concurrent dose escalation studies that are 
being conducted with ABT -263.  These decisions will be based on the judgment of the 
AbbVie Medical Monitor in consultation with the investigator.
Subject assessments for safet y and clinical progression will continue weekly through the 
first 2 cy cles (6 weeks).  Subsequently , subject assessments for safet y and clinical 
progression will be p erformed once every  cycle (every  3 weeks) or more frequently , as 
needed. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
22
Phase 1 -14/21 Day Dosing
ABT -263 will be administered for 14 consecutive day s followed by  7 day s off drug to 
complete a 21- day cycle.  Subjects will be instructed to self -administer ABT -263 orall y 
once dail y (QD) within 30 minutes after the completion of breakfast.
Figure 3. ABT -263 Dosing Schematic –Phase 1
Additionally , a continuous dosing regimen will be evaluated and compared to the 
14/21 cyclic dosing regimen.
Phase 1 –21/21 Day Continuous Dosing
Once either the MTD is defined or dosing in the 4thdose level is completed for the 
14/21 day dosing schedule, whichever occurs first, a continuous dosing schedule will be 
assessed.  Dosing with ABT -263 under the continuous dosing schedule (21/21 day ) will 
begin at the dose estimated to provide exposure equivalent to the highest dosing level 
cleared (4thdose level) or the MTD from the 14/21 day schedule.  For example, if the 
highest dose level cleared or the MTD from the 14/21 day  dosing schedule is 375 mg, the 
continuous starting dose (defined C ycle 1 Day 1 dose) would be (375 14)/21 or 250 mg.  
A minimum of three subjects will be enrolled in each cohort.  The ABT -263 dose will be ABT -263 once daily dosing =7 21 14 1
7 days off 
drug15
x xAll Cycles 
    
  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
23
escalated using a modified CRM as described previously  for the 14/21 day  regimen 
(Figure 2).
Prior to beginning the assigned 21/21 day continuous dosing regimen, a 7 -day lead -in 
dose titration period will be implemented.  In preclinical experiments in which stepwise 
increases in ABT- 263 doses were administered to dogs every  one or two weeks, the 
thrombocy topenic effect of higher doses was significantly  attenuated.  These data 
combined with the clinically  observed rebound in platelet counts from nadir during 
continued ABT -263 dosing suggest that a lead -in period may  help reduce the depth of the 
initial platelet nadir and provide an additional margin of safet y.
Subjects will begin dosing at 100 mg on Lead- in Day  1 (LD1).  This is the dose level at 
which a mean maximal platelet drop of approximately  60% from baseline with recovery  
during 14 day s of dosing is expected based on observations in this study  to date.  The 
lead-in titration dose may  be adj usted if the defined dose level fails to significantly 
mitigate ABT -263-induced thrombocy topenia following the lead -in period or the defined 
dose level results in significant occurrence of DLT in the lead -in period.
A subject may  only  proceed from the lead -in period to the defined dose level for C ycle 1 
Day 1 and bey ond if platelet count is ≥ 50,000/mm3after Lead -in Day  7 and stable or 
increasing.  If the platelet count is < 50,000/mm3after Lead -in Day  7, the visit day  will be 
considered Lead- in Day  8 and the subject will continue to receive the lead -in dose until 
the platelet count is ≥ 50,000/mm3.
When the platelet count is ≥ 50,000/mm3, the subject will receive the lead- in dose that 
day,and the next day  (defined as C ycle 1 Day 1) the subject will recei ve the defined dose 
for Cy cle 1 Day  1, provided the pre -dose platelet count that day  is ≥ 50,000/mm3and 
platelets are stable or increasing.  For example, if a subject's platelet count is 
≥50,000/mm3on Lead-in Day  9, the subject will take the lead -in dos e on Day  9.  The 
next day  will be considered Cy cle 1 Day  1 and the subject will begin receiving the defined 
dose for C ycle 1 Day 1.  However, if the pre -dose platelet count is < 50,000/mm3or  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
25
Intra -subject Dose Escalation in Phase 1
In order to maximize the collection of information at relevant doses and to minimize the 
exposure of individuals to sub- optimal doses, subjects may  progressively  escalate their 
current dose to the highest dose level tolera ted through 2 cy cles of ABT -263 
administration.  I ndividuals will need to complete at least two cy cles at their originall y 
assigned dose level, as well as subsequent dose levels, prior to an y dose escalation.
All intra -subject dose escalation decisions wil l be based on the judgment of the 
investigator in coordination with the AbbVie Medical Monitor.  Once the MTD is 
declared and/or the RPTD determined, subjects who remain on study and continue to 
tolerate the drug may  escalate to the dose level determined to be the RPTD or the dose 
level below the RPTD.  Phase 1 subjects will be allowed to switch their current dosing 
schedule to the recommended Phase 2a schedule once it has been declared.  The RPTD 
will be defined b y observed DLTs and/or determination of MTD .
Subject assessments for safet y (ph ysical examination, vital signs, chemistry, hematology , 
urinaly sis, ECOG performance score and adverse event assessment) will be performed 
weekl y during the first cycle at the new escalated dose and then may resume to on ce every  
cycle.  All other procedures (platelet count, echocardiogram and ECG) will be performed 
according to the schedule of assessments as outlined in Table 1and Table 2for the 
subject's cumulative cy cle.
Transition From Phase 1 Portion to Phase 2a Portion
Once the MTD and/or the RPTD is declared on the 21/21 day  continuous dosing schedule, 
a safet y analysis will be performed as described in Section 8.1.4.  The results of the safet y 
analysis as well as the recommended Phase 2 dose and dosing schedule will be 
communicated to all participating research sites prior to the start of enrollment in the 
Phase 2a portion of the study .  Phase 1 subjects are not eligible for enrollment in the 
Phase 2a portion of the study , but may  continue receiving ABT -263 monotherap y for up 
to 11years after the last subject transitions to the Extension Study  provided they  continue 
to tolerate the drug, have no evidence of disease progression, and do not meet an y of the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
26
criteria for subject discontinuation (Section 5.4).  Subjects who enter the Extension Study  
will continue taking ABT -263 at the same dose and schedule they  were receiving in the 
Phase 1 portion of the study .
Subje cts who enter the Extension Study  must continue to meet all Inclusion and Exclusion 
criteria, with the exception of Laboratory  Criteria.  However, subjects must meet 
laboratory  criteria as stated in Section 5.2.5.
Phase 2a
In the Phase 2a portion of the study, 250 mg of ABT -263 will be administered under a 
21/21 day  continuous dosing schedule.  All subjects will self -administer ABT- 263 within 
30 minutes after the completion of breakfast unless specified otherwise.
A 7-day lead -in dose titration period will be implemented.  Subjects will begin dosing at 
100 mg on Lead -in Day  1 (LD1).  A subject may  only  proceed from the lead -in period to 
250 mg on C ycle 1 Day 1 and beyond if platelet count is ≥ 50,000/mm3after Lead- in 
Day 7 and stable or increasing.  If the platelet count is < 50,000/mm3after Lead -in Day  7, 
the visit day  will be considered Lead -in Day  8 and the subject will continue to receive the 
lead-in dose unti l the platelet count is ≥ 50,000/mm3.
When the platelet count is ≥ 50,000/mm3, the subject will receive the lead- in dose that 
day, and the next day  (defined as C ycle 1 Day 1) the subject will receive the defined dose 
for Cy cle 1 Day  1, provided the pre-dose platelet count that day  is ≥ 50,000/mm3and 
platelets are stable or increasing.  For example, if a subject's platelet count is 
≥50,000/mm3on Lead-in Day  9, the subject will take the lead -in dose on Day  9.  The 
next day  will be considered Cy cle 1 Day 1 and the subject will begin receiving the defined 
dose for C ycle 1 Day 1.  However, if the pre -dose platelet count is < 50,000/mm3or 
platelets are decreasing, then the day  becomes Lead -in Day  10 and the subject continues 
dosing at the lead- in dose.
If the platelet count is < 50,000/mm3after 14 days at the lead in dose, the lead in dose will 
become the subject's dose for the duration of the study.  To change from the lead in dose  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
27
to a higher dose (for subjects who continue receiving the lead in dose beyond the lead in 
period), a discussion between the investigator and the AbbVie Medical Monitor is 
required.
For the purpose of subject assessments for safet y and clinical progression under a 
21/21 day dosing schedule, a cy cle will be defined as 21 day s. These assessments for 
safet y and clinical progression will continue weekly through the first two cycles (6 weeks) 
of ABT -263.  Subsequently , subject assessments for safety and clinical progression will 
be performed once every  cycle (every  3 weeks) of ABT -263.
If, during Phase 2a, dose -limiting toxicities are observed at a frequency higher than the 
definition of MTD (> 30%), the principal investigator and the AbbVie Medical Monitor 
will review the data and jointly  determine whether dosing should continue or a new, lower 
recommended Phase 2 dose or alternate dosing schedule should be defined.
Subjects with stable disease in the Phase 2a portion of the study may continue receiving 
ABT -263 monotherapy  for up to 11years after the last subject transitions to the Extension 
Study , provided they  continue to tolerate the drug, have no evidence of disease 
progression, and do not meet an y of the criteria for subject discontinuation (Section 5.4).  
Subjects who enter the Extension Study  will continue taking ABT -263 at the same dose 
and schedule they were receiving in the Phase 2a portion of the study .
Subjects who enter the Extension Study  must continue to meet all Inclusion and E xclusion 
criteria, with the exception of Laboratory  Criteria.  However, subjects must meet 
laboratory  criteria stated in Section 5.2.5.
5.2 Selection of Study  Populatio n
Subjects will undergo screening procedures within 14 days prior to initial study  drug 
administration (Lead -in Day  1/Cy cle 1 Day  1).  Adult male and female subjects with CLL 
who meet the inclusion criteria and who do not meet an y of the exclusion criteria will be 
eligible for enrollment into the study . 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
28
5.2.1 Phase 1 Inclusion Criteria
A subject will be eligible for study participation if he/she meets the following criteria:
1. The subject must be ≥ 18 y ears of age.
2. The subject must have relapsed or refractory  CLL a nd require treatment in the 
opinion of the investigator.
3. The subject has an Eastern Cooperative Oncology Group performance score of 1.
4. Subjects receiving Selective Serotonin Reuptake Inhibitor (SSRI) anti -depressants 
(e.g.,Prozac) must be receiving a st able dose for at least 21 day s prior to the 
firstdose of study  drug.
5. The subject must have adequate bone marrow independent of growth factor support 
(with the exception of subjects with ANC < 1000/ L and bone marrow heavily  
infiltrated with underl ying disease [80% or more]), renal and hepatic function, per 
local laboratory reference range at Screening as follows:
●Bone marrow:  Absolute Neutrophil count (ANC) ≥ 1000/ L; 
Platelets ≥75,000/mm3(entry  platelet count must be independent of 
transfusion withi n 14 days of Screening), Hemoglobin ≥ 9.0 g/dL ;
●Renal function:  S erum creatinine 2.0 mg/dL  or calculated creatinine 
clearance ≥ 50 mL/min;
●Hepatic function and enzymes:  AST and ALT  3.0the upper normal limit 
(ULN) of institution's normal range; Bil irubin  1.5 
ULN.  Subjects with 
Gilbert's S yndrome may  have a Bilirubin > 1.5 ULN;
●Coagulation:  aPTT, PT, not to exceed 1.2  ULN.
6. Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or 
have negative results for a pregna ncy test performed as follows:
●At Screening on a serum sample obtained within 14 days prior to initial study  
drug administration, and 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
29
●Prior to dosing on a urine sample obtained on Cycle 1 Day  1 or Lead -in Day 1 
(lead -in period) if it has been > 7 day s sinc e obtaining the serum pregnancy  
test results.
7. All female subjects not surgically  sterile or postmenopausal (for at least 1 y ear) and 
non-vasectomized male subjects must practice at least one of the following 
methods of birth control:
●total abstinence from sexual intercourse (minimum one complete menstrual 
cycle);
●a vasectomized partner;
●hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months 
prior to study  drug administration;
●double -barrier method (including condoms, contraceptive s ponge, diaphragm 
or vaginal ring with spermicidal jellies or cream).
8. The subject must voluntarily  sign and date an informed consent, approved by  an 
Independent Ethics Committee (IEC)/Institutional Review Board (I RB), prior to 
the initiation of any  screenin g or stud y-specific procedures.
5.2.2 Phase 1 Exclusion Criteria
A subject will not be eligible for study participation if he/she meets an y of the following 
criteria:
1. The subject has a history  or is clinically  suspicious for cancer -related Central 
Nervous System (CNS) disease.
2. The subject has undergone an allogeneic or autologous stem cell transplant.
3. The subject has a recent history  (within 1 y ear prior to first dose of study d rug) of 
an underl ying, predisposing condition of bleeding or currently  exhibits signs of 
bleeding.
4. The subject has active peptic ulcer disease or other potentially hemorrhagic 
esophagitis/gastritis. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
30
5. The subject has active immune thrombocytopenic purpura or a history  of being 
refractory  to platelet transfusions (within 1 y ear prior to the first dose of study 
drug).
6. The subject has received aspirin within 7 day s prior to the first dose of study  drug.
7. The subject is currently  receiving or requires anticoagulation therapy  or any  drugs 
or herbal supplements that affect platelet function, wi th the exception of low -dose 
anticoagulation medications that are used to maintain the patency of a central 
intravenous catheter.
8. Subject has received steroid therap y for anti -neoplastic intent within 7 days prior to 
the first dose of stud y drug with the e xception of inhaled steroids for asthma, 
topical steroids, or replacement/stress corticosteroids.
9. The subject has received any  anti-cancer therap y including chemotherap y, 
immunotherapy , radiotherapy , hormonal (with the exception of hormones for 
thyroid con ditions or estrogen replacement therapy  [ERT]), or any  investigational 
therap y within 14 days prior to the first dose of study drug, or has not recovered to 
less than grade 2 clinically significant adverse effect(s)/toxicity (ies) of the previous 
therap y.
10. The subject has received a biologic within 30 day s prior to the first dose of study  
drug.
11. The subject has consumed grapefruit or grapefruit products within 3 days prior to 
the first dose of stud y drug.
12. The subject has a significant history of cardiovascular disease (e.g., m yocardial 
infarction [MI ], thrombotic, or thromboembolic event in the last 6 months), renal, 
neurologic, ps ychiatric, endocrinologic, metabolic, immunologic, or hepatic 
disease that in the opinion of the investigator would adversel y affect his/her 
participating in this study.
13. A female subject is pregnant or breast- feeding. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
31
14. The subject has tested positive for HIV (due to potential drug -drug interactions 
between anti -retroviral medications and ABT -263, as well as anticipated ABT- 263 
mechanism based l ymphopenia that may  potentially  increase the risk of 
opportunistic infections and potential drug -drug interactions with certain 
anti-infective agents).
15. The subject has a history  of other active malignancies within the past 3 y ears prior 
to study  entry, with the exception of:
●adequatel y treated in situ carcinoma of the cervix uteri;
●basal or squamous cell carcinoma of the skin;
●previous malignancy  confined and surgically  resected with curative intent.
16. The subject exhibits evidence of other clinicall ysignificant uncontrolled 
condition(s) including, but not limited to:
●Uncontrolled s ystemic infection (viral, bacterial, or fungal)
●diagnosis of fever and neutropenia within 1 week prior to study drug 
administration.
5.2.3 Phase 2a Inclusion Criteria
A subject will be eligible for study  participation if he/she meets the following criteria:
1. The subject must be ≥ 18 y ears of age.
2. The subject must have CLL and require treatment in the opinion of the investigator.
3. The subject has relapsed disease and has received no more than 5 prior 
myelosuppressive/chemotherap y regimens.
4. Subject has an Eastern Cooperative Oncology Group performance score of 1.
5. Subjects receiving Selective Serotonin Reuptake Inhibitor (SSRI) anti -depressants 
(e.g., Prozac) must be receiving a stable dose for at least 21 day s prior to the 
firstdose of study  drug. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
32
6. The subject must have adequate bone marrow independent of growth factor support 
(with the exception of subjects with ANC < 1000/ L and bone marrow heavily  
infiltrated with underl ying disea se [80% or more]), renal and hepatic function, per 
local laboratory reference range at Screening as follows:
●Bone marrow:  Absolute Neutrophil count (ANC) ≥ 1000/ L; 
Platelets ≥75,000/mm3(entry  platelet count must be independent of 
transfusion within 14 days of Screening); Hemoglobin ≥ 9.0 g/dL ;
●Renal function:  S erum creatinine 2.0 mg/dL  or calculated creatinine 
clearance ≥ 50 mL/min;
●Hepatic function and enzymes:  AST and ALT  3.0the upper normal limit 
(ULN) of institution's normal range; Bilirubi n 
1.5  ULN.  Subjects with 
Gilbert's S yndrome may  have a Bilirubin > 1.5 ULN;
●Coagulation:  aPTT, PT must not exceed 1.2  ULN.
7. Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or 
have negative results for a pregnancy  test performed as follows:
●At Screening on a serum sample obtained within 14 days prior to initial study  
drug administration, and
●Prior to dosing on a urine sample obtained on Lead -in Day  1 if it has been 
> 7days since obtaining the serum pregnancy  test r esults.
8. All female subjects not surgically  sterile or postmenopausal (for at least 1 y ear) and 
non-vasectomized male subjects must practice at least one of the following 
methods of birth control:
●total abstinence from sexual intercourse (minimum one comple te menstrual 
cycle);
●a vasectomized partner;
●hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months 
prior to study  drug administration;
●double -barrier method (including condoms, contraceptive sponge, diaphragm 
or vaginal ring with spermicidal jellies or cream). 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
33
9. The subject must voluntarily  sign and date an informed consent, approved by  an 
Independent Ethics Committee (IEC)/Institutional Review Board (I RB), prior to 
the initiation of any  screening or stud y-specific procedures.
5.2.4 Phase 2a Exclusion Criteria
A subject will not be eligible for study participation if he/she meets an y of the following 
criteria:
1. The subject has a history  or is clinically  suspicious for cancer -related Central 
Nervous System (CNS) disease.
2. The subject has a re cent history  (within 1 y ear prior to first dose of study d rug) of 
an underl ying, predisposing condition of bleeding or currently  exhibits signs of 
bleeding.
3. The subject has undergone an allogeneic or autologous stem cell transplant.
4. The subject has active peptic ulcer disease or other potentially  hemorrhagic 
esophagitis/gastritis.
5. The subject has active immune thrombocytopenic purpura or a history  of being 
refractory  to platelet transfusions (within 1 y ear prior to the first dose of study  
drug).
6. The subject is currently  receiving or requires anticoagulation therapy  or any  drugs 
or herbal supplements that affect platelet function, with the exception of low- dose 
anticoagulation medications that are used to maintain the patency of a central 
intravenous catheter .
7. The subject has received steroid therap y for anti -neoplastic intent within 7 day s 
prior to the first dose of study  drug with the exception of inhaled steroids for 
asthma, topical steroids or replacement/stress corticosteroids.
8. The subject has received as pirin within 7 day s prior to the first dose of study  drug. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
34
9. The subject has received any  anti-cancer therap y including chemotherap y, 
immunotherapy , radiotherapy , hormonal (with the exception of hormones for 
thyroid conditions or estrogen replacement therapy [ERT]), or any  investigational 
therap y within 14 days prior to the first dose of study drug, or has not recovered to 
less than grade 2 clinically significant adverse effect(s)/toxicity (ies) of the previous 
therap y.
10. The subject has received a biologic with in 30 day s prior to the first dose of study  
drug.
11. The subject has consumed grapefruit or grapefruit products within 3 days prior to 
the first dose of stud y drug.
12. The subject has a significant history of cardiovascular disease (e.g., m yocardial 
infarction [ MI], thrombotic, or thromboembolic event in the last 6 months), renal, 
neurologic, ps ychiatric, endocrinologic, metabolic, immunologic, or hepatic 
disease that in the opinion of the investigator would adversel y affect his/her 
participating in this study.
13. Afemale subject is pregnant or breast -feeding.
14. The subject has tested positive for HIV (due to potential drug -drug interactions 
between anti -retroviral medications and ABT -263, as well as anticipated ABT- 263 
mechanism based l ymphopenia that may  potentially increase the risk of 
opportunistic infections and potential drug -drug interactions with certain 
anti-infective agents).
15. The subject has a history  of other active malignancies within the past 3 y ears prior 
to study  entry , with the exception of:
●adequatel y treated in situ carcinoma of the cervix uteri;
●basal or squamous cell carcinoma of the skin;
●previous malignancy  confined and surgically  resected with curative intent. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
35
16. The subject exhibits evidence of other clinicall y significant uncontrolled 
condition(s) including, but not limited to:
●uncontrolled sy stemic infection (viral, bacterial, or fungal);
●diagnosis of fever and neutropenia within one week prior to study drug 
administration.
17. The subject has received known CYP3A inhibitors (e.g., ketoconazole) within
7days prior to first dose of study  drug.
5.2.5 Extension Study  Inclusion Criteria
Subjects who enter the Extension Study  must continue to meet all Inclusion and Exclusion 
criteria (excluding laboratory  parameters) from Phase 1 or in Phase 2a as listed above. 
Subjects entering the Extension Study  must also have stable lab values per applicable 
laboratory  reference ranges.
●Subjects must meet the following hematology  and coagulation lab criteria:
○Platelet counts must be ≥ 25,000/mm3(untransfused).  Platelet cou nts 
50,000/mm3must be stable and monitored at an increased frequency at 
the discretion of the investigator.
○Absolute Neutrophil count (ANC) ≥ 500/ L.  ANC ≥ 500/µL  and 
<1,000/µL  should be monitored at an increased frequency  at the discretion 
of the investigator.
○Hemoglobin of ≥ 8.0 g/dL.
○aPTT, PT is not to exceed 1.2 
ULN.
●Subjects must meet the following chemistry  criteria:
○Subjects' chemistry  values must not exceed Grade 2.  Grade 2 chemistry  
labs should be monitored at an increased frequency at t he discretion of the 
investigator.
○Serum creatinine 3.0  the upper normal limit (ULN) of institution's 
normal range. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
36
○AST and ALT  5.0  the upper normal limit (ULN) of institution's normal 
range.
○Bilirubin 3.0  ULN.  Subjects with Gilbert's Sy ndrome may  be allowed 
to have a Bilirubin > 3.0 ULN based on a joint decision between the 
investigator and AbbVie medical monitor.
5.2.6 Prior and Concomitant Therapy
If a subject reports taking any over -the-counter or prescri ption medication, vitamins, 
and/or herbal supplements or if administration of any medication becomes necessary from 
the time of screening and throughout the stud y, the name of the medication, dosage 
information including dose and frequency, date(s) of admi nistration including start and 
end dates, and reason for use must be recorded on the appropriate case report form (CRF).  
AbbVie will provide subject diaries to serve as a tool for the subjects to record 
concomitant medications and adverse events.
Steroid therap y, for anti -neoplastic intent, will not be allowed within 7 days prior to the 
first dose of study  drug and during ABT -263 administration with the exception of inhaled 
steroids for asthma, topical steroids, or replacement/stress corticosteroids.
Aspir in will not be allowed within 7 day s prior to the first dose of stud y drug or during 
ABT -263 administration.  However, subjects who have previousl y received aspirin 
therap y for thrombosis prevention, may resume a low dose (i.e., maximum 100 mg QD) 
of aspir in if platelet counts are stable ( ≥ 50,000/mm3) through 2 Cycles of ABT- 263 
administration.  All decisions regarding treatment with aspirin therap y will be determined 
by the investigator in conjunction with the AbbVie Medical Monitor.
CYP3A inhibitors such as ketoconazole and clarithromycin are not allowed 7 days prior to 
the first dose of stud y drug or during ABT -263 administration.
Anti-cancer therap y including chemotherap y, immunotherap y, radiotherap y, hormonal 
(with the exception of hormones for th yroid conditions or estrogen replacement therap y 
[ERT]), and other investigational agents will not be allowed within 14 days prior to the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
37
first dose of study  drug, or has not recovered to less than grade 2 clinically  significant 
adverse effect(s)/toxicity(ies) of the previous therapy .  These agents will not be allowed 
during ABT- 263 administration.
Biologics will not be allowed within 30 days prior to the first dose of study drug and 
during ABT- 263 administration.
Colony  stimulating factors (G -CSF, GM -CSF) or hu man ery thropoietin will be considered 
during administration of ABT -263 if deemed necessary  by the investigator and if mutually 
agreed upon b y AbbVie Medical Monitor.
Best supportive care and treatment will be allowed for each subject (antiemetics, 
antibiot ics, transfusions, nutritional support, pain control, etc.) with the exception of the 
following:
●Plavix, ibuprofen, Aggrastat and other anticoagulants, drugs or herbal 
supplements that affect platelet function (due to expected dose limiting toxicity 
of thr ombocy topenia).  Administration of heparin to keep subject's infusion 
lines patent is allowed.  Low -dose anticoagulation medications that are used to 
maintain the patency  of a central intravenous catheter are allowed.
●disulfiram (due to percentage of ethanol content in the drug formulation).
Concomitant medications of the following categories could potentially lead to adverse 
reaction(s).  It is important to assess whether potential study subjects are taking an y of the 
cautionary  medications.  If a potenti al stud y subject is taking an y of the medications in the 
categories described below, the investigator will assess and document the use of 
medications known or suspected to fall in the following medication categories.  A sample 
list of medications that fall into the cautionary categories mentioned below can be found 
in Appendix E.  It is not possible to produce a 100% exhaustive list of medications that 
fall into the categories, so if in question, please refer to the appropriate product label.  If 
the investigator determines that such a medication is medically necessary, the investigator 
will notify  the AbbVie Medical Monitor and discuss the investigator's use of these 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
38
medications and the investigator's plans to medically  monitor the potential study  subject 
under consideration.
●CYP2C8 substrates such as glitazones and select statins (due to expected 
inhibition of the metabolism of CYP2C8 substrates).
●CYP2C9 substrates s uch as phen ytoin and tolbutamide (due to expected 
inhibition of the metabolism of CYP2C9 substrates).
●CYP3A inducers such as rifampin and carbamazepine (due to possible 
induction of the metabolism of ABT- 263).
If clinicall y indicated, anti -herpes and anti -PCP (Pneumocy stis carinii pneumonia) 
prophy laxis should be considered.  Although there is a potential for drug -drug 
interactions, there is likely to be limited potential clinical effects, therefore Bactrim 
(trimethoprim -sulfamethoxazole) can be considered for PCP prophy laxis with close 
clinical monitoring.
A list of common medications in the excluded classifications described above is provided 
in Appendix E.  This is a partial list; all medications in these classifications are excluded.
Contact the AbbVie Medical Monitor identified in Section 6.5, if there are any  questions 
regarding concomitant or prior therapies.
5.3 Efficacy , Pharmacokinetic, Pharmacody namic, 
Pharmacogenetic and Safety  Assessments/Variables
5.3.1 Efficacy  and Safety  Measurements A ssessed and Flo w
Chart
Study  procedures will be performed as summarized in Table 1through Table 6below for 
the Phase 1 and Phase 2a portions of the study .
Study  procedures for subjects in the Extension Study  can be found in Appendix G. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
39
Table 1. Schedule of Assessments – 14/21 Day Dosing (Phase 1)
Procedure ScreeningaCycle 1 
Day 1 
(C1D1)Cycle 1 
Day 2 
(C1D2)Cycle 1 
Day 3 
(C1D3)Cycle 1
Day 14
(C1D14)Weekly 
Through 
Cycle 2Day 1 of Each 
Cycle 
After Cycle 2bEnd of 
Every 3rd
CycleFinal 
Visitr30 Day Safety
Follow -Upr
Informed Consent X
Physical Exam (including weight) XcX XdX X X
Medical History X X
Oncologic History X
Vital Signs X X X X X X
12-lead ECGeX X X XeX
2D Echocardiogram with DopplerfX X X XfX
Platelet CountgX X X X X X X X X
Lymphocyte EnumerationhX X X X
Pregnancy TestiX X
ChemistryjX X X X X X X X
HematologyjX X X X X X X X
UrinalysisjX X X X X X
Performance Status (ECOG) X X X X X X
Tumor AssessmentskXlXm,nX
Bone Marrow Aspirate and 
Biopsyn Xo
Adverse Event/Concomitant 
Medications AssessmentXpX X X X X Xq 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
40
Table 1. Schedule of Assessments – 14/21 Day Dosing (Phase 1) (Continued)
Procedure ScreeningaCycle 1 
Day 1 
(C1D1)Cycle 1 
Day 2 
(C1D2)Cycle 1 
Day 3 
(C1D3)Cycle 1
Day 14
(C1D14)Weekly 
Through 
Cycle 2Day 1 of Each 
Cycle 
After Cycle 2bEnd of 
Every 3rd
CycleFinal 
Visitr30 Day Safety
Follow -Upr
Dispense Meds/Subject Dosing 
LogX X X
Collect Unused Study Drug X X X
a. Screening procedures must be performed within 14 days prior to study drug administration, except tumor assessment scans (if clinically indicated) and bone marrow 
aspirate/biopsy, which must be performed within 21 days prior to study drug administration.
b. Study procedures (except platelets) may be performed within 72 hour s prior to Day 1 for each cycle.  Platelets counts must be performed within 24 hours prior to dosing on 
Day 1 of each cycle.
c. Height will be assessed at Screening only.
d. A symptom directed physical exam may be performed weekly through Cycle 2.
e. ECG w ill be performed at Screening, Day 1 and Day 14 of Cycle 1, Day 1 of each subsequent cycle and at the Final Visit for all sub jects in the first 2 cohorts.  ECG will be 
performed at Screening, Day 1 and Day 14 of Cycle 1, Day 1 and Day 14 of Cycle 3 and at the Final Visit for subjects in subsequent cohorts.  Every effort should be made to 
obtain all ECGs approximately 4 -8 hours post -dose (however, 6 -8 hours post -dose is preferred), and if possible at approximately the same time of day.  If pharmacokinetic 
data indicates the C maxof parent drug or a major metabolite occurs at a time different than this specified range, the timing of the ECG may be modif ied.  Repeat ECGs will be 
performed whenever clinically necessary.
f. 2D Echocardiogram with Doppler will be performed at Screening, Day 1 and Day 14 of Cycle 1, Day 1 of each subsequent cycle and at the Final Visit for all subjects i n the 
first 2 cohorts.  Echocardiogram with Doppler will be performed at Screening, Day 1 and Day 14 of Cycle 1, Day 1 and Day 14 o f Cycle 3 and at the Final Visit for subjects 
in subsequent cohorts.  Every effort should be made to obtain all echocardiograms approximately 4 -8 hours post -dose (however, 6 -8 hours post -dose is preferred), and if 
possible at approximately the same time of day.  If pharmacokinetic data indicates the C maxof parent drug or a major metabolite occurs at a time different than this specified 
range, the timing of the echocardiogram may be modified.  Repeat echocardiograms will be performed whenever clinically nec essary.
g. Platelet counts will be performed Cycle 1:  Pre -dose on Days 1, 2, 3, 4, 5, 6, 8, 14 (in addition, at all PK time points per Table 4), Day 16 and as needed; Subsequent Cycles:  
Days 1, 3, 5, 8, 16 and as needed.  If the investigator and the AbbVie Medical Monitor jointly agree that platelet counts thr ough Cycle 4 have been stable, then the frequency 
of platelet counts in Cycle 5 and beyond may be decreased to Day 1 of each cycle and as needed.  If platelet count performed on any given day is less than 50,000/mm3, 
additional platelet counts should be performed every day or at the discretion of the investigator. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
41
Table 1. Schedule of Assessments – 14/21 Day Dosing (Phase 1) (Continued)
h. Lymphocyte enumeration will be performed at Screening, Day 14 of Cycle 1, end of Cycle 4, the end of every 3rdcycle thereafter and at the Final Visit.
i. For women of child bearing potential, a serum sample is to be tested at Screening and a urine sample (if it has been > 7 days since obtaining the serum pregnancy test results) 
is to be tested prior to dosing on Day 1 of the first cycle.
j. The specific laboratory tests required for chemistry, hematology and urinalysis are listed in Table 7.  Triglycerides will only be collected at Screening and at the Final Visit.  
Amylase and lipase will be collected at Screening, Cycle 1 Day 14, and Final Visit.  For any subjects who are at high risk for tumor lysis syndrome (TLS) during Cycle 2 and 
beyond, additional samples for hematology and chemistry may be collected as per the management gu idelines in Section 6.7.4 .
k. Assessment for tumor response will be performed at the end of Cycle 2, end of Cycle 4, end of every 4 cycles through Cycle 20 (i.e., C8, C12, C16, C20), end of every 
8cycles thereafter (i.e., C28, C36, C44. . .) and at the Final Visit.  Analysis of peripheral blood for tumor response will be performed on Day 1 (pre -dose) of the following 
cycle for every tumor assessment .
l. A CT scan will be performed at Screening (within 21 days prior to study drug administration).
m. Assessments for tumor response will be repeated at least 2 months after NCI -WG criteria for a complete remission (CR or CRi) or partial remission (PR) are first met.
n. If clinical and laboratory criteria for a CR or PR are met, a bone marrow aspirate/biopsy and CT scan should be performed at least 2 months after the criteria are first met in 
order to confirm a CR or PR.
o. Bone marrow aspirate/biopsy will be done at Screening (within 21 days prior to study drug administration) unless a bone marrow aspirate and biopsy was obtaine d within 
12weeks of starting study drug without intervening treatment and is representative of the subject's existing disease.
p. Serious adverse event assessment will be performed at Screening after informed consent has been obtained.
q. Adverse events will be followed until satisfactory clinical resolution of the adverse event is achieved.
r. For subjects who continue in the Extens ion Study, the Final Visit and 30 Day Safety Follow -Up Visit procedures will be performed upon completion of the Extension Study.  
Refer to Appendix Gfor the Sched ule of Assessments for subjects enrolled in the Extension Study.
Note: A schedule of assessments for subjects enrolled in Phase 1 –21/21 Day Dosing can be found in Table 2.  A schedule of assessments for subjects enrolled in Phase 2a can 
be found in Table 3.  Pharmacokinetic (PK) collection time po ints for Phase 1 are located in Table 4and Table 5.  PK collection time points for Phase 2a are located in 
Table 6.  Biomarker collection time points for Phase 1 are in Table 8.  Biomarker collection time points for Phase 2a are located in Table 9. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
42
Table 2. Schedule of Assessments – 21/21 Day Dosing with Lead -in Period (Phas e 1)
Procedure ScreeningaLead -in 
Day 1
(LD1)Lead -in 
Day 2
(LD2)Lead -in 
Day 3
(LD3)Cycle 1 
Day 1 
(C1D1)Cycle 1 
Day 2 
(C1D2)Cycle 1 
Day 3 
(C1D3)Cycle 1
Day 14
(C1D14)Weekly 
Through 
Cycle 2Day 1 of 
Each 
Cycle 
After 
Cycle 2bEnd of 
Every 3rd
CycleFinal 
Visitr30 Day 
Safety
Follow - Upr
Informed Consent X
Physical Exam 
(including weight)XcX X XdX X X
Medical History X X
Oncologic History X
Vital Signs X X X X X X X
12-lead ECGeX X X X X
2D Echocardiogram 
with Dopplerf X X X X X
Platelet CountgX X X X X X X X X X X X
Lymphocyte 
Enumerationh X X X X
Pregnancy TestiX X
ChemistryjX X X X X X X X X X X
HematologyjX X X X X X X X X X X
UrinalysisjX X X X X X X 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
43
Table 2. Schedule of Assessments – 21/21 Day Dosing with Lead -in Period (Phase 1) (Continued)
Procedure ScreeningaLead -in 
Day 1
(LD1)Lead -in 
Day 2
(LD2)Lead -in 
Day 3
(LD3)Cycle 1 
Day 1 
(C1D1)Cycle 1 
Day 2 
(C1D2)Cycle 1 
Day 3 
(C1D3)Cycle 1
Day 14
(C1D14)Weekly 
Through 
Cycle 2Day 1 of Each 
Cycle After 
Cycle 2bEnd of 
Every 
3rdCycleFinal 
Visitr30 Day 
Safety
Follow -Upr
Performance Status (ECOG) X X X X X X X
Tumor AssessmentskXlXm,nX
Bone Marrow Aspirate and 
BiopsynXo
Adverse Event/Concomitant 
Medications AssessmentXpX X X X X X Xq
Dispense Meds/Subject Dosing 
LogX X X X
Collect Unused Study Drug X X X
a. Screening procedures must be performed within 14 days prior to study drug administration, except baseline tumor assessment (if clinically indicated) and b one marrow 
aspirate/biopsy, which must be performed within 21 days prior to study drug administration.
b. Study procedures (except platelets) may be performed within 72 hours prior to Day 1 for each cycle.  Platelets counts must be performed within 24 hour s prior to dosing on 
Day 1 of each cycle.
c. Height will be assessed at Screening only.
d. A symptom directed physical exam may be performed weekly through Cycle 2.
e. ECG will be performed at Screening, Lead -in Day 1, Day 1 and Day 14 of Cycle 1, Day 1 and Day 14 of Cycle 3 and at the Final Visit.  Every effort should be made to ob tain 
all ECGs approximately 4 -8 hours post -dose (however, 6 -8 hours post -dose is preferred), and if possible at approximately the same time of day.  If pharmacokinetic data 
indicates the C maxof parent drug or a major metabolite occurs at a time different than this specified range, the timing of the ECG may be modified.  Repeat ECGs will be 
performed whenever clinically necessary.
f. 2D Echocardiogram with Doppler will be performed at Screening, Lead -in Day 1, Day 1 and Day 14 of Cycle 1, Day 1 and Day 14 of Cycle 3 and at the Final Visit.  Every 
effort shoul d be made to obtain all echocardiograms approximately 4 -8 hours post -dose (however, 6 -8 hours post -dose is preferred), and if possible at approximately the same 
time of day.  If pharmacokinetic data indicates the C maxof parent drug or a major metabolite occurs at a time different than this specified range, the timing of the 
echocardiogram may be modified.  Repeat echocardiograms will be performed whenever clinically necessary. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
44
Table 2. Schedule of Assessments – 21/21 Day Dosing with Lead -in Period (Phase 1) (Continued)
g. Platelet counts will be performed at Screening, Lead -in Days 1, 2, 3, 5 and 7 and then daily if the lead -in period extends beyond Day 7.  Cycle 1:  Pre -dose on Days 1, 2, 3, 5, 
8, 14 (in addition, at all PK time points per Table 4), Day 16, and as needed.  Subsequent Cycles:  Weekly and as needed.  If the investigator and the AbbVie Medical Monitor 
jointly agr ee that platelet counts through Cycle 4 have been stable, then the frequency of platelet counts in Cycle 5 and beyond may be decreased to Day 1 of each cycle and 
as needed.  If platelet count on any given day is less than 50,000/mm3, additional platelet co unts should be performed every day or at the discretion of the investigator.
h. Lymphocyte enumeration will be performed at Screening, Day 14 of Cycle 1, end of Cycle 4, the end of every 3rdcycle thereafter and at the Final Visit.
i. For women of child be aring potential, a serum sample is to be tested at Screening and a urine sample is to be tested (if it has been > 7 days sinc e obtaining the serum 
pregnancy test results) prior to dosing on Lead-in Day 1 (lead -in period).
j. The specific laboratory tests r equired for chemistry, hematology and urinalysis are listed in Table 7.  Triglycerides will only be collected at Screening and at the Final Visit.  
Amylase and lipase will be collected at Screening, Cycle 1 Day 14, and Final Visit.  For any subjects who are at high risk for tumor lysis syndrome (TLS) during Cycle 2 and 
beyond, additional samples for hematology and chemistry may be collected as per the m anagement guidelines in Section 6.7.4 .
k. Assessment for tumor response will be performed at the end of Cycle 2, end of Cycle 4, end of every 4 cycles through Cycle 20 (i.e., C8, C12, C16, C20), end of every 
8cycles thereafter (i.e., C28, C36, C44. . .) and at the Final Visit.  Analysis of peripheral blood for tumor response will be performed on Day 1 (pre -dose) of the following 
cycle for every tumor assessment .
l. A CT scan will be performed at Screening (within 21 days prior to study drug administration).
m. Assessments for tumor response will be repeated at least 2 months after NCI -WG criteria for a complete remission (CR or CRi) or partial remission (PR) are first met.
n. If clinical and laboratory criteria for a CR or PR are met, a bone marrow aspirate/biopsy and CT scan should be performed at least 2 months after the criteria are first met in 
order to confirm a CR or PR.
o. Bone marrow aspirate/biopsy will be done at Screening (within 21 days prior to study drug administration) unless a bone marrow aspirate and biopsy was obtaine d within 
12weeks of starting study drug without intervening treatment and is representative of the subject's existing disease.
p. Serious adverse event assessment will be performed at Screening after informed consent has been obtained.
q. Adverse events will be followed until satisfactory clinical resolution of the adverse event is achieved.
r. For subjects who continue in the Extens ion Study, the Final Visit and 30 Day Safety Follow -Up Visit procedures will be performed upon completion of the Extension Study.  
Refer to Appendix Gfor the Sched ule of Assessments for subjects enrolled in the Extension Study.
Note: A schedule of assessments for subjects enrolled in Phase 1 –14/21 Day Dosing can be found in Table 1.  A schedule of assessments for subjects enrolled in Phase 2a can 
be found in Table 3.  Pharmacokinetic (PK) collection time points for Phase 1 are located in Table 4and Table 5.  PK collection time points for Phase 2a are located in 
Table 6.  Biomarker collection time points for Phase 1 are in Table 8.  Biomarker collection time points for Phase 2a are in Table 9. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
45
Table 3. Schedule of Assessments (Phase 2a) –21/21 Day Continuous Dosing Schedule with Lead -in Period
Procedure ScreeningaLD1 LD2 LD3C1
D1C1
D2C1
D3C1
D15Weekly 
Through 
C2D1 of Each 
Cycle After 
C2bEnd of 
Every 3rd
CycleC5
D1C9
D1Final 
Visits30 Day 
Safety
Follow -
UpsPost-
Treat ment
Informed Consent X
Physical Exam (including weight) XcX X XdX X X
Medical History X X
Oncologic History X
Vital Signs X X X X X X X
12-lead ECGeX X X X X
2D Echocardiogram with DopplerfX X X X X
Platelet CountgX X X X X X X X X X X X X X
Lymphocyte EnumerationhX X X X
Pregnancy TestiX X
ChemistryjX X X X X X X X X X X
HematologyjX X X X X X X X X X X
UrinalysisjX X X X X X X
Performance Status (ECOG) X X X X X X X
Tumor AssessmentskXlXm,nX
Bone Marrow Aspirate/BiopsynXo
Clinical Disease Progression 
AssessmentX X X
Adverse Event/Concomitant 
Medications AssessmentXpX X X X X X Xq 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
46
Table 3. Schedule of Assessments (Phase 2a) – 21/21 Day Continuous Dosing Schedule with Lead -in Period 
(Continued)
Procedure ScreeningaLD1 LD2 LD3C1
D1C1
D2C1
D3C1
D15Weekly 
Through 
C2D1 of Each 
Cycle After 
C2bEnd of 
Every 3rd
CycleC5
D1C9
D1Final 
Visits30 Day 
Safety
Follow -
UpsPost-
Treat ment
Dispense Meds/Subject Dosing 
LogX X X X
Collect Unused Study Drug X X X
Survival Assessment(s)rX
C = Cycle; D = Day; L = Lead -in
a. Screening procedures must be performed within 14 days prior to study drug administration, except baseline tumor assessment sc ans (if clinically indicated) and bone marrow 
aspirate/biopsy, which must be performed within 21 days prior to study drug administration.
b. Study procedures (except platelets) may be performed within 72 hours prior to Day 1 for each cycle.  Platelet counts must b e performed within 24 hours prior to dosing on 
Day 1 of each cycle.
c. Height will be assessed at Screening only.
d. A symptom directed physical exam may be performed weekly through Cycle 2.
e. Every effort should be made to obtain all ECGs approximately 4 to 8 hours post -dose (however, 6 to 8 hours post- dose is preferred), and if possible at approximately the same 
time of day.  Repeat ECGs will be performed whenever clinically necessary.  If nec essary, ECGs may be performed within 3 days of the visit, except Screening, which must 
be performed within 14 days prior to study drug administration.  
f. Every effort should be made to obtain all echocardiograms approximately 4 to 8 hours post dose (howe ver, 6 to 8 hours post dose is preferred), and if possible at 
approximately the same time of day.  Repeat echocardiograms will be performed whenever clinically necessary.  If necessary, E CHOs may be performed within 3 days of the 
visit, except Screening, w hich must be performed within 14 days prior to study drug administration.
g. Platelet counts will be performed at Screening, Lead -in Days 1, 2, 3, 5 and 7 and then daily if the lead -in period extends beyond Day 7.  Cycle 1:  Pre -dose on Days 1, 2, 3, 5, 
8,15 and as needed.  Subsequent Cycles:  Weekly and as needed.  If platelet count on any given day is less than 50,000/mm3, additional platelet counts should be performed 
every day or at the discretion of the investigator.  If the investigator and the AbbVi e Medical Monitor jointly agree that platelet counts through Cycle 4 have been stable, then 
the frequency of platelet counts in Cycle 5 and beyond may be decreased to Day 1 of each Cycle and as needed. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
47
Table 3. Schedule of Assessments (Phase 2a) –21/21 Day Continuous Dosing Schedule with Lead -in Period 
(Continued)
h. Lymphocyte enumeration will be performed at Screening, Day 15 of Cycle 1, end of Cycle 4, the end of every 3rdcycle thereafter and at the Final Visit.
i. For women of childbearing potential, a serum sample is to be tested at Screening and a urine sample is to be tested (if it has been > 7 days since obtaining the serum 
pregnancy test results) prior to dosing on Lead-in Day 1 (lead -in period).
j. The specific laboratory tests required for chemistry, hematology and urinalysis are listed in Table 7.  Triglycerides will only be collected at Screeni ng and at the Final Visit.  
Amylase and lipase will be collected at Screening, Cycle 1 Day 15, and Final Visit.  For any subjects who are at high risk fo r tumor lysis syndrome (TLS) during Cycle 2 and 
beyond, additional samples for hematology and chemistry may be collected as per the management guidelines in Section 6.7.4 .
k Assessment for tumor response will be performed at the end of Cycle 2, end of Cycle 4, end of every 4 cycles through Cycle 20 (i.e., C8, C12, C16, C20), end of every 
8cycles thereafter (i.e., C28, C36, C44. . .) and at the Final Visit.  Analysis of peripheral blood for tumor response will be performed on Day 1 (pre -dose) of the f ollowing 
cycle for every tumor assessment.
l. A CT scan will be performed at Screening (within 21 days prior to study drug administration).
m. Assessments for tumor response will be repeated 2 months after NCI -WG (1996) criteria for a complete remission (C R) are first met and/or at least 2 months after IWCLL 
updated NCI-WG (2008) criteria for a complete remission (CR or CRi) or partial remission (PR) are first met.
n. If clinical and laboratory criteria for a CR or PR are met), a bone marrow aspirate/biopsy and CT scan should be performed at least 2 months after the criteria are first met in 
order to confirm a CR or PR.  A bone marrow aspirate/biopsy will be performed at the end of Cycle 8 (for all subjects regardl ess of response) if the subject is continuin g to 
receive ABT -263.
o. Bone marrow aspirate/biopsy will be done at Screening (within 21 days prior to study drug administration) unless a bone marro w aspirate and biopsy was obtained within 
12weeks of starting study drug without intervening treatment an d is representative of the subject's existing disease.
p. Serious adverse event assessment will be performed at Screening after informed consent has been obtained.
q. Adverse events will be followed until satisfactory clinical resolution of the adverse eve nt is achieved.
r. Survival assessments will be collected every 3 months for 2 years following discontinuation from the study (including the ext ension portion of the study).  In Protocol 
Amendment #12 this information will no longer be collected.
s. For su bjects who continue in the Extension Study, the Final Visit and 30 Day Safety Follow -Up Visit procedures will be performed upon completion of the Extension Study.  
Refer to Appendix Gfor the Schedule of Assessments for subjects enrolled in the Extension Study.
Note: A schedule of assessments for subjects enrolled in Phase 1 can be found in Table 1and Table 2.  Pharmacokinetic (PK) collection time points for Phase 1 are located in 
Table 4and Table 5.  PK collection time points for Phase 2a are located in Table 6.  Biomarker collection time points for Phase 1 are in Table 8.  Biomarker collection 
time points for Phase 2a are located in Table 9. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
48
Table 4. Schedule of Blood Collection for ABT -263 Assay (Pharmacokinetic Samp ling) –Phase 1, Cycle 1
PhaseCycle 1
Day 1Cycle 1
Day 2Cycle 1
Day 14
Phase 1 –14/21 day schedule 0 (pre -dose)
2, 4, 6, 8 hours post- dose24 hours post-dose Day 1 
(pre-dose Day 2)0 (pre -dose)
2, 4, 6, 8 hours post- dose
Phase 1 –21/21 day schedule –with lead -in 0 (pre -dose) 
2, 4, 6, 8 hours post- dose24 hours post-dose Day 1 
(pre-dose Day 2)0 (pre -dose)
2, 4, 6, 8 hours post- dose
All 0 hour (pre -dose) PK samples will be collected around the same time for platelet sample collection.
Note: In ad dition, serial pharmacokinetic samples will be obtained from subjects who develop Grade 4 thrombocytopenia (< 25,000/mm3).  The first pharmacokinetic sample 
should be collected as soon as possible after determination of the Grade 4 thrombocytopenia and the n 24 and 48 hours thereafter.
Table 5. Schedule of Blood Collection for ABT -263 Assay (Pharmacokinetic Sampling) –Phase 1, Cycle 2 and Beyond
PhaseCycle 2
Day 3Cycle 2
Day 8Cycle 2
Day 14Cycle 3
Day 1Cycle 3
Day 14Day 14 of Cycles 6, 
9, 12 and 15
Phase 1 –14/21 day schedule 0 hour (pre -dose) 0 hour (pre -dose) 0 hour (pre -dose) 4 to 8 hours post-dose 
(immediately after ECG)0 hour (pre -dose) and 
4to 8 hours post -dose 
(immediately after ECG)0 (pre -dose)
PhaseCycle 2
Day 3Cycle 2
Day 8Cycle 2
Day 14Cycle 3
Day 1Cycle 3
Day 14Day 1 of Cycles 6, 9, 
12 and 15
Phase 1 –21/21 day schedule 
–with lead -in0 hour (pre -dose) 0 hour (pre -dose) 0 hour (pre -dose) 4 to 8 hours post-dose 
(immediately after ECG)0 hour (pre -dose) and 
4to 8 hours post -dose 
(immediately after ECG)0 (pre -dose)
All 0 hour (pre -dose) PK samples will be collected around the same time for platelet sample collection.
Note: In addition, serial pharmacokinetic samples will be obtained from subjects (including subjects in the Extension Study) who develop Grade 4 thrombocytopenia 
(<25,000/mm3).  The first pharmacokinetic sample should be collected as soon as possible after determination of the Grade 4 thrombocytope nia and then 24 and 
48hours thereaft er.  Starting with Protocol Amendment 13, PK samples will NOT be collected. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
49
Table 6. Schedule of Blood Collection for ABT -263 Assay (Pharmacokinetic Sampling) –Phase 2a, 21/21 Day 
Continuous Dosing Schedule
ProcedureCycle 1
Day 15Cycle 3
Day 1 Day 1 of Cycles 5 and 9
Phase 2a 0 (pre -dose) and 4 to 8 hours post -dose 
(immediately after ECG)0 (pre -dose) 0 (pre -dose) and 4 to 8 hours post -dose 
(immediately after ECG)
All 0 hour (pre -dose) PK samples will be collected around the same time for platelet sample collection.
Note: In addition, serial pharmacokinetic samples will be obtained from subjects (including subjects in the Extension Study) who de velop Grade 4 thrombocytopenia 
(<25,000/mm3).  The first pharmacokinetic sample should be collected as soon as possible after determination of the Grade 4 thrombocytopenia and then 24 and 
48hours thereafter.   Starting with Protocol Amendment 13, PK samples will NOT be collected. 
  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
50
5.3.1.1 Study Procedures
For subjects who continue in the Extension Study , the Final Visit, and 30 Day Safet y 
Follow -Up Visit procedures will be performed only  once upon completion of the 
Extension Study .
Study  visits may  be impacted due to the COVID -19 pandemic. This may  include changes 
such as phone or virtual visits, visits at alternative locations, or changes in the visit 
frequency  and timing of study  procedures, among others. Additional details are provided 
in the subsequent section. Every  effort should be made to ensure the safety of subjects 
and site staff, while maintaining the integrit y of the study. If visits cannot be conducted 
onsite due to travel restrictions or other pandemic -related reasons, follow the updates 
below how to proceed.
COVID -19 Pandemic -Related Acceptable Protoco l Modifications
During the COVID- 19 pandemic, if it is not possible for all study  procedures to be 
performed as specified due to travel restrictions or other reasons, the following 
modifications are allowed:
●If permitted b y local regulations, the I RB/IEC a nd the subject, the subject 
visitsmay be conducted in the subject's home residence.
●Some study  visits and/or activities may  be performed by  phone/virtually .  
These are indicated b y a hashtag (#) in the activity table ( Appendix G)
○During a virtual visit, activities that do not need to be performed are 
indicated b y a (#) in the activity table ( Appendix G).
● S tudy visits and/or activities may  be performed b y a local 
clinic/hospital/laboratory. All procedures performed at local facilities must be 
performed b y appropriately  qualified personnel.
●Study  Visits and/or activities should be performed as scheduled whenever 
possible. If it is not possible to do so due to the pandemic, perform the activity  
at the earliest feasible opportunity . Laboratory  draws must be obtained within 
24 hours from the s cheduled visit. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
51
Informed Consent
Signed informed consent will be obtained from the subject or the subject's legally 
acceptable representative before an y stud y-specific procedures are undertaken or before 
any prohibited medications are withheld from the su bject in order to participate in this 
study .  Informed consent is also required for the pharmacod ynamic (PD) and 
pharmacogenetic (PG) sampling portions of the study.  A separate informed consent will 
be required for subjects entering the Extension Study .  Details about how informed 
consent will be obtained and documented are provided in Section 9.3.
Due to the COVID -19 pandemic, it is possible that additional protocol modifications not 
outlined in this protocol may become necessary . If this situation arises, in addition to the 
study  informed consent, additional verbal consent may  be obtained prior to these 
adaptations or substantial changes in stud y conduct in accord ance with local regulations.
Medical History
The following will be collected during the Screening Visit:
●Complete medical history, including documentation of an y clinicall y 
significant medical condition
●History  of tobacco and alcohol use
●Detailed oncology  history  including:
●Histology
●Date of cancer diagnosis
●Stage
●Any surgical procedures
●Treatments administered (including dates and t ype of modality)
At each visit, the subject's medical history will be reviewed and an y changes from 
baseline will be recorded on the adverse event CRF.  On C ycle 1 Day 1 (14/21 day dosing 
schedule), an y changes observed from the Screening assessments prior to dosing will be 
recorded in the subject's medical history.  During the lead -in period, any  changes from the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
52
Screening asse ssment prior to dosing will be recorded in the subject's history on Lead -in 
Day 1 (21/21 day  dosing schedule).  All medication (prescription or over -the-counter, 
including vitamins and/or herbal supplements) will be recorded beginning with the 
Screening Vi sit and continuing until 30 day s following the last dose of ABT -263.
Physical Examination
A phy sical examination (including weight) will be performed at Screening, Day  1 of 
Cycle 1, Day  1 of each subsequent cy cle (or within 72 hours prior), at the Final Vi sit and 
at the Safet y Follow -up Visit.  During the lead -in period (21/21 day  dosing schedule), a 
physical examination (including weight) will also be performed at Lead -in Day  1.  A 
symptom -directed ph ysical examination may  be performed weekl y through the 
first2cycles and when necessary .  Height will be measured onl y at Screening.  The 
physical examination performed at Screening will serve as the baseline ph ysical 
examination for clinical assessment.  For the Extension Study , a phy sical examination will 
beperformed at Day  1, every  4 cy cles (e.g., C ycle 4 Day  1, Cy cle 8 Day  1, etc.), Final 
Visit and at the Safet y Follow -up Visit.  Any  significant ph ysical examination findings 
after dosing will be recorded as adverse events.
Vital Signs
Body temperature (ora l or ty mpanic), blood pressure and pulse will be measured at 
Screening, Day  1 of C ycle 1, weekl y through the first 2 cycles, Day 1 of each subsequent 
cycle (or within 72 hours prior), at the Final Visit and at the Safet y Follow -up Visit.  
During the lead-i n period (21/21 day  dosing schedule), bod y temperature (oral), blood 
pressure and pulse will also be measured at Lead -in Day  1.  The vital signs measurements 
at Screening will serve as the baseline measurements for clinical assessment.  For the 
Extension S tudy, bod y temperature, blood pressure and pulse will be measured at Day 1, 
every  4 cy cles (e.g., Cy cle 4 Day  1, C ycle 8 Day 1, etc.), Final Visit and at the Safet y 
Follow -up Visit.
In Phase 1, blood pressure and pulse rate will be measured approximately 3 0 to 
60minutes after stud y drug administration. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
53
Blood pressure and pulse rate will be measured after the subject has been sitting for at 
least 5 minutes on day s study  drug is administered in the clinic.
COVID -19 Pandemic -Related Acceptable Protocol Modifi cations 
Due to the COVID -19 pandemic, subject visits may  be conducted via phone or video 
conference.  In these situations, weight, and vital signs measurements may be performed 
by the subject or caregiver as needed.
Platelet Count
The platelet count measu rement obtained on C ycle 1 Day  1 (pre -dose) will serve as the 
baseline for clinical assessment for the 14/21 day dosing schedule.  The platelet count 
measurement obtained on L ead-in Day  1 (pre -dose) will serve as the baseline for clinical 
assessment for th e 21/21 day  dosing schedule with lead -in period.
If platelet count on an y given day  is less than 50,000/mm3, additional platelet counts 
should be performed every day  or at the discretion of the investigator.
If a platelet transfusion is deemed necessary, a post-transfusion platelet count should be 
obtained within 10 to 60 minutes.
Platelet counts < 25,000/mm3should be confirmed the same day b y manual reading and a 
separate peripheral draw.  Additional platelet counts will be obtained from a subject if 
ABT -263 is either held or interrupted per the management guidelines in Section 6.7.1 and 
Section 6.7.2.
All platelet count measurements obtained during Cy cle 1 through C ycle 4 in the Phase 1 
portion of the study  will be either entered immediately  on the eCRF or faxed to the 
Oncology  Safet y Management Team within 24 hours of report availability  via the contact 
information provided in Section 6.5. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
54
COVID -19 Pandemic -Related Acceptable Protocol Modifications 
If travel restrictions or other cha nges in local regulations in light of the COVID -19 
pandemic prevent the subject from having blood drawn for laboratory  testing at the stud y 
site, if possible, arrange for subjects to have laboratory work done at a local lab, hospital, 
or other facility . Local lab results should be obtained along with reference ranges and 
kept within the subjects' source documentation. Local lab results should be reviewed b y 
the investigator as soon as possible. If laboratory  samples cannot be obtained, study  drug 
administration may  be continued provided the investigator has reviewed all prior 
laboratory  results and confirms and discusses with the subject that there is no safet y 
concern for the subject to continue use of the study drug in the absence of current labs. 
The subject should be scheduled for laboratory  draws as soon as feasible within 14 day s 
from the scheduled visit.
The platelet count schedule of assessment may  be modified as information is obtained 
regarding the expected decrease in platelets in response to s tudy drug administration.  
This will be based upon discussion between the investigator and the AbbVie Medical 
Monitor.
Platelet count assessments will be performed stat and assessed b y the investigator prior to 
study  drug administration as follows:
Phase 1 –14/21 Day Dosing Schedule:
Screening
Cycle 1:
●Days 1, 2, 3, 4, 5, 6, 8, 14 and 16 
●Platelet counts performed in Cy cle 1 can be obtained within 24 hours prior to 
the visit, except on Day s 1 and 14 when platelet counts are required at all of 
the pharmacok inetic sampling time points as indicated in Table 4and Table 5.
●As needed 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
55
Subsequent Cycles:
●Days 1, 3, 5, 8 and 16
●As needed
●If the investigator and the AbbVie Medical Monitor jointly  agree that platelet 
counts through C ycle 4 have been stable, then the frequency of platelet counts 
in Cy cle 5 and bey ond may  be decreased to Day  1 of each cy cle and as needed.
Final Visit and Safety Follow -up Visit
For the Extension Study , platelet count assessments will be performed at Day 1, every  
4cycles (e.g., Cy cle 4 Day  1, C ycle 8 Day  1, etc.), Final Visit and at the Safety  Follow -up 
Visit.
Phase 1 –21/21 Day Dosing Schedule:
Screening
During the lead- in period, the following platelet counts will be obtained:
●Lead -in Day s 1, 2, 3, 5 and 7
●Daily  if lead -in period extends bey ond Day  7 (i.e., L ead-in Days 8- 14)
Cycle 1:
●Days 1, 2, 3, 5, 8, 14 and 16
●Platelet counts performed in Cy cle 1 can be obtained within 24 hours prior to 
the visit, except on Day s 1 and 14 when platelet counts are required at all of 
the pharmacokinetic sampling time points as indicated in Table 4.
●As needed
Subsequent Cycles:
●Weekly 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
56
●As needed
●If the investigator and the AbbVie Medical Monitor jointly  agree that platelet 
counts through C ycle 4 have been stable, then the frequency of platelet counts 
in Cy cle 5 and bey ond may  be decreased to Day  1 of each cy cle and as needed.
Final Visit and Safety Follow -up Visit
For the Extension Study , platelet count assessments will be performed at Day 1, every  
4cycles (e.g., Cy cle 4 Day  1, C ycle 8 Day  1, etc.), Final Visit and at the Safety  Follow -up 
Visit.
Phase 2a:
Screening
During the lead- in period, the following platelet counts will also be obtained:
●Lead -in Day s 1, 2, 3, 5 and 7
●Daily  if lead -in period extends bey ond Day  7 (i.e., L ead-in Days 8 -14)
Cycle 1:
●Days 1, 2, 3, 5, 8 and 15 
●As needed
Subsequent Cycles:
●Weekly
●As needed
●If the investigator and the AbbVie Medical Monitor jointly  agree that platelet 
counts through C ycle 4 have been stable, then the frequency of platelet counts 
in Cy cle 5 and bey ond may  be decreased to Day  1 of each cy cle and as needed. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
57
Final Visit and Safety Follow -up Visit
For the Extension Study , platelet count assessments will be performed at Day 1, every  
4cycles (e.g., Cy cle 4 Day  1, C ycle 8 Day  1, etc.), Final Visit and at the Safety  Follow -up 
Visit.
Lymphocyte Enumeration
Lym phocy te enumeration to identify  B and T cell ly mphocy te subpopulations will be 
performed at Screening, Day  14 of C ycle 1 (14/21 day dosing schedule), Day 15 of 
Cycle1 (21/21 day  dosing sch edule), end of C ycle 4, at the end of every 3rdcycle 
thereafter, and at the Final Visit for each subject.  The lymphocyte enumeration results 
from Screening will serve as the baseline for clinical assessment.  For the Extension 
Study , lymphocy te enumerati on will be performed if deemed necessary  by the 
investigator and at the Final Visit.
All ly mphocy te enumeration results obtained in the Phase 1 portion of the study  will be 
either entered immediately on the eCRF or faxed to the Oncology  Safet y Management 
Team within 24 hours of report availability  via the contact information provided in 
Section 6.5.
ECOG Performance Status
The ECOG performance status39will be assessed at Screening, Day 1 of Cycle 1, weekly 
through the first 2 cy cles, Day  1 of each subsequent cy cle (or within 72 hours prior), at the 
Final Visit and at the Safe ty Follow -up Visit.  For the Extension Study , the ECOG 
performance status will be assessed at the Final Visit and Safety Follow -up Visit.
Grade Description
0 Fully  active, able to carry  on all pre -disease performance without 
restriction.
1 Restricted in phy sically  strenuous activity  but ambulatory  and able to 
carry out work of a light or sedentary nature, e.g., light housework, 
office work. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
58
2 Ambulatory  and capable of all self -care but unable to carry  out an y work 
activities.  Up and about more than 50% of waking hours.
3 Capable of onl y limited self -care, confined to bed or chair more than 
50% of waking hours.
4 Completely  disabled.  Cannot carry  on any  self-care.  Totall y confined 
to bed or chair.
During the lead- in period, ECOG performance status will also be assessed on L ead-in 
Day 1 (21/21 day  dosing schedule).
The ECOG performance status assessed at Screening will serve as the baseline for clinical 
assessment.
12-Lead Electrocardiogram (ECG) (Phase 1)
A 12 -lead resting ECG will be performed for all subjects in the first 2 cohorts of the study  
at Screening, Day  1 and Day  14 of C ycle 1, Day 1 of each subsequent cycle and at the 
Final Visit.  For subsequent cohorts, an ECG will be performed at Screening, Day  1 and 
Day 14 of C ycle 1, Day 1 and Day 14 of Cycle 3 and at the Final Visit.  For the Extension 
Study , a 12 -lead resting ECG will be performed at the Final Visit.
If necessary , the C ycle 1 Day  14 and C ycle 3 Day 14 ECGs may be performed within 
3days prior to Day  14.  During the lead -in period, a n ECG will also be performed on 
Lead -in Day  1.  The test results will be assessed for each subject on an ongoing basis b y 
the AbbVie Medical Monitor and an independent cardiology expert, and monitoring may 
be adjusted depending on the observation of an y clinically  significant findings.
Every  effort should be made to obtain all ECGs approximately  4-8 hours post -dose 
(however, 6 -8 hours post -dose is preferred), and if possible at approximately  the same 
time of day .  If pharmacokinetic data indicates the C maxof parent drug or a major 
metabolite occurs at a time different than this specified range, the timing of the ECG may 
be modified.  A qualified phy sician will sign and date the ECGs, determine if an y findings 
outside normal phy siological variation are clini cally  significant (in consultation with a  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
59
cardiologist, if necessary) and document this on the appropriate CRF.  The original ECG 
tracing with physician assessment will be retained in the subject's records at the study  site 
and a cop y will be faxed to the Oncology  Safet y Management Team within 24 hours of 
report availability  via the contact information provided in Section 6.5.  The ECG 
measurement obtained at Screening will be used to document baseline status of the subject 
so that safet y comparisons can be made, if necessary.  Repeat ECGs will be performed 
whenever clinicall y necessary .
12-Lead Electrocardiogram (ECG) (Phase 2a)
A 12 -lead resting ECG will be performed for all subjects in Phase 2a at the following 
visits:
●Screening
●Cycle 1 Day  15
●Cycle 5 Day  1
●Cycle 9 Day  1
●Final Visit
For the Extension Study , a 12 -lead resting ECG will be performed at the Final Visit.
If necessary , ECGs may  be performed within 3 day sof the visit, except Screening, which 
must be performed within 14 day s prior to study  drug administration.
The test results will be assessed for each subject on an ongoing basis by the AbbVie 
Medical Monitor and an independent cardiology  expert, and monit oring may be adjusted 
depending on the observation of an y clinicall y significant findings.
Every  effort should be made to obtain all ECGs approximately  4-8 hours post -dose 
(however, 6 -8 hours post -dose is preferred), and if possible at approximately  the sa me 
time of day .  If pharmacokinetic data indicates the C maxof parent drug or a major 
metabolite occurs at a time different than this specified range, the timing of the ECG may 
be modified.  A qualified phy sician will sign and date the ECGs, determine if a ny findings  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
60
outside normal phy siological variation are clinically significant (in consultation with a 
cardiologist, if necessary) and document this on the appropriate CRF.  The original ECG 
tracing with phy sician assessment will be retained in the subject' s records at the study  site 
and a cop y will be faxed to the Oncology Safet y Management Team within 5 day s of 
report availability  via the contact information provided in Section 6.5.  The QT, QTc and 
heart rate will be recorded for all ECGs on the eCRF.  The ECG measurement obtained at 
Screening will be used to document baseline status of the subject so that safety 
comparisons can be made, if necessary .  Repeat ECGs w ill be performed whenever 
clinically  necessary .
2D Echocardiogram with Doppler (Phase 1)
A 2D echocardiogram with Doppler will be performed for all subjects in the 
first2cohorts at Screening, Day  1 and Day  14 of Cy cle 1, Day  1 of each subsequent cy cle 
and at the Final Visit.  For subsequent cohorts, an echocardiogram with Doppler will be 
performed at Screening, Day  1 and Day  14 of C ycle 1, Day  1 and Day  14 of Cy cle 3 and 
at the Final Visit.  If necessary , the Cy cle 1 Day  14 and Cy cle 3 Day  14 echocardiogr ams 
may be performed within 3 day s prior to Day  14.  During the lead -in period, an 
echocardiogram will also be performed on Lead -in Day  1.  For the Extension Study , a 
2Dechocardiogram with Doppler will be performed at the Final Visit.
The test results for each subject will be assessed on an ongoing basis by the AbbVie 
Medical Monitor and an independent cardiology  expert, and monitoring may  be adjusted 
depending on the observation of an y clinicall y significant findings.
Every  effort should be made to obtain all echocardiograms approximately  4-8 hours 
post-dose (however, 6 -8 hours post -dose is preferred), and if possible at approximately  the 
same time of day .  If pharmacokinetic data indicates the C maxof parent drug or a major 
metabolite occurs at a time dif ferent than this specified range, the timing of the 
echocardiogram may  be modified.  A qualified phy sician will sign and date the 
echocardiogram reports, determine if an y findings outside normal phy siological variation 
are clinically  significant and docume nt this on the appropriate CRF.  The original  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
61
echocardiogram report with phy sician assessment will be retained in the subject's records 
at the study  site and a copy  will be faxed to the Oncology  Safet y Management Team 
within 24 hours of report availability via the contact information provided in Section 6.5.  
In addition, AbbVie (or designee) will require access to the recording of the 
echocardiogram as necessary .  The echocardiogram results obtained at Screening will be 
used to document baseline status of the subject so that safet y comparisons can be made, if 
necessary .  Repeat echocardiograms will be performed whenever clinicall y necessary .
2D Echoca rdiogram with Doppler (Phase 2a)
A 2D echocardiogram with Doppler will be performed for all subjects in Phase 2a at the 
following visits:
●Screening
●Cycle 1 Day  15
●Cycle 5 Day  1
●Cycle 9 Day  1
●Final Visit
For the Extension Study , a 2D echocardiogram with Do ppler will be performed at the 
Final Visit.
If necessary , ECHOs may  be performed within 3 day s of the visit except Screening, which 
must be performed within 14 day s prior to study  drug administration.
The test results for each subject will be assessed on an ongoing basis by  the AbbVie 
Medical Monitor and an independent cardiology  expert, and monitoring may  be adjusted 
depending on the observation of an y clinicall y significant findings.
Every  effort should be made to obtain all echocardiograms approximately 4-8 hours 
post-dose (however, 6 -8 hours post -dose is preferred), and if possible at approximately  the 
same time of day .  If pharmacokinetic data indicates the C maxof parent drug or a major 
metabolite occurs at a time different than this specified range, the timing of the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
62
echocardiogram may  be modified.  A qualified phy sician will sign and date the 
echocardiogram reports, determine if an y findings outside normal phy siological variation 
are clinically  significant and document this on the appropriate CRF.  T he original 
echocardiogram report with phy sician assessment will be retained in the subject's records 
at the study  site and a copy  will be faxed to the Oncology  Safet y Management Team 
within 5 day s of report availability  via the contact information provide d in Section 6.5.  I n 
addition, AbbVie (or designee) will require access to the recording of the echocardiogram 
as necessary .  The echocardiogram results obtained at Screening will be used to document 
baseline status of the subject so that safet y comparisons can be made, if necessary.  
Repeat echocardiograms will be performed whenever clinicall y necessary.  The sponsor 
(AbbVie) may  choose to introduce performance of serial echocardiograms to be evaluated 
by an independent cardiologist.
Bone Marrow Aspirate and Biopsy
A bone marrow aspirate and biopsy  will be done at Screening (within 21 day s prior to the 
first dose of study  drug) unless a bone marrow aspirate and bio psy was obtained within 
12weeks of starting study drug without intervening treatment and is representative of the 
subject's existing disease.  The bone marrow aspirate and biops y should be performed 
after all other eligibility  criteria have been met, unle ss otherwise obtained through 
standard of care.  Bone marrow aspirates and biopsies performed as standard of care 
throughout the stud y should also be captured on a case report form.
In the Phase 2a portion of the study, a bone marrow aspirate/biops y will b e performed at 
the end of C ycle 8 (for all subjects regardless of response) if the subject is continuing to 
receive ABT- 263.
If a subject meets all the clinical and laboratory  criteria for a complete remission (CR), a 
bone marrow aspirate and biopsy  should be performed at least 2 months after the criteria 
are first met in order to confirm a CR.  I n the Phase 2a portion of the stud y, a bone 
marrow aspirate and biopsy  should be performed at least 2 months after the IWCLL  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
63
updated NCI -WG (2008) criteria are fir st met and 2 months after NCI -WG (1996) criteria 
are first met in order to confirm a CR.
Computed Tomography (CT) Scans and Magnetic Resonance Imaging (MRI)
A CT scan of involved anatomic regions (or MRI, if medically indicated) will be done at 
Screening ( within 21 days prior to the first dose of study  drug).  CT scans and MRI s 
performed as standard of care throughout the study should also be captured on a case 
report form.
Phase 1
If a subject meets all the clinical and laboratory  criteria for a complete r emission (CR) or 
a partial remission (PR), a CT scan should be performed at least 2 months after the criteria 
are first met in order to confirm a CR or PR.
Phase 2a
If a subject meets all the clinical and laboratory  criteria for a complete remission (CR) o r 
a partial remission (PR), a CT scan should be performed at least 2 months after the criteria 
are first met in order to confirm a CR or PR.
Tumor Assessments
Analy sis of peripheral blood, phy sical examination, bone marrow aspirate and biopsy , 
CTscan of i nvolved anatomic regions and MRI (if medically  indicated), will be utilized 
for disease assessment as described above.
Phase 1
Subjects will be evaluated against the I WCLL updated NCI -WG (January  2008) criteria31
(physical examination/CT/MRI ) at the end of C ycle 2, the end of C ycle 4, end of every 
4cycles through C ycle 20 (i.e., C8, C12, C16, C20), end of every 8 cycles thereafter 
(i.e., C28, C36, C4 4. . .) and at the Final Visit.  For the Extension Study , subjects will be 
evaluated against the I WCL L updated NCI -WG (January  2008) criteria (phy sical  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
64
examination/CT/MRI ) at the Final Visit.  Anal ysis of peripheral blood will be evaluated 
against the NCI -WG criteria for tumor response assessment on Day  1 (pre -dose) of the 
following cy cle for every tumor assessment.  For example, when a subject completes 
Cycle 2, the laboratory  values from Day  1 of C ycle 3 (pre -dose) will be used to assess 
tumor response.
The tumor assessment performed at Screening will serve as the baseline for clinical 
assessment.  Assessments for tumor response will be repeated at least 2 months after 
NCI-WG criteria for complete remission (CR or CRi) are first met.  Assessments for 
tumor response will be repeated at least 2 months after criteria for a partial remission (PR) 
are first met.  Response criteria will be assessed while subjects continue treatment with 
ABT -263.  Response criteria definitions are outlined in Section 5.3.3.1 .
Phase 2a
Subjects will be evaluated against the NCI -WG (1996) criteria30andthe IWCLL updated 
NCI-WG (January  2008) criteria31(physical examination/CT/MRI ) at the end of Cy cle 2, 
the end of C ycle 4, end of every 4 cycles through Cycle 20 (i.e., C8, C12, C16, C20), end 
of every  8 cy cles thereafter (i.e., C28, C36, C44. . .) and at the Final Visit.  For the 
Extension Study , subjects will be evaluated against the NCI -WG (1996) criteria and the 
IWCLL updated NCI -WG (January  2008) criteria (ph ysical examination/CT/MRI ) at the 
Final Visit.  Analysis of peripheral blood will be evaluated against the NCI- WG criteria 
for tumor response assessment on Day  1 (pre -dose) of the following cy cle for every  tumor 
assessment.  For example, when a subject com pletes Cy cle 2, the laboratory  values from 
Day 1 of C ycle 3 (pre -dose) will be used to assess tumor response.
The tumor assessment performed at Screening will serve as the baseline for clinical 
assessment.  Assessments for tumor response will be repeated 2 months after NCI -WG 
(1996) criteria for complete remission (CR) are first met and/or at least 2 months after the 
IWCLL updated NCI -WG (2008) criteria for complete remission (CR or CRi) are 
firstmet.  Assessments for tumor response will be repeated at lea st 2 months after criteria 
for a partial remission (PR) are first met.  Response criteria will be assessed while  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
65
subjects continue treatment with ABT- 263.  Response criteria definitions are outlined in 
Section 5.3.3.1 .
Disease Progression Assessment (Extension Study)
Subjects should be evaluated for disease progression at a minimum of every 4 cy cles and 
as deemed appropriate by  the investigator per standar d of care for tumor assessments.  At 
each visit, the investigator should assess whether or not there is evidence of disease 
progression and record the date of progression on the paper Case Report Form if 
applicable.  If a CT scan, MRI , or bone marrow aspir ate or biops y is performed per 
standard of care, the data should be recorded on the appropriate paper Case Report Form.  
Subjects exhibiting disease progression should be discontinued from the study per 
Section 5.4.1.
Pregnancy Test
For female subjects of childbearing potential, the local reference laboratory will perform a 
serum pregnancy  test at Screening and a urine pregnancy  test before dosing on C ycle 1 
Day 1 (14/21 day  dosing schedule) or Lead -in Day 1 (21/21 day  dosing schedule), if it has 
been > 7 day s since obtaining the serum pregnancy  test results.  The test results must be 
reviewed and determined to be negative prior to dosing.
Subjects considered not of c hildbearing potential must be documented as being surgicall y 
sterile or post -menopausal (for at least 1 y ear).
Survival (Phase 2a)
Survival information (i.e., the date and cause of death, post -treatment cancer therapies, 
etc.) will be collected at 3 month intervals after the last study visit for a period of 2 years 
after the subject has discontinued from the study.  I n Protocol Amendment #12 this 
information will be no longer collected. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
66
Clinical Laboratory Tests
Phase 1
In the Phase 1 portion of the study , local laboratories will be utilized to process and 
provide results for the clinical laboratory tests.  Subjects who move into the Extension 
Study  from Phase 1 will continue to use local laboratories for the clinical laboratory  tests.  
The principal investi gator or sub -investigator will review, initial and date all laboratory  
results.  The laboratory  test results will be collected on the electronic Case Report Forms.  
The laboratory  test results from the Extension Study  will be collected on paper Case 
Report Forms.
Hematology , chemistry  and urinaly sis samples will be collected at Screening, C ycle 1 
Day 1, Cy cle 1 Day s 2 and 3 (chemistry  and hematology  only), weekl y through the 
first2cycles, Day  1 of each subsequent cy cle (or within 72 hours prior), at the F inal Visit 
and at the Safet y Follow -up Visit.
For the Extension Study , hematology  and chemistry  will be collected at Day  1, every  
4cycles (e.g., Cy cle 4 Day  1, C ycle 8 Day  1, etc.), Final Visit and at the Safety  Follow -up 
Visit.
During the lead- in period, hematology , chemistry  and urinal ysis samples will also be 
collected on Lead- in Day 1 and Lead -in Day s 2 and 3 (chemistry and hematology  only).
For an y subjects who are at high risk for tumor lysis syndrome (TL S) during C ycle 2 and 
beyond, additional sampl es for hematology  and chemistry  may  be collected as per the 
management guidelines in Section 6.7.4.  ANC ≥ 500/µL  and < 1,000/µL should be 
monitored at an increased frequency  at the discretion of the investigator.  Grade 2 
chemistry  labs should be monitored at an increased frequency  at the discretion of the 
investigator.
The laboratory  test results from Screening (except platelet count) will serve as the 
baseline for clinical assessment. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
67
All laboratory  measurements obtained through Day  1 of C ycle 2 in the Phase 1 portion of 
the study  will be either entered on the eCRF or faxed to the Oncology  Safety  Management 
Team within 24 hours of report availabilit y via the contact information provided in 
Section 6.5.
Phase 2a
Hematology , chemistry  and urinaly sis samples will be collected at Screening, C ycle 1 
Day 1, Cy cle 1 Days 2 and 3 (chemistry  and hematology  only), weekl y through the 
first2cycles, Day  1 of each subsequent cy cle (or within 72 hours prior), at Final Visit and 
at the Safet y Follow -up Visit.
For the Extension Study , hematology  and chemistry  will be collect ed at Day  1, every  
4cycles (e.g., Cy cle 4 Day  1, C ycle 8 Day  1, etc.), Final Visit and at the Safety  Follow -up 
Visit.
During the lead- in period (21/21 day  dosing schedule), hematology , chemistry  and 
urinaly sis samples will also be collected on Lead -in Day 1 and Lead- in Days 2 and 3 
(chemistry  and hematology  only).
For an y subjects who are at high risk for tumor lysis syndrome (TL S) during C ycle 2 and 
beyond, additional samples for hematology  and chemistry  may  be collected as per the 
management guidelines i n Section 6.7.4.  ANC ≥ 500/µL  and < 1,000/µL should be 
monitored at an increased frequency  at the discretion of the investigator.  Grade 2 
chemist ry labs should be monitored at an increased frequency  at the discretion of the 
investigator.
Local laboratories will be utilized in Phase 2a to process and provide results for the 
hematology  samples.  The principal investigator or sub -investigator will rev iew, initial 
and date all laboratory  results.  The hematology  test results will be collected on the 
electronic Case Report Forms.  All other (i.e., l ymphocy te enumeration, chemistry  and 
urinaly sis) clinical laboratory  samples obtained in Phase 2a will be a ssessed using a 
certified central laboratory (Quest Diagnostics).  The central laboratory for this study  will  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
68
provide instructions regarding the collection, processing and shipping of these samples.  
All laboratory  samples, except hematology samples, shoul d be shipped to the central 
laboratory .
Starting with Protocol Amendment 13, subjects in the Extension Study  from Phase 2a will 
use local laboratories for all clinical laboratory samples.  
The local laboratory  test results from the Extension Study  will be collected on paper Case 
Report Forms.
A certified local reference laboratory may  perform chemistry  tests for immediate subject 
management in Phase 2a; however split or concurrent samples must be drawn and sent to 
the central laboratory  for anal ysis.
Local laboratories will be utilized to process and provide results for all platelet counts.  
Platelet count results must be available and reviewed prior to dosing.  The laboratory test 
results from Screening (except platelet count) will serve as the baseline fo r clinical 
assessment. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
69
Table 7. Clinical Laboratory Tests
Hem atology Clinical Che mistrya,bUrinalysis
Hem atocrit
Hem oglobin
Red blood cell (RBC) count
White blood cell (WBC) count
Neutrophils
Bands
Lymphocytes
Monocytes
Basophils
Eosinophils
Platelet count (estimate not
acceptable)
Prothrombin time (PT)
Activated partial thromboplastin 
time (aPTT)
Mean platelet volume (MPV)
Mean corpuscular hemoglobin 
(MCH)
Mean corpuscular volume 
(MCV)
Mean corpuscular hemoglobin 
concentration (MCHC)
Reticulocyte countBlood urea nitrogen (BUN)
Creatinine
Total bilirubin
Serum glutamic -pyruvic
transaminase (SGPT/ALT)
Serum glutamic -oxaloacetic
transaminase (SGOT/AST)
Alkaline phosphatase
Sodium
Potassium
Calcium
Inorganic phosphorus
Uric acid
Cholesterol
Total protein
Glucose
Triglycerides
Albumin
Lactate dehydrogenase (LDH)
Magnesium
Chloride
Bicarbonate
Amylase (only at Screening, 
  C1D14 or C1D15 and Final Visit)
Lipase (only at Screening, C1D14 
  or C1D15 and Final Visit)Specific gravit y
Ketones
pH
Protein
Blood
Glucose
Microscopic examination (as 
indicated)
a. Chemistry tests should be obtained under fasting conditions if possible.
b. Triglycerides will only be performed at Screening and Final Visit.
For an y laboratory  test value outside the reference range that the investigator considers to 
be clinically  significant:
●The investigator may  repeat the test to verify  the out -of-range value.
●The investigator will follow the out -of-range value to a satisfactory  clinical 
resolution.
●A laboratory  test value that requires a subject to be discontinued from the 
study  or requires a subject to receive treatment will be recorded as an adverse 
event. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
70
Assignment of Subject Numbers
Phase 1
The results of all screening and pre -dose Study  Day  1 (or Lead -in Day  1 for lead -in 
period) evaluations must be within clinically  acceptable limits (per inclusion criteria in 
Section 5.2.1 ), upon review b y the investigator with the concurrence of the AbbVie 
Medical Monitor or designee, before a subject can be administered stud y drug.  Screening 
results will be faxed to the Clinical Team Leader as indicated in Section 7.0.  Subjects 
will not be enrolled in the study  if laboratory  or other screening results are not within 
clinically  acceptable limits.  Subjects who meet the inclusion criteria and do not meet an y 
of the exclusion criteria will be assigned a unique subject nu mber b y AbbVie, as 
described in Section 5.5.3 .
Phase 2a
The results of all screening and pre -dose Lead -in Day  1 evaluations must be within 
clinically  acceptable li mits (per inclusion criteria in Section 5.2.1), upon review by  the 
investigator before a subject can be administered study  drug.  Subjects will not be enrolled 
in the study  if laboratory  or other screening results are not within clinicall y acceptable 
limits.  Subjects who meet the inclusion criteria and do not meet an y of the exclusion 
criteria will be assigned a unique subject number by AbbVie, as described in 
Section5.5.3.
Extension Study
Subjects who meet the inclusion criteria and do not meet an y of the exclusion criteria 
(refer to Section 5.2) and who continue in the Extension Study  will retain the subject 
number that was assigned in the Phase 1 or Phase 2a portion of the study.
5.3.1.2 Meals and Dietary  Requirements
Subjects will self -administer ABT -263 orall y once daily (QD) within 30 minutes 
following the completion of breakfast, unless otherwise specified.  Subjects may not  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
71
consume grapefruit or grapefruit products within the 3 -day period prior to initial study  
drug administration and until the last treatment cycle is completed due to possible CYP3A 
mediated metabolic interaction.
5.3.1.3 Blood Samples for Pharmacogenetic A nalyses
DNA
All Sites
Phase 1 and 2a:  Optional
One 4 mL blood sample for DNA isolation will be collected at Screening (pre ferred) or 
prior to treatment on Lead- in Day  1 (21/21 day  dosing schedule) or C ycle 1 Day 1 
(14/21 day dosing schedule) from each subject who consents to provide samples for 
pharmacogenetic anal ysis.  The collection, processing, and shipping of the specime ns 
should be performed as described in the M06 -873 laboratory  manual.
Samples will be shipped to AbbVie for DNA extraction and long -term storage.  AbbVie 
or a designated laboratory will store the DNA samples in a secure storage space with 
adequate measures to protect confidentialit y.
If pharmacogenetic testing is performed, results from individual subjects will be kept 
coded and confidential.  Samples will be coded so that subject identities will not be 
available to the scientists conducting the genot yping analysis.  The samples will be 
retained while research on ABT- 263 or Bcl -2 inhibitors continues.  Upon completion of 
the research, the samples will be destroy ed. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
72
5.3.1.4 Specimens for Pharmacody namic A nalyses
Blood Collection for Proteomics
All Sites
Phase 1:  Opt ional
Approximately  4 mL of blood will be collected by  venipuncture into one 4 mL  EDTA 
(purple top) tube at Screening (preferred) or prior to treatment on Day 1, C ycle 1 Day 14, 
Cycle 2 Day  14, and an additional sample will be prepared at Final Visit, incl uding the 
Final Visit of the Extension Study , from all subjects who consent to participate.  The 
collection, processing, and shipping of the specimens should be performed as described in 
the M06- 873 laboratory  manual.  The complete process of centrifugatio n, transfer to 
cryovial, and freezing should be accomplished in less than 1 hour from blood draw.
Phase 2a:  Required
Approximately  6 mL of blood will be collected by  venipuncture into one 6 mL  EDTA 
(purple top) tube at Screening (preferred) or prior to treatment on Day  1, C ycle 1 Day 15, 
Cycle 2 Day  15 and an additional sample will be prepared at Final Visit.  Including the 
Final Visit of the Extension Study .  In Protocol Amendment #12 this sample will no 
longer be required to be collected from subjects in the extension study .  The collection, 
processing, and shipping of the specimens should be performed as described in the M06 -
873 laboratory  manual.  The complete process of centrifugation, transfer to cry ovial, and 
freezing should be accomplished in less than 1 hour from blood draw.
Blood Collection and Storage for Bcl -2 Family Analysis
All Sites
Phase 1 and 2a:  Required
Approximately  2 mL of blood will be collected by  venipuncture into pediatric EDTA 
tubes at Screening (preferred) or prior to treatment on Lead-in Day  1 (21/21 day  dosing 
schedule) or C ycle 1 Day 1 (14/21 day  dosing schedule), C ycle 1 Day 14 (14/21 day  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
73
dosing schedule), or C ycle 1 Day  15 (21/21 day  dosing schedule), end of Cycle 4, and 
Final Visit.  I ncluding the Final Visit of the Extensi on Study .  In Protocol 
Amendment #12 this sample will no longer be required to be collected from subjects in 
the extension study .
The collection, processing, and shipping of the specimens should be performed as 
described in the M06- 873 laboratory  manual.  It is preferable for the process of inversion, 
fixing, mixing and freezing occur within 30 minutes of the blood draw.
ACD Tube of Blood for ZAP70/CD38 -Ship Day of Draw
US Sites Only
Phase 1:  Optional
Phase 2a:  Required
Approximately  6 mL of blood will be collected by venipuncture into appropriately labeled 
6 mL  ACD tube (y ellow top) at Screening (preferred) or prior to treatment on L ead-in 
Day 1 (21/21 day  dosing schedule) or C ycle 1 Day 1 (14/21 day  dosing schedule), end of 
Cycle 4 and an additional samp le will be prepared at Final Visit.  The specimen must be 
shipped Monday -Thursday  and on the same day  of collection.  The collection, processing, 
and shipping of the specimens should be performed as described in the M06 -873 
laboratory  manual.
Heparin Tube of Blood for CGH/FISH -Ship Day of Draw
Australian Sites and US Sites
Phase 1 and 2a:  Required
Approximately  6 mL of blood will be collected by  venipuncture into appropriately  labeled 
6 mL  heparin tube (green top) at Screening (preferred) or prior to treat ment on L ead-in 
Day 1 (21/21 day  dosing schedule) or C ycle 1 Day 1 (14/21 day  dosing schedule), end of 
Cycle 4 and at Final Visit including the Final Visit of the Extension Study .  In Protocol 
Amendment #12 this sample will no longer be required to be coll ected from subjects in  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
74
the extension study .  The collection, processing, and shipping of the specimens should be 
performed as described in the M06- 873 laboratory manual.
Bone Marrow Aspirate/Biopsy Collection
All Sites
Phase 2a Only:  Required
Bone Marrow Aspirate
Bone marrow aspirates should be drawn at baseline into a green top heparin tube in 
conjunction with the diagnostic biopsy  for all subjects in Phase 2a at Screening and at the 
end of Cy cle 8 if the subject is continuing to receive ABT -263.  If a bo ne marrow aspirate 
was obtained within 12 weeks of starting stud y drug without intervening treatment and is 
representative of the subject's existing disease, a Screening sample does not need to be 
obtained.  A portion of the aspirate may  be processed accor ding to the institutional 
standard procedures (for tumor assessment) and a portion must be processed according to 
the M06- 873 lab manual for pharmacod ynamic analysis of tumor cells.  If a procedure 
other than what is described in the M06 -873 lab manual is used, a description of the 
procedure should be provided to AbbVie.
Bone Marrow Core Biopsy
If bone marrow aspirate is not collected, a bone marrow core biops y ma y be obtained at 
Screening and the end of Cy cle 8 for Phase 2a.  The core may  be processed acco rding to 
the institutional standard procedures or per the M06 -873 lab manual.  If a procedure other 
than what is described in the M06- 873 lab manual is used, a description of the procedure 
should be provided to AbbVie. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
75
Bcl-2/Bim Ratio- Ship Day of Draw
Australian Sites and US Sites
Phase 1 and 2a:  Optional
Approximately  4 mL of blood will be collected by  venipuncture into an appropriatel y 
labeled 4 mL heparin tube (green top) at Screening (preferred) or prior to treatment on 
Lead -in Day  1 (21/21 day  dosing schedule) or Cycle 1 Day 1 (14/21 day dosing schedule), 
end of Cy cle 4 and Final Visit.  The specimen must be shipped Monday -Thursday  and on 
the same day  of collection.  The collection, processing, and shipping of the specimens 
should be performed as descr ibed in the M06- 873 laboratory  manual.
Assays for in vivo Apoptosis of CLL Cells -Ship Day of Draw
Australian Sites Only
Phase 1 and 2a:  Optional
Approximately  6 mL of blood (and/or 1 mL  of bone marrow aspirate, if patient is 
undergoing a bone marrow biopsy ) will be collected by  venipuncture (or aspirate) into an 
appropriatel y labeled 6 mL  heparin tube (green top) at Screening (preferred) or prior to 
treatment on Lead -in Day  1 (21/21 day  dosing schedule) or C ycle 1 Day 1 (14/21 day 
dosing schedule), C ycle 1 Day  7 or C ycle 1 Day 8, Cycle 1 Day 14 or C ycle 1 Day  15, 
Cycle 2 Day  1, C ycle 2 Day 7 or C ycle 2 Day 8, and Cycle 2 Day 14 or Cycle 2 Day 15.  
The collection, processing, and shipping of the specimens should be performed as 
described in the M06- 873 laboratory  manual.
Assays for in vitro Sensitivity of CLL Cells -Ship Day of Draw
Australian Sites Only
Phase 1 and 2a:  Optional
Approximately  10 mL of blood (and/or 1 mL  of bone marrow aspirate, if patient is 
undergoing a bone marrow biopsy ) will be colle cted by  venipuncture (or aspirate) into an  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
76
appropriatel y labeled 10 mL  EDTA tube (pink top) at Screening (preferred) or prior to 
treatment on Lead -in Day  1 (21/21 day  dosing schedule) or C ycle 1 Day 1 (14/21 day 
dosing schedule), C ycle 1 Day 14 or C ycle 1 Day 15 and Cy cle 3 Day  1 (prior to 
treatment).  The collection, processing, and shipping of the specimens should be 
performed as described in the M06- 873 laboratory manual.
Table 8. Schedule of Biomarker Sample Collection (Phase 1)
ScreeningaC1D7 C1D14 C2D1 C2D7 C2D14 C3D1End of 
C4Final 
Visitf
Pharmacogeneticsb4 mL
Proteomics -plasmab4 mL 4 mL 4 mL 4 mL
CD38/ZAP 70b,c6 mL 6 mL
Bcl-2 Family analysis 2 mL 2 mL 2 mL 2 mL
CGH/FISHd6 mL 6 mL
Bcl-2/Bim Ratiob,d4 mL 4 mL
Markers of 
apoptosisa,b,e6 mL 6 mL 6 mL 6 mL 6 mL 6 mL
In vitro sensitivitya,b,e10 mL 10 mL 10 mL
C = Cycle; D = Day
a. Screening samples not collected at the time of screening should be collected pre -dose on Lead -in Day 1 (21/21 day 
dosing) or Cycle 1 Day 1 (14/21 day dosing), however, every effort should be made to collect at screening to 
decrease the blood volumes obtained on Lead -in Day 1/Cycle 1 Day 1.
b. Blood collection is optional in the Phase 1 port ion of the study.
c. Study will only be performed in the US.
d. Studies will only be performed in US and Australia.
e. Studies will only be performed in Australia.
f. For subjects who continue in the Extension Study, the Final Visit procedures will be perf ormed upon completion of 
the Extension Study.  Refer to Appendix Gfor the Schedule of Assessments for subjects enrolled in the Extension 
Study. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
77
Table 9. Schedule of Biomarker Sample Collection (Phase 2a)
ScreeningaC1D7 C1D15 C2D1 C2D7 C2D15 C3D1End of 
C4End of 
C8Final 
Visith
Pharmacogeneticsb4 mL
Proteomics -plasma 6 mL 6 mL 6 mL 6 mL
CD38/ZAP 70c6 mL 6 mL
Bcl-2 Family 
analysis2 mL 2 mL 2 mL 2 mL
CGH/FISHd6 mL 6 mL 6 mL
Bcl-2/Bim Ratiob,d4 mL 4 mL
Markers of 
apoptosisa,b,e6 mL 6 mL 6 mL 6 mL 6 mL 6 mL
In vitro 
sensitivitya,b,e10 mL 10 mL 10 mL
Tumor cells bone 
marrow aspirate2 mLf2 mLg
C = Cycle; D = Day
a. Screening samples not collected at the time of screening should be collected pre -dose on Lead -in Day 1, however, 
every effort should be made to collect at Screening to decrease the blood volumes obtained on Lead -in Day 1.
b. Blood collection is optional in the Phase 2a portion of the study.
c. Study will only be performed in the US.
d. Studies will only be performed in US and Australia.
e. Studies will only be performed in Australia.
f. If a bone marrow aspirate was obtained within 12 weeks of starting study drug without intervening treatment and is 
representative of the subject's existing disease, a Screening sample does not need to be obtained.
g. A bone marrow aspirate/biopsy will be performed at the e nd of Cycle 8, if the subject is continuing to receive 
ABT-263.
h. Prior to Amendment 12, subjects who continue in the Extension Study, the Final Visit procedures were performed 
upon completion of the Extension Study, collection of these specimens are no l onger required.  Refer to 
Appendix Gfor the Schedule of Assessments for subjects enrolled in the Extension Study.
5.3.1.5 Disposition of Samples for 
Pharmacogenetic/Pharm acodynamic A nalyses
The blood samples for pharmacogenetic and pharmacod ynamic anal yses will be shipped 
from the study  site to AbbVie or designate according to instructions from AbbVie.  The 
samples should be labeled with the drug number name, type of sample (e.g., blood), the 
protocol number, the subject number, the stud y cycle and day and/or collection date.  An  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
78
inventory  of the samples included will accompan y the package.  Arrangements will be 
made with AbbVie for the shipment of stored samples to: 
Attn:   AbbVie Sample Receiving
c/o:  Delivery  Services
1150 S. Northpoint Blvd.
Waukegan, IL  60085
Phone: (847) 937- 0889
Fax: (847) 938- 9898
Email: sample.receiving@abbvie.com
5.3.2 Drug Concentration Measurements
5.3.2.1 Collection of Sa mples for A nalysis
Blood Samples for ABT -263 Assay
Phase 1 –14/21 Day Dosing Schedule
Blood samples for ABT -263 assay  will be collected by  venipuncture into 3 mL  evacuated 
potassium EDTA -containing collection tubes during C ycle 1 at the following times:  
Day 1, pre -dose (0 hour) and at 2, 4, 6, 8 and 24 (C1D2 pre -dose) hours after dosing; 
Day 14, pre -dose (0 hour) and at 2, 4, 6 and 8 hours after dosing.  Sufficient blood will be 
collected to provide approximately  1 mL plasma from each sample.  A total of 11 blood 
samples (approximately  33 mL ) will be collected per subject for pharmacokinetic anal ysis 
during C ycle 1.  Blood samples will be collected in subsequent cycles as follows:  
pre-dose on C ycle 2, Days 3, 8 and 14; Cy cle 3, Day  1 (4 -8 hours post -dose immediately  
after ECG) and Day  14 (pre -dose and 4- 8 hours post -dose immediately  after ECG).  
Additional blood samples will be collected pre -dose (0 hour) on Day  14 of Cy cles 6, 9, 12 
and 15.  See Table 4and Table 5for a schedule of the blood collection for ABT -263 
assay . 

ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
79
Phase 1 -21/21 Day Dosing Schedule
Blood samples for ABT -263 assay  will be collected by  venipuncture into 3 mL  evacuated 
potassium EDTA -containing collection tubes during C ycle 1 at the following times:  
Day 1, pre -dose (0 hour) and at 2, 4, 6, 8 and 24 (C1D2 pre -dose) hours after dosing; 
Day 14, pre -dose (0 hour ) and at 2, 4, 6 and 8 hours after dosing.  Sufficient blood will be 
collected to provide approximately  1 mL plasma from each sample.  A total of 11 blood 
samples (approximately  33 mL ) will be collected per subject for pharmacokinetic anal ysis 
during C ycle 1.  Blood samples will be collected in subsequent cy cles as follows:  
pre-dose on C ycle 2, Days 3, 8 and 14; Cy cle 3, Day  1 (4 -8 hours post -dose immediately  
after ECG) and Day  14 (pre -dose and 4- 8 hours post -dose immediately  after ECG).  
Additional blood samples will be collected pre -dose (0 hour) on Day  1 of Cy cles 6, 9, 12 
and 15.
See Table 4and Table 5for a schedule of the blood collection for ABT- 263 assay .
Phase 2a
Blood samples for ABT -263 assay  will be collected by  venipuncture into 3 mL  evacuated 
potassium EDTA -containing collection tubes during C ycle 1 at the following t imes:  
Day 15 (pre -dose [0 hour] and 4- 8 hours post -dose immediately  after ECG).  Sufficient 
blood will be collected to provide approximately 1 mL  plasma from each sample.  A total 
of 2 blood samples (approximately  6 mL) will be collected per subject for 
pharmacokinetic anal ysis during C ycle 1.  Additional blood samples will be collected 
pre-dose (0 hour) on C ycle 3 Day  1 and pre -dose (0 hour) and 4 -8 hours post -dose 
(immediately  after ECG) on Day  1 of Cycles 5 and 9.
See Table 6for a schedule of the blood collection for ABT -263 assay .
Phase 1, Phase 2a and Extension Study
In addition, serial pharmacokinetic samples will be obtained from subjects who develop 
Grade 4 thrombocy topenia (< 25,000/mm3).  The first pharmacokinetic sample should be 
collected as soon as possible after determination of the first Grade 4 thrombocytopenia  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
80
event and then 24 and 48 hours thereafter.   Starting with Protocol Amendment 13, PK 
samples w ill NOT be collected.
Blood and plasma samples must be protected from direct sunlight during collection, 
processing and storage.  Immediately  after collection, the blood samples will be inverted 
several times to ensure good mixing of the blood and anticoag ulant, and will be placed in 
an ice bath.
The timing of blood collections will take priority over all other scheduled study activities 
except for dosing.  The order of blood collections will be maintained to the minute such 
that the time intervals relative to the preceding dosing will be the same for all subjects.  
The date and time (to the nearest minute) of each blood sample collection will be recorded 
on the eCRF.  In addition, the date and time (to the nearest minute) of dose and whether or 
not doses were taken within 30 minutes of completing breakfast for the pre -dose (0 hour) 
PK sampling day  and for the 2 day s prior to each PK sampling day  will be recorded on the 
eCRF.  Sites should ensure that the data are captured via source document (e.g., subject
calendar, clinic notes).
5.3.2.2 Handling/Processing of Samples
Blood Samples for ABT -263 Assay
The processing of all pharmacokinetic specimens should be performed as described in the 
M06- 873 laboratory  manual.
5.3.2.3 Disposition of Samples for A BT-263 A ssay
Samples should be labeled using the labels provided by AbbVie with the drug number 
name, ty pe of sample (plasma), the protocol number, the subject number, the study  cycle 
and day  and the planned time of sampling relative to dosing.  The frozen plasma samples 
for A BT-263 assay  will be packed in dry  ice sufficient to last during transport and shipped 
from the study  site to AbbVie according to instructions from AbbVie.  An inventory  of 
the samples included will accompan y the package.  Arrangements will be made with 
AbbVie for the shipment of samples to: 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
81
Attn:  AbbVie Sample Receiving
c/o Delivery  Services
1150 S. Northpoint Blvd.
Waukegan, IL  60085
Phone: (847) 937- 0889
Fax: (847) 938- 9898
Email: sample.receiving@abbvie.com
5.3.2.4 Measurem ent Methods
Analysis of Plasma Samples
Plasma concentrations of ABT- 263 will be determined under the supervision of the Drug 
Analy sis Department at AbbVie.
5.3.3 Efficacy  Variables
For the Phase 2a portion of the study , all efficacy  anal yses are exploratory  in nature.  The 
exploratory  efficacy  endpoints include tumor response (determined using NCI -WG 
Criteria), progression free survival (PFS), time to tumor progression (TTP), overall 
survival (OS), duration of overall response and ECOG performance status.  Analys es of 
these endpoints are described in Section 8.1.3 .
5.3.3.1 NCI-WG Criteria for Tumor Response
Only  subjects with active disease requiring treatment (in the opinion of th e investigator) 
will be enrolled in the study .  Response over the course of therapy  will be evaluated using 
the 1996 National Cancer Institute Working Group Guidelines for Chronic Lymphocytic 
Leukemia (NCI -WG) criteria30and the I nternational Workshop for Chronic Ly mphocy tic 
Leukemia (IWCLL) updated 2008 National Cancer Institute Working Group Guidelines 
(NCI -WG) for Chronic Ly mphocy tic Leukemia crite ria.31  Response criteria will be 
assessed while subjects continue treatment with ABT -263. 

ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
82
5.3.3.1.1 NCI-WG Criteria -1996
Methods of Measurement
Disease res ponse and progression will be assessed by  anal ysis of peripheral blood, clinical 
examination, radiographic techniques when clinically  indicated (e.g., splenomegaly , 
lymphadenopathy ), and bone marrow aspirate and biopsy  (if needed to confirm active 
disease at baseline and to confirm a CR).
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closel y as possible to the 
beginning of treatment and never more than four weeks before the beginning of the 
treatment.
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow -up.
Clinical lesions will only  be considered measurable when they  are superficial (e.g., skin 
nodules and palpable l ymph nodes).  For the case of skin lesions, documentation by color 
photography including a ruler to estimate the size of the lesion is required.
The diameter, in two planes, of the largest palpable nodes in each of the following sites 
should be measured:  cervical, axillary, supraclavicular, inguinal, and femoral.
CT is the preferred method to measure lesions selected for response assessment.  MRI  
may be used if medically indicated (e.g., severe contrast alle rgy).  Conventional CT and 
MRI  should be performed with cuts of 7 mm or less in slice thickness contiguousl y.
For accurate objective response evaluation, ultrasound (US) should not be used to 
measure tumor lesions.  However, US is a possible alternative to clinical measurements of 
superficial palpable l ymph nodes, subcutaneous lesions and thy roid nodules.  US might 
also be useful to confirm the complete disappearance of superficial lesions usually 
assessed b y clinical examination. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
83
Cytology  and histology  can be used to differentiate between partial remission (PR) and 
complete remission (CR) in rare cases (e.g., after treatment to differentiate between 
residual benign lesions and residual malignant lesions in tumor ty pes such as germ cell 
tumors).
Assessment o f response will be performed b y the investigator and documented on the 
appropriate CRF.
Complete Remission (CR) requires all of the following for a period of at least 2 months :
1. Absence of ly mphadenopathy  by physical examination and appropriate 
radiographic techniques.
2. No hepatomegal y or splenomegaly  by physical examination and appropriate 
radiographic techniques.
3. Absence of constitutional sy mptoms.
4. Normal CBC as exhibited by :
●Polymorphonuclear leukocy tes ≥ 1,500/ L.
●Platelets > l00,000/ L.
● Hemoglobin > 11.0 g/dL (untransfused).
5. Bone marrow aspirate and biopsy  should be performed 2 months after clinical and 
laboratory  results demonstrate that all of the requirements above have been met to 
demonstrate that a CR has been achieved.  The marrow sample must be at least 
normocellular for age, with less than 30% of nucleated cells being l ymphocytes.  
Lym phoid nodules should be absent.  If the bone marrow is h ypocellular, a repeat 
determination should be made in 4 weeks.  Samples should be re -reviewed in 
conjunction w ith the prior pathology . 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
84
Partial Remission (PR) requires all of the following for a period of at least 2 months :
1. ≥ 50% decrease in peripheral blood ly mphocy te count from the pretreatment 
baseline value.
2. ≥ 50% reduction in ly mphadenopathy .
3. ≥ 50% reduction in the size of the liver and/or spleen (if abnormal prior to therap y).
In addition one or more of the following criteria must be met:
●Polymorphonuclear leukocy tes ≥ 1,500/ L or 50% improvement over baseline.
●Platelets > l00,000/ L or 50% improvement over baseline.
●Hemoglobin > 11.0 g/dL or 50% improvement over baseline without 
transfusions.
Progressive Disease (PD) requires at least one of the following :
1. ≥ 50% increase in the sum of the products of at least two lymph nodes on 
twoconsecutive determination s 2 weeks apart (at least one node must be ≥ 2 cm); 
appearance of new palpable ly mph nodes.
2. ≥ 50% increase in the size of the liver and/or spleen as determined b y measurement 
below the respective costal margin; appearance of palpable hepatomegal y or 
splenomegaly , which was not previously  present.
3. ≥ 50% increase in the absolute number of circulating l ymphocy tes with at least 
5,000/ L.
4. Transformation to a more aggressive histology  (e.g., Richter's s yndrome or PLL 
with > 55% prol ymphocy tes).
Subjects who have not achieved a CR or a PR, or who have not exhibited PD will be 
considered to have Stable Disease (SD). 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
85
Subjects who meet the criteria above for a CR but exhibit persistent bone marrow 
lymphoid infiltration will be referred to as nodular PRs (nPR).  I n addition, subjects who 
meet the criteria above for a CR but exhibit persistent thrombocytopenia or anemia 
unrelated to disease activity  and attributable to a persistent drug toxicity  will be 
considered PR's.
A summary  of the criteria described above is inclu ded in Table 10. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
86
Table 10. NCI-WG Criteria for Tumor Response (1996) 
CriteriaComplete 
Remission (CR)Nodular Partial 
Remission (nPR)#Partial 
Remission (PR)Progressive 
Disease (PD)
Symptoms Absent Absent Absent or present Not specified
Lymphadenopathy Absent Absent ≥ 50% reduction ≥ 50% increase* or 
new nodes
Hepatomegaly 
and/or 
SplenomegalyAbsent Absent ≥ 50% reduction ≥ 50% increase or 
new hepatomegaly 
and/or 
splenomegaly
Neutrophils/ 
Polymorphonuclear 
Leukocytes 
(109/L)≥ 1.5 ≥ 1.5 ≥ 1.5 or ≥ 50% 
improvement from 
baselineNot specified
Lymphocytes 
(109/L) < 4 < 4 ≥ 50% reduction 
from baseline≥ 50% increase 
with at le ast
5 109/L
Platelets ( 109/L) > 100 > 100 > 100 or ≥ 50% 
improvement from 
baselineNot specified
Hem oglobin (g/dL) 
untransfused> 11 > 11 > 11 or ≥ 50% 
improvement from 
baselineNot specified
Bone Marrow  
Aspirate/BiopsyNormocelluar 
<30% 
lymphocytes; No 
intestinal or 
nodular infiltratesNormocelluar 
<30% 
lymphocytes; 
Nodular infiltratesMay be normal 
(i.e., < 30% 
lymphocytes 
without interstitial 
or nodular 
infiltrates) or 
persistent diseaseNot specified
Other NA NA NA Transformation to 
RS or PLL
NA = not applicable; RS = Richter syndrome; PLL = Prolymphocytic Leukemia (with > 55% prolymphocytes); # = nPR 
is no longer applicable due to the utilization of immunohistochemistry; * = sum of products of at least 2 lymph nodes 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
87
5.3.3.1.2 IWCLL Updated NCI -WG Criteria –2008
Methods of Measurement
Disease response and progression will be assessed by  anal ysis of peripheral blood, clinical 
examination, radiographic techniques to assess splenomegal y, lymphadenopathy  and/or 
bone marrow aspirate and biopsy  toconfirm active disease at baseline and if needed to 
confirm a CR.
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closel y as possible to the 
beginning of treatmen t and never more than 4 weeks before the beginning of the 
treatment.
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow -up.
Clinical lesions will only  be con sidered measurable when they  are superficial (e.g., skin 
nodules and palpable l ymph nodes).  For the case of skin lesions, documentation by color 
photography including a ruler to estimate the size of the lesion is required.
The diameter, in two planes, of the largest palpable nodes in each of the following sites 
should be measured:  cervical, axillary, supraclavicular, inguinal, and femoral.
CT is the preferred method to measure lesions selected for response assessment.  MRI  
may be used if medically indicat ed (e.g., severe contrast allergy).  Conventional CT and 
MRI  should be performed with cuts of 7 mm or less in slice thickness contiguousl y.
For accurate objective response evaluation, ultrasound (US) should not be used to 
measure tumor lesions.  However, U S is a possible alternative to clinical measurements of 
superficial palpable l ymph nodes, subcutaneous lesions and thy roid nodules.  US might 
also be useful to confirm the complete disappearance of superficial lesions usually 
assessed b y clinical examinati on. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
88
Assessment of response will be performed b y the investigator and documented on the 
appropriate CRF.
Complete Remission (CR) requires all of the following for a period of at least 2 months:
1. Absence of clonal l ymphocy tes in the peripheral blood.
2. Absence of significant l ymphadenopath y by physical examination and appropriate 
radiographic techniques.  A CT scan of the abdomen, pelvis and thorax should be 
performed if previously abnormal.  Lymph nodes should not be larger than 1.5 cm 
in diameter.
3. No hepatomeg aly or splenomegaly  by physical examination.  A CT scan of the 
abdomen should be performed at response assessment if found to be abnormal prior 
to the start of study  drug or if phy sical exam is inconclusive at the time of 
evaluation.
4. Absence of constitutional sy mptoms.
5. Normal CBC as exhibited by :
●Polymorphonuclear leukocy tes ≥ 1,500/ L without G -CSF support.
●Platelets > 100,000/ L.
●Hemoglobin > 11.0 g/dL (untransfused or without ery thropoietin support).
Bone marrow aspirate and biopsy  should be performed at least 2 months after clinical and 
laboratory  results demonstrate that all of the requirements above have been met to 
demonstrate that a CR has been achieved.  The marrow should be anal yzed by  flow 
cytometry  and/or immunochemistry  to demonstrate that the marrow is free of clonal 
B-CLL cells.  Note:  cases with residual CLL cells by  conventional flow cy tometry  or 
immunohistochemistry  are defined as a PR.
Subjects who fulfill all the criteria for a CR, but who have persistent anemia, 
thrombocy topenia or neutropenia apparentl y unrelated to CLL, but related to drug toxicity 
should be considered as a different category  of remission, CR with incomplete bone  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
89
marrow recovery  (CRi).  The marrow evaluation should be performed with scrutiny  and 
not show any  clonal infiltrate.  Subjects should be monitored prospectivel y to determine 
whether or not their outcome differs from that of patients with detectable residual di sease 
or with non- cytopenic PR.
Partial Remission (PR) requires at least two of the following for a period of at least 
2months:
1. ≥ 50% decrease in peripheral blood ly mphocy te count from the pretreatment 
baseline value.
2. ≥ 50% reduction in ly mphadenopathy  (assessed by  CT scan):
●In the sum of products of up to 6 ly mph nodes, or
●In one ly mph node diameter if only  a single ly mph node was present at 
baseline.
3. No increase in an y lymph node, and no new enlarged lym ph node.  In small ly mph 
nodes (< 2 cm), an increase of < 25% is not considered to be significant.
4. ≥ 50% reduction in the size of the liver and/or spleen (if abnormal prior to therap y) 
as defined b y CT scan.
In addition one or more of the following criteria must be met:
●Polymorphonuclear leukocy tes ≥ 1,500/ L or 50% improvement over baseline 
without G -CSF support.
●Platelets > 100,000/ L or 50% improvement over baseline.
●Hemoglobin > 11.0 g/dL or 50% improvement over baseline without 
transfusions or ery thropoietin support.
Progressive Disease (PD) requires at least one of the following:
1. Appearance of an y new lesions such as enlarged ly mph nodes (> 1.5 cm), 
splenomegaly , hepatomegal y or other organ infiltrates. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
90
2. ≥ 50% increase in the sum of the products of diameters of multiple nodes
3. ≥ 50% in the greatest det ermined diameter of an y previous site.  A ly mph node of 
1-1.5 cm must increase by  ≥ 50% to a size greater than 1.5 cm in the longest axis.  
A lymph node of more than 1.5 cm must increase to more than 2.0 cm in the 
longest axis.
4. ≥ 50% increase in the size of the liver and/or spleen or the de novo appearance of 
hepatomegal y or splenomegaly.
5. ≥ 50% increase in the absolute number of blood lymphocytes with at least 
5,000 B-lymphocy tes per L.
6. Transformation to a more aggressive histology  (e.g., Richter's s yndrom e or PLL 
with > 55% prol ymphocy tes).
7. Occurrence of cy topenia (neutropenia, anemia or thrombocy topenia) attributable to 
CLL.
●The progression of an y cyt openia (unrelated to autoimmune cy topenia), as 
documented b y a decrease of Hb levels b y more than 2 g/dL o r to less than 
10g/dL, or b y a decrease of platelet counts b y more than 50% or to less than 
100,000/ L, defines disease progression, if the marrow biops y demonstrates an 
infiltrate of clonal CLL cells.
Subjects who have not achieved a CR or a PR, or who have not exhibited PD will be 
considered to have Stable Disease (SD).
A summary  of the criteria described above is included in Table 11. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
91
Table 11. IWCLL Updated NCI -WG Criteria for Tumor Response (2008)
CriteriaComplete 
Remission (CR)Partial Remission 
(PR)Progressive 
Disease (PD)Stable Disease 
(SD)
Lymphadenopathy None above 
1.5cm≥ 50% reduction ≥ 50% increase Change of –49% 
to +49%
Hepatomegaly and/or 
SplenomegalyAbsent ≥ 50% reduction ≥ 50% increase 
or new 
hepatomegaly 
and/or 
splenomegalyChange of –49% 
to +49%
Constitutional Symptoms Absent Present Present Present
Polymorphonuclear Leukocytes ≥ 1500/ L ≥ 1500/ L or 
>50% 
improve ment over 
baseline without 
G-CSF supportNot specified Not specified
Circulating clonal 
B-lymphocytesNone ≥ 50% reduction 
from baseline≥ 50% increase 
over baselineChange of –49% 
to +49%
Platelets > 100,000/ L > 100,000/ L or 
≥50% 
improvement from 
baselineDecrease of 
≥50% from 
baseline 
secondary to 
CLLChange of –49% 
to +49%
Hemoglobin > 11 g/dL 
(untransfused and 
without 
erythropoietin)> 11 g/dL or 
≥50% 
improvement from 
baselineDecrease of 
> 2g/dL from 
baseline 
secondary to 
CLLIncrease 
<11g/dl or 
<50% over 
baseline or 
decrease 
< 2g/dL
Bone Marrow Aspirate/Biopsy Normocellular, 
<30% 
lymphocytes, no 
B-lymphoid 
nodules, 
Hypocellular 
marrow defines 
CRi≥30% 
lymphocytes, or 
B-lymphoid 
nodules, or not 
doneIncrease of 
lymphocytes to 
more than 30% 
from normalNo change in 
marrow infiltrate
5.3.3.1.3 Definition of Clinical Disease Progression (Phase 2a)
Clinical disease progression is defined as determined by the investigator only, which may 
be characterized as, but is not limited to: 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
92
●Constitution al symptoms attributable to CLL progression (e.g., unintentional 
weight loss, significant fatigue [e.g., ECOG performance score ≥ 2], persistent 
fevers without signs of infection or night sweats)
●Requirement for palliative radiation, chemotherapy, surgery, immunotherapy  
or biologics
●Death from disease progression
5.3.4 Safety  Variables
The following safet y evaluations will be performed during the stud y:  adverse event 
monitoring, vital signs, phy sical examination, platelet counts, ly mphocy te enumeration, 
ECG, echocardiogram, and laboratory assessments.
5.3.5 Pharmacokinetic Variables
Values for the pharmacokinetic parameters of ABT -263, including the maximum 
observed plasma concentration (C max), the time to C max(peak time, T max), the terminal 
phase elimination rate constant ( ), terminal elimination half -life (t 1/2), the area under the 
plasma concentration- time curve (AUC) from time 0 to 24 hours (AUC 0-24) for the dose 
on C1D1 in Phase 1 will be determined using noncompartmental methods.  For C1D14 in 
Phase 1, values will be determined for C max, Tmaxand AUC from time 0 to 8 hours 
(AUC 0-
8).
5.3.6 Pharmacogenetic Variables
DNA samples may  be analy zed for genetic factors contributing to the subject's response to 
ABT -263 in terms of pharmacokinetics, efficacy  and safet y.  The samples may  also be 
used for the development of a diagnostic test for such a drug response.  Such genetic 
factors may  include, for example, drug metabolizing enz ymes, drug transport proteins, 
and Bcl -2 famil y members.  Genetic studies in general may includ e determination of the 
relationship of genetic haploty pes and drug metabolism, transport, therapeutic response 
and adverse events.  If clear differences of pharmacokinetics, safet y or efficacy are noted 
during the clinical development of ABT -263 and believed to have a genetic basis, these  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
93
samples may  be analy zed as part of a multicenter, multi -study  project to identify  genetic 
factors involved in the response to study  drugs.  The samples may  also be used for the 
development of a diagnostic test for drug res ponse.
5.3.7 Pharmacody namic Variables
Several putative biomarkers of efficacy  and response will be evaluated in this protocol 
with the goal of defining the relationship between drug concentration and disease status.
Examination of the proteomic profiles of pati ents in the ABT- 263 clinical trials may  
reveal patterns of protein/peptide concentrations that may be further evaluated in future 
clinical studies to determine an y prognostic value and any correlation with clinical 
response.  Plasma samples will be analyze d for predictive or drug -responsive proteomic 
markers.  In addition circulating tumor -derived DNA or RNA may  be extracted from 
plasma and assessed for expression or methy lation and mutational status of genes relevant 
to either the disease status or ABT -263mechanism of action.
In the event that an y plasma or serum samples are unused, remaining samples will be 
banked for use in diagnostic test development efforts.  Measurement of relevant RNAs 
and proteins including the Bcl -2 famil y members in CLL cells in t he blood, pre -treatment, 
during therap y and at time of relapse, may be examined for putative stratification markers 
for correlation with efficacy.  Additional studies may  include determination of the 
Bcl-2/Bim ratio at the mitochondrial level, a highly pre dictive marker of sensitivity  to the 
Bcl-2 family  inhibitors.  For sites in Australia, additional studies may  include assay s to 
measure in vivo apoptosis and in vitro studies of patient CLL cell sensitivity to ABT -263.
Fluorescent In -situHybridization (FI SH) may  be conducted on CLL whole blood samples 
from patients participating in this study  to assess amplifications and translocations in the 
Bcl-2 gene and other genes which may  prove to be informative including standard CLL 
cytogenetic markers.  Whole gen ome analy sis by  CGH array  may  also be performed on 
CLL samples to identify  genomic markers of CLL.  The potential relationship between 
amplification of these genes and the clinical outcome in these patients will be examined as  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
94
a stratification tool.  Biosp ecimens collected during the course of this study may  be 
banked and used in the future to investigate new scientific questions related to this study .
5.4 Removal of Subjects from Therapy  or Assessment
5.4.1 Discontinuation of Individual Subjects
Each subject has the right to withdraw from the study  at any  time.  In addition, the 
investigator will discontinue a subject from the study at an y time if the investigator 
considers it necessary  for any  reason including:
●The investigator believes it is in the best interest of the subject.
●The subject's response to therapy is unsatisfactory, as evidenced b y 
progression of disease.
●The subject experiences toxicities that require more than a 3 -week dose 
interruption.
●The subject requires more than two dose reductions, in the abse nce of 
objective response to ABT -263.
●The subject requires radiotherap y, cancer -related surgery , or alternate 
anti-neoplastic agents during the stud y period.
●The subject becomes pregnant or begins breastfeeding.
●The occurrence of an adverse event that precludes further investigational drug 
administration.
●Noncompliance with the protocol.
●The subject requires anti -coagulant or anti- platelet therapy  during the stud y 
period.
In addition, subjects in the Extension Study  may  also be discontinued for followi ng 
reasons:
●The Extension Study  has been ongoing for 11years since the transition of the 
last subject into the Extension Study .
●ABT -263 becomes commerciall y available. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
95
●AbbVie no longer pursues ABT -263 in this indication.
The investigator will inform AbbVie prior to discontinuing a subject from the study b y 
contacting the Clinical Team Leader as identified in Section 7.0.
During the COVID- 19 pandemic, it has been necessary  to employ  mitigation strategies to 
enable the investigator to ensure subject safet y and continuity of care.
The investigator should contact the sponsor medical contact before discontinuing a subject
from the study  for a reason other than "planned per protocol," to ensure all acceptable 
mitigation steps have been explored.
All subjects will be included for anal ysis of safety data.  Subjects in the Phase 1 portion of 
the study  who withdraw from the stu dy will not be replaced unless they  are not evaluable.  
Evaluable subjects are defined as those subjects who:
● Experience a DLT
●Complete at least 80% of dosing in the first cycle (of either 14/21 or 21/21 day 
dosing schedule)
In the event that a subject wi thdraws or is discontinued from the stud y, reason(s) for the 
discontinuation from the study  will be recorded.  A phy sical examination, ECG, 
echocardiogram, vital signs measurement, laboratory  anal yses, performance status 
assessment, collection of unused st udy drug, an assessment of adverse events and tumor 
assessment (if needed) will be performed as soon as possible after discontinuation from 
the study .
A Safet y Follow -up Visit should be performed for all subjects approximately  30 day s 
following discontinua tion of ABT -263 and then as clinically  appropriate for safet y 
assessment.  The subject will be followed until a satisfactory clinical resolution of the 
adverse event(s) is achieved.  If the subject refuses a follow- up visit or the visit is not 
performed, t he reason should be noted in the subject's source documentation. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
96
In the event of a positive pregnancy test for a subject during the stud y, the administration 
of study  drug to that subject must be discontinued immediately .  The investigator will 
report the positive pregnancy  test result b y telephone within 1 working day to the contact 
listed in Section 6.5.
5.4.2 Discontinuation of Entire Study
AbbVie may  terminate this st udy, either in its entirety  or at a study  site provided that 
written notice is submitted at a reasonable time in advance of the intended termination.  
The following procedures for discontinuation will be followed:
●If the sponsor has decided to prematurel y discontinue the study , the sponsor 
will promptly  notify  in writing the investigator as well as regulatory  authorities 
of the decision and give detailed reasons for the discontinuation.
●The investigator must promptly  notify  the IRB/IEC and give detailed rea sons 
for the discontinuation.
●The investigator must promptly  notify  the enrolled subjects of the premature 
discontinuation and administer appropriate treatments such as replacement of 
the treatment regimen, if applicable, b y other appropriate regimens.
5.5 Treatments
5.5.1 Treatments A dministered
Subjects will self -administer ABT- 263 orall y once daily (QD).  Each dose will be taken 
with approximately  240 mL  of water.  On day s that pre -dose pharmacokinetic sampling is 
required, dosing will occur in the morning (appro ximately  8 AM) in the clinic to facilitate 
pharmacokinetic sampling.  All subjects will self -administer ABT- 263 within 30 minutes 
after the completion of breakfast.  The effect of food on pharmacokinetics will be 
evaluated outside of this study  protocol an d changes will be initiated if fasting conditions 
are superior.
On dosing day s with PK collection (per Table 4through Table 6), the time of each drug 
administration will be recorded to the nearest minute.  On all other days, subjects will be  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
97
instructed to record the date and time they  take study  drug.  Subject diari es will be 
provided b y AbbVie.
During the Study  Drug Dosing Period, a subject with confirmed (viral test positive) or 
suspected COVID- 19 infection can onl y be dosed with study  drug if the following 
COVID- 19 viral clearance criteria are met:
●Symptomatic sub jects:  At least 2 negative viral tests in a row, ≥ 24 hours apart 
after at least 10 days have passed since recovery , defined as resolution of fever 
without use of antipy retics and improvement in respiratory  symptoms (e.g., 
cough, shortness of breath)
●Asymptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (note:  
subjects who develop s ymptoms will follow guidance above for symptomatic 
subjects)
Delay s in study  drug d osing due to the above COVID -19 testing guidance for subjects 
must be discussed with the AbbVie medical contact, along with the possibility  of 
premature discontinuation from the study  drug dosing period.  Frequency  or timing of 
COVID- 19 testing and intervals between testing for the above viral clearance criteria may  
be adjusted to account for epidemiologic trends, updated information regarding 
infectivity , and local/institutional guidelines.
5.5.2 Identity  of Investigational Product
The individual study  drug information is presented in Table 12. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
98
Table 12. Identity of Investigational Products
Study Drug Trademark* Form ulati onRoute of 
Administration Manufacturer
ABT -263
(Navitoclax)N/A ABT -263 Stabilized Oral 
Solution (25 mg/mL, 
90mL/bottle)Oral AbbVie/Abbott
ABT -263
(Navitoclax)N/A Tablets (25 mg) Oral AbbVie/Abbott
ABT -263
(Navitoclax)N/A Tablets (100 mg) Oral AbbVie/Abbott
* N/A = Not Applicable
ABT -263 Stabilized Oral Solution
AbbVie (or designee) will supply, at a minimum:
●ABT -263 Stabilized Oral Solution packaged in amber glass bottles containing 
a solution of 25 mg/mL concentration of ABT -263 per bottle. Each bottle will 
be supplied in a carton.
●Written instructions for dosing and handling of drug supplies for the subject.
●Written instructions for preparation and dispensing of prefilled s yringes b y the 
site pharmacist (or designee).
Ancillary  Materials:
●Amber oral s yringes with caps.
●Child -resistant sy ringe cartons.
●Adapt -a-Caps (for bottles of stabilized oral solution).
●Dispensing labels for prefilled sy ringes and corresponding child -resistant 
cartons.
●Insulated cooler bags with freezable gel packs, to allow subject to transport of 
syringe cartons under recommended cold storage conditions. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
99
ABT -263 Tablets
ABT -263 tablets and an y applicable ancillary materials will be provided b y AbbVie.
5.5.2.1 Packaging and Labeling
ABT -263 Stabilized Oral Solution (25 mg/mL ) will be packaged in amber glass bottles 
containing 90 mL solution per bottle.  Each bottle will be supplied in a carton.
ABT -263 tablets will be packaged in HDPE (high density  polyethylene) plastic bottles.
Each bottle and carton will be labeled as required per country  requirement.  L abels must 
remain affixed to the bottles and cartons.  Blank spaces on the label will be completed b y 
the site.
ABT -263 Stabilized Oral Solution
The pharmacist (or designee) will prepare (prefill) the appropriate size oral syrin ges 
according to the dosing schedule and instructions provided.  Prefilled s yringes will be 
placed in a child resistant carton for the subject to take home.  All prefilled syringes and 
child resistant cartons provided to the subject will also contain a label (completed by  the 
site pharmacist or designee).  Each s yringe and child resistant carton will be labeled as 
required per country  requirements.  Labels must remain affixed to the sy ringes and child 
resistant cartons.  AbbVie will provide detailed instruc tions and training for the handling 
of study  supplies to the study  site.
5.5.2.2 Storage and Disposition of Study Drug
The investigational products supplied in this study are for investigational use only, and are 
to be used only  within the context of this study .  All clinical supplies must be maintained 
under adequate securit y until dispensed for subject use, destro yed or returned to AbbVie.  
All clinical supplies must be stored per the conditions specified on the label. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
100
ABT -263 Stabilized Oral Solution
ABT -263 Sta bilized Oral Solution (25 mg/mL ) must be stored at 15° to 25°C (59° to 
77°F).  For additional oral solution storage information, please refer to labeled storage 
conditions.  Prefilled sy ringes must be stored at 2° to 8°C (36° to 46°F) and protected 
from li ght.
ABT -263 Tablets
ABT -263 tablets must be stored at 15° to 25°C (59° to 77°F) and protected from moisture 
and light.
5.5.2.3 Preparation/Reconstitution of Dosage Form
Written instructions for the preparation of ABT -263 oral solution and sy ringes will be 
provided to the site pharmacists as separate documents outside of this protocol.
5.5.3 Method of Assigning Subjects to Treatment Groups
As they  are enrolled in the Phase 1 portion of the study , subjects will be assigned a dose 
and unique consecutive subject numb er, beginning with 501.  A detailed description for 
the methodology  of allocating subjects to treatment groups according to the continual 
assessment methodology  is provided in Section 8.1.1 .  As the study  progresses, subjects 
may progressivel y escalate to the highest dose level tolerated through 2 cycles of 
ABT -263 administration.  These decisions will be based on the judgment of the 
investigator in coordination with the AbbVie Medical Monitor.  As they are enrolled in 
the Phase 2a portion of the study , subjects will be assigned a unique consecutive subject 
number, beginning with 601.  The site, in conjunction with the sponsor, will be 
responsible for assignment of a ll unique subject numbers and dose assignments.  Subjects 
who continue in the Extension Study  will retain the subject number that was assigned in 
the Phase 1 or Phase 2a portion of the study . 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
101
5.5.4 Selection and Timing of Dose for Each Subject
Selection of the dose for this study  is discussed in Section 5.6.4.  The same dose will be 
administered to all subjects in each dose level.  All subjects will receive ABT -263 within 
30minutes following the completion of breakfast, unless specified otherwise.
COVID -19 Pandemic -Related Acceptable Protocol Modifications
Study  drug may  be shipped from the stud y site directly to the stud y subject's home if all 
the following criteria are met:
●Direct -to-patient (DTP) shipment of study  drug is allowed by  local regulations 
and the relevant ethics committee
●Study  drug can be administered by  the subject (or subject's caregiver) at home
●Subject agrees to have the study  drug shipped directly  to their home
●Shipments may  also include other study  supplies (e.g., drug dosing diaries).  
Instructions will be provided by AbbVie as to how a study site can initiate a 
DTP shipment using Marken, a global vendor selected b y AbbVie to provide 
this service when necessary .  Shipments of study  drugs from the study  site to a 
subject's home will be appropriately temperature controlled (qualified shipper 
or temperature monitoring) within the labeled storage conditions. Signature is 
required upon delive ry; due to COVID- 19 related social distancing, this may  
be provided b y the courier after delivery.  Documentation of the shipment is to 
be retained b y the clinical site.
●AbbVie will not receive subject identify ing information related to these 
shipments, as the site will work directl y with the courier.
The study  site is responsible for meeting IRB/IEC reporting requirements related to DTP 
shipments of study  drug, and for obtaining consent to provide delivery  information to the 
courier and documenting this c onsent in source documents.
5.5.5 Blinding
This is an open -label study . 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
102
5.5.6 Treatment Compliance
To document compliance with the treatment regimen, subjects will be instructed to return 
all prefilled drug s yringes or bottles, even if empty, and an y other stud y relat ed items as 
necessary , to the appropriate study  site personnel at scheduled clinic visit.  Compliance 
will be monitored and documented b y the stud y site personnel on the appropriate form.  
The study  site personnel will question the subject regarding adhere nce to the dosing 
regimen, record either the number of prefilled s yringes returned in the carton or the 
number of bottles returned, the date returned and determine treatment compliance before 
dispensing new medication to the study  subject.  Compliance belo w 80% will require 
counseling of the subject by  study  site personnel.
5.5.7 Drug A ccountability
The investigator or his/her designated representatives will administer study drug onl y to 
subjects enrolled in the study .  Documentation of the receipt of supplies will be supported 
by a signed and dated Proof of Receipt or similar document.  A current (running) and 
accurate inventory  of ABT -263 will be kept b y the site and will include lot number, Proof 
of Receipt number(s), bottle numbers, number of prefilled s yringes or bottles dispensed, 
and the date on which study  drug is administered or dispensed to the subject.  An overall 
accountability  of the study  drug will be performed and verified by  the AbbVie designated 
monitors throughout the study  and at the study  site closeout visit.  Subjects will be 
instructed to return all prefilled syringes or bottles at each stud y visit, used or unused.  
The site will maintain a current and accurate inventory of supplies returned by the subject, 
whether used or unused.  Upon compl etion or termination of the study , all original 
containers (containing unused study drug) will be returned to AbbVie according to 
instructions from AbbVie.  If pre -arranged between AbbVie and the site, destruction of 
used and unused stud y drug bottles and syringes will be performed at the site.  Empty  
bottles will be destroy ed at the site per the site's destruction policy .  Labels must remain 
attached to the containers. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
103
5.6 Discussion and Justification of Study  Design
5.6.1 Discussion of Study  Design and Choice of Co ntrol Groups
Phase 1
For the Phase 1 portion of the study, the experimental design is an adaptation of the 
continual reassessment method (CRM).  The CRM is expected to locate the MTD 
efficientl y.  The MTD is defined as the dose at which 30% of subjects exp erience a DLT 
during the first cy cle.  The CRM attempts to estimate the target MTD from a continuum 
of doses, whereas a fixed design merel y selects a dose from a discrete set.  If the true 
target dose is not among the choices set out in advance b y fixed de signs, they  can onl y 
approximate it.  A CRM based design uses a statistical model for dose and toxicity  by 
including the accumulating data to guide selection of the next dose.  Simulations and 
literature have shown that compared to the conventional fixed 3 +3 design, the CRM 
typicall y requires fewer subjects to find the MTD, does not greatl y overshoot the MTD 
(that is, subjects are not expected to be treated with dangerousl y high doses), and does not 
greatl y underestimate the MTD.
During Phase 1, this study will employ  a CRM design.32,33  Dosing with ABT- 263 will 
begin at 10 mg with a cohort of three subjects.  The study  drug dose will be escalated to 
the CRM estimated MTD, not to exceed an increase of more than 100 mg or 40% increase 
from the current dose level.  A minimum of three subjects will be treated per dose level to 
account for potential inter -subject variability .  The study  design will be based on the 
concept of entering every subject at the best current statistical estimation of the MTD 
given the previous observations.  The dose escalat ion strategy  will be based on a dose and 
probability  of DLT response model.  The model will be adjusted using all of the available 
data and a new estimate of MTD will be projected from the updated model.  There are no 
control groups in this study . 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
104
Phase 2a
The Phase 2a portion of the study  will be open -label at the recommended Phase 2 dose 
(RPTD) and dosing schedule.  The RPTD will be defined b y observed DLTs and/or 
determination of MTD from the Phase 1 portion of the study .
5.6.2 Appropriateness of Measurements
Standard pharmacokinetic, statistical, clinical, and laboratory  procedures will be utilized 
in this study .
5.6.3 Suitability  of Subject Population
Subjects with relapsed or refractory CLL will be selected to participate in this study .  
Pre-clinical findings support the possibility  of efficacy  in this patient population.  Due to 
the expected mechanism based, potentially dose -limiting thrombocy topenia, the study  
eligibility  requirements take into consideration a potential subject's baseline platelet 
count, history  of bleeding or active bleeding, coagulation parameters, CNS metastasis, 
ongoing immune thrombocy topenic purpura, and transplant history .
5.6.4 Selection of Doses in the Study
The starting dose in this Phase 1/2a trial is derived from the results obtained in the 
ABT -263 1 -month rat and dog toxicity  studies.  The initial starting dose of 10 mg was 
obtained by  appl ying a safety  factor of 10 to the lowest dosage used in the 1 -month rat 
study  (10 mg/kg/day ) and the second -lowest dosage used in the 1 -month dog study  
(3mg/kg/day ).  Although mild changes in platelets were noted in the rats and mild to 
moderate changes in platelets and lymphocy tes were noted in dogs at these doses, the 
degree of platelet and l ymphocyte decrease was well tolerated.  At all dosages, the 
decrease in platelets was readil y reversible upon discontinuation of ABT -263.  
Additionally , at the dosages of 10 mg/kg/day  in the rat or 3 mg/kg/day  in the dog, 
platelets returned to baseline or near baseline values in the face of continued dosing.  
Given th e ability  to monitor the anticipated dose -limiting toxicity  (thrombocy topenia) and 
the intended subject population, the safet y factor of 10 provides an appropriate margin of  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
105
safet y and safeguard against variability when extrapolating between species.  The 
conversion of the 10 mg/kg dose in rats and the 3 mg/kg dose in dogs to the human 
equivalent dose of approximately  10 mg was made using bod y surface area scaling for a 
60 kg human.  Projections of human pharmacokinetic data suggest that the proposed dose 
of 10 mg taken once daily to a 60 kg human would be expected to produce at stead y state 
a C maxin plasma of 0.2 g/mL and an AUC over a dosing interval (AUC 24) of 
2.6g
•hr/mL.  These predicted values are below those concentrations that resulted in a 
No-Obs erved- Adverse -Effect -Level (NOAEL) in the dog or a tolerated dose in the rat.  
An AUC value of at least 53 g
•hr/mL -88 g•hr/mL  is projected to provide an efficacious 
concentration.  Subsequent to the 10 mg dose, the study  drug dose will be escalated to th e 
estimated MTD not to exceed an increase of 100 mg or a 40% increase from the current 
dose level, whichever is greater.
Phase 1
Selection of doses will be based on CRM by using a dose and probability of DLT 
response model.  A prior model will be employ ed based on preclinical and clinical data.  
Estimates of the model parameters and the probability  of toxicity  will be updated at each 
dose level.  The methodology  for fitting the dose -toxicity  response model is described in 
Section 8.1.1 .  Subjects will be assigned to the dose level that estimates the targeted 
MTD, defined as the dose to reflect 30% rate of DLT according to the model.  The design 
is adaptive because at each d ose level, the model will be updated using all of the previous 
available data and a new estimate of MTD will be projected from the updated model.  
Aminimum of three subjects will be enrolled to warrant reasonable accuracy for the 
estimates.  The modeling process provides flexibility  so that the new estimated MTD may  
be escalated or decreased from the previous dose.  The design continues in this fashion by 
assigning subjects to the MTD as estimated from current results.  When the next predicted 
MTD is withi n 10% of the current dose, the model is considered to have converged and 
MTD will be declared.  However, dose -determination will stop if the predetermined 
sample size of subjects is reached, based on operational considerations. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
106
Once either the MTD is defin ed or dosing in the 4th dose level is completed for the 
14/21 day dosing schedule, whichever occurs first, a continuous dosing schedule will be 
assessed.  Dosing with ABT -263 under the continuous dosing schedule (21/21 day ) will 
begin at the dose estimated to provide exposure equivalent to the highest dosing level 
cleared (4thdose level) or the MTD from the 14/21 day schedule.
The starting dose for continuous dosing will be determined by  calculating a dose of 
equivalent exposure from a 14/21 day  schedule t o a 21/21 day  schedule (MTD 14)/21.  
For example if the highest tolerated dose is determined to be 375 mg then ABT- 263 will 
be dosed at 250 mg once daily  (375 mg 14/21 = 250 mg).
A 7 day  period of dosing with a lead -in dose of ABT -263 will be explored with the 
21/21 day dosing schedule in order to interrogate whether higher doses may then be given 
with overall less reduction in platelet counts.  Subjects will begin dosing at 100 mg on 
Lead -in Day  1 (LD1).  This is the dose level at which a mean maximal platelet drop of 
approximately  60% from baseline with recovery  during 14 day s of continued dosing is 
expected based on observations in this study  to date.  The lead -in titration dose may  be 
adjusted if the defined dose level fails to significantly mitigate ABT -263-induced 
thrombocy topenia following the lead -in period or the defined dose level results in 
significant occurrence of DLT in the lead -in period.
Phase 2a
Once the MTD and/or RPTD is declared on the Phase 1
-21/21 day  continuous dosing 
schedule, a sa fety anal ysis will be performed as described in Section 8.1.4.  The results of 
the safet y anal ysis as well as the recommended Phase 2 dose and dosing schedule will be 
communicated to all participating research sites prior to the start of enrollment in the 
Phase 2a portion of the study .
6.0 Adverse Events
The investigator will monitor each subject for clinical and laboratory evidence of adverse 
events on a routine basis throughout the stud y.  The investigator will assess and record  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
107
any adverse event in detail including the date of onset, event diagnosis (if known) or 
sign/sy mptom, severity , time course, outcome, relationship of the adverse event to study  
drug, and an y action(s) taken.  For serious adverse events not considered "probably  
related" to study  drug, the investigator will provide an Other cause of the event.  For 
adverse events to be considered intermittent, the events must be of similar nature and 
severit y.  Adv erse events, whether in response to a query , observed b y site personnel, or 
reported spontaneously  by the subject will be recorded.
All adverse events will be followed to a satisfactory conclusion.
6.1 Definitions
6.1.1 Adverse Event
An adverse event (AE) is defined as any  untoward medical occurrence in a patient or 
clinical investigation subject administered a pharmaceutical product and which does not 
necessarily  have a causal relationship with this treatment.  An adverse event can therefore 
be an y unfavorable and u nintended sign (including an abnormal laboratory  finding), 
symptom, or disease temporally  associated with the use of a medicinal (investigational) 
product, whether or not the event is considered causally related to the use of the product.
Such an event can result from use of the drug as stipulated in the protocol or labeling, as 
well as from accidental or intentional overdose, drug abuse, or drug withdrawal.  An y 
worsening of a pre -existing condition or illness is considered an adverse event.  
Laboratory  abnormalities and changes in vital signs are considered to be adverse events 
only if they  result in discontinuation from the study , necessitate therapeutic medical 
intervention, meets protocol specific criteria (see Section 6.7regarding toxicity  
management) and/or if the investigator considers them to be adverse events.
An elective surgery /procedure scheduled to occur during a stud y will not be considered an 
adverse event if the surgery /procedure is being performed for a preexisting condition and 
the surgery /procedure has been pre planned prior to study  entry .  However, if the 
pre-existing condition deteriorates unexpectedl y during the study (e.g., surgery performed  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
108
earlier than planned), then the deterioration of the condition for which the elective 
surgery /procedure is being done will be considered an adverse event.
Hospitalization for the purpose of TLS proph ylaxis (e.g., for I.V. h ydration) will not be 
captured as a serious adverse event (SAE), unless there is an additional reason for 
hospitalization or an additional criterion for seriousness other than hospitalization.
A treatment -emergent adverse event is defined as any adverse event with onset or 
worsening report ed by a subject from the time that the first dose of study drug is 
administered until 30 days have elapsed following discontinuation of study drug 
administration.
6.1.2 Serious A dverse Events
If an adverse event meets any of the following criteria, it is to be r eported to AbbVie as a 
serious adverse event (SAE) within 24 hours of the site being made aware of the serious 
adverse event.
Death of Subject An event that results in the death of a subject.
Life-Threatening An event that, in the opinion of the investigator, would have 
resulted in immediate fatality  if medical intervention had 
not been taken.  This does not include an event that would 
have been fatal if it had occurred in a more severe form.
Hospitalization or 
Prolongation of 
HospitalizationAn event that results in an admission to the hospital for an y 
length of time or prolongs the subject's hospital stay.  This 
does not include an emergency  room visit or admission to 
an outpatient facilit y.
Congenital Anomaly An anomal y detected at or after bi rth, or an y anomaly that 
results in fetal loss.
Persistent or 
Significant 
Disability/IncapacityAn event that results in a condition that substantially 
interferes with the activities of daily living of a study 
subject.  Disability  is not intended to include experiences of 
relativel y minor medical significance such as headache, 
nausea, vomiting, diarrhea, influenza, and accidental trauma 
(e.g., sprained ankle). 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
109
Important Medical 
Event Requiring 
Medical or Surgical 
Intervention to Prevent 
Serious OutcomeAn important medical event that may  not be immediately  
life-threatening or result in death or hospitalization, but 
based on medical judgment may  jeopardize the subject and 
may require medical or surgical intervention to prevent an y 
of the outcomes liste d above (i.e., death of subject, 
life-threatening, hospitalization, prolongation of 
hospitalization, congenital anomal y, or persistent or 
significant disability /incapacity ).  Examples of such events 
include allergic bronchospasm requiring intensive treatme nt 
in an emergency  room or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospitalization, or 
the development of drug dependency  or drug abuse.
Spontaneous Abortion Miscarriage experienced by  study  subject.
Elective Abortion Elective abortion performed on study  subject.
6.2 Adverse Event Severity
The investigator will rate the severit y of each adverse event according to the National 
Cancer Institute Common Terminology  Criteria for Adverse Events, Version 3.0 
(NCI CTCAE).34
If a reported adverse event increases in severit y the initial adverse event should be given 
an outcome date and a new adverse event reported to reflect the change in sev erity.  For 
all reported serious adverse events that increase in severit y, the supplemental eCRFs 
(paper CRFs for the Extension Study ) also need to be updated to reflect the change in 
severit y.
For adverse events not captured by the Common Terminology Crit eria, the following 
should be used:
Grade 1 (Mild) The adverse event is transient and easil y tolerated by the 
subject.
Grade 2 (Moderate) The adverse event causes the subject discomfort and interrupts 
the subject's usual activities. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
110
Grade 3/4 (Severe) The adverse event causes considerable interference with the 
subject's usual activities and may  be incapacitating or 
life-threatening.
Grade 5 The adverse event resulted in death of the subject.
6.3 Relationship to Study Drug
The investigator will use the following definitions to assess the relationship of the adverse 
event to the use of stud y drug:
Probably Related An adverse event has a strong temporal relationship to study  
drug or recurs on re -challenge and an Other cause of event is 
unlikely  or signific antly less likely .
Possibly Related An adverse event has a strong temporal relationship to the 
study  drug and an Other cause of event is equall y or less likely  
compared to the potential relationship to study  drug.
Probably Not 
RelatedAn adverse event ha s little or no temporal relationship to the 
study  drug and/or a more likely  Other cause of event exists.
Not Related An adverse event is due to an underl ying or concurrent illness 
or effect of another drug and is not related to the study drug 
(e.g., has n o temporal relationship to study  drug or has a much 
more likely  Other cause of event).
For causality  assessments, events meeting the categories of probabl y or possibly  will be 
considered "associated."  Events that are probabl y not or not related will be considered 
"not associated."  In addition, when the investigator has not reported a causality or 
deemed it not assessable, AbbVie will consider the event associated.
If an investigator's opinion of possibly , probabl y not, or not related to study drug is given, 
an Other cause of event must be provided by the investigator for the serious adverse 
event. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
111
6.4 Adverse Event Collection Period
All serious and non- serious adverse events reported from the time of study  drug 
administration until 30 days following discon tinuation of study  drug administration will 
be collected, whether elicited or spontaneously reported by the subject.
Serious adverse events occurring after the study -specific informed consent is signed but 
prior to the initial dose of the investigational p roduct will be collected onl y if they  are 
considered b y the investigator to be causally related to the study required procedures.
For subjects in the Extension Study , all adverse events that occur after Day  1 visit in the 
Extension Study  should be captured in the Extension Study  paper Case Report Forms.
Adverse event information will be collected as shown in Figure 5.
Figure 5. Adverse Event Col lection
Participation -
related
SAEs*SAEs and Nonserious AEs
Elicited and/or Spontaneously Reported
   
Consent 
SignedStudy 
Drug 
StartStudy 
Drug 
Stopped30 Days 
After Study 
Drug Stopped
* Only if considered by the investigator to be causally related to study required procedures.
6.5 Adverse Event Reporting
In the event of a serious adverse event, whether related to study drug or not, the 
investigator will notify  Oncology  Safet y Management within 24 hours of the site being 
made aware of the serious adverse event b y faxing the appropriate serious adverse event 
forms to the AbbVie Oncology  Safety  Management Team.
FAX to:  +1 (847) 785 -8224
Email:  SafetyManagement_Oncology@abbvie.com 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
113
COVID- 19 infections should be captured as adverse events.  If the event meets the criteria 
for a serious adverse event (SAE), then follow the SAE reporting directions per the 
protocol and above.  The following COVID -19 related supplemental eCRFs should be 
completed:
● COVID- 19 Supplemental Signs/sy mptoms
● COVID- 19 Status Form
6.6 Pregnancy
In the event of a positive pregnancy test, subjects must immediately  discontinue study  
drug and must be discontinued from the study .  The investigator must report the positive 
pregnancy  test to the appropriate contact listed in protocol Section 6.5within 1 working 
day of the site becoming aware of the pregnancy .
Information regarding a pregnancy  occurrence in a study  subject and the outcome of the 
pregnancy  will be collected.  The investigator must follow the pregnancy  to completion 
and provide an update to AbbVie after delivery .
Male subjects should be informed that contraceptive measures should be taken by their 
female partners.  If the subject's partner should become pregnant during the study, this 
should also be reported and data may  be collected.
Pregnan cy in a stud y subject is not considered an adverse event.  However, the medical 
outcome of an elective or spontaneous abortion, stillbirth or congenital anomaly is 
considered a serious adverse event and must be reported to AbbVie within 24 hours of the 
site becoming aware of the event.
6.7 Toxicity  Management
6.7.1 Definition -Dose Limiting Toxicity
Dose -limiting toxicities for dose -escalation purposes will be determined during the 
firstcycle.  Adverse events occurring following the first cy cle will also be evaluat ed by  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
114
the investigator and the AbbVie Medical Monitor and may be considered as dose limiting.  
Any of the following events, which are considered possibly  or probabl y related to the 
administration of ABT -263, will be considered a dose limiting toxicity  (DLT ).
●Thrombocy topenia:
○Grade 4 thrombocy topenia (< 25,000/mm3)
●Platelet counts < 25,000/mm3should be confirmed the same day b y manual 
reading and a separate peripheral draw.  If the repeat platelet count is 
≥25,000/mm3, this will not be considered a DLT.  If the repeat platelet count 
cannot be obtained within the same day  as the initial measurement of 
<25,000/mm3, then the initial measurement will constitute a DL T.
●Grade 2 or higher bleeding associated with thrombocytopenia
●All other Grade 3, 4 or 5 advers e events will be considered a DLT.  Exceptions 
include:
○Grade 3, 4 Afebrile Neutropenia less than 7 days
○Grade 3, 4 Leukopenia
○Grade 3, 4 Lymphopenia
○Grade 3 nausea, vomiting and/or diarrhea unless unresponsive to treatment
○Grade 2 toxicity  that requires dose modification or delay  of > 1 week, will 
be considered a DLT (e.g., peripheral neuropath y)
Any DLT will require an interruption and possible discontinuation of ABT -263.  
ABT -263 may  be reintroduced, but only  at a reduced dose, if the toxicity grade re turns to 
Grade 1 or to baseline if Grade 2 at stud y entr y.  Following a DLT of thrombocytopenia, 
ABT -263 may  be reintroduced, but only  at a reduced dose, if the platelet toxicity  grade 
returns to Grade 2 ( ≥ 50,000/mm3).  Any  reduced dose level will be jointly  defined by  
the investigator and the AbbVie Medical Monitor.  The dose may  be increased thereafter 
upon joint determination of the investigator and the AbbVie Medical Monitor.  This dose 
is not to exceed the highest tolerated dose level.
For the Phase 1 portion of the study, all decisions regarding continued dosing for 
individual subjects will be medicall y managed b y the investigator, in conjunction with the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
115
AbbVie Medical Monitor, as appropriate.  These decisions will be driven by the def inition 
of DLTs as described above.
6.7.2 Management of Thrombocytopenia
ABT -263 induces apoptosis, rather than l ysis, of circulating platelets, which differs from 
typical chemotherapy  induced thrombocy topenia related to my elosuppression.
All decisions regarding continued ABT- 263 dosing for individual subjects will be 
determined b y the investigator, in conjunction with the AbbVie Medical Monitor, as 
appropriate.  These decisions should be guided b y the following:
Administration of ABT- 263 will be interrupted or d iscontinued for:
●Any pre-dose platelet count < 25,000/mm3
●Any clinically  significant bleeding, defined as Grade 2 or higher hemorrhage
If ABT- 263 is held, it may  be restarted, but only  at a reduced dose to be jointly  defined b y 
the investigator and the A bbVie Medical Monitor, once the subject's platelet count is 
≥50,000/mm3.  The dose may be increased (not to exceed the highest tolerated dose) 
thereafter upon joint determination of the AbbVie Medical Monitor and the investigator.
After an y Grade 4 platel et count < 25,000/ mm3is observed for the first time in a subject, 
serial PK samples will be collected.  PK samples will be collected as soon as possible 
after the Grade 4 platelet count is determined and then 24 and 48 hours after the event.   
Starting wi th Protocol Amendment 13, PK samples will NOT be collected.
Limited human clinical data are available to understand the response to infusion of 
exogenous platelets in the presence of circulating drug levels.  Platelet transfusion studies 
conducted in beagl e dogs demonstrated that transfusion of one -day old platelets 
administered near the time of ABT- 263 C max, resulted in higher platelet levels than dogs 
not receiving supplemental platelets.  Platelet concentrations remained higher after 
24hours with declin ing ABT- 263 concentrations.  This study  suggests that infusion of  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
116
platelets may  have beneficial effects in treating acute thrombocy topenia following oral 
dosing with ABT -263.
If platelet transfusions are required in response to active bleeding, dosing of ABT -263 
should be suspended.  It should be noted that platelet response with transfusions may not 
follow ty pical platelet kinetics of thrombocy topenia as with ty pical chemotherapy  induced 
myelosuppression.  Procedures consistent with local institutional blo od banking 
guidelines regarding platelet transfusions should be followed.
Platelet Transfusion Recommendations:
If a platelet transfusion is deemed necessary, the treating ph ysician should be aware of the 
following:
●Due to the rapid apoptotic effect of ABT -263 on mature platelets, the initial 
increase in platelets post -transfusion may  be smaller and the duration of 
response may  be shorter.  For this reason, donor platelets collected as recently  
as possible prior to transfusion should be considered.
●A post -transfusion platelet count should be obtained within 10 to 60 minutes.
●Additional transfusions may  be necessary  to achieve the desired platelet 
response.
6.7.3 Management of Ly mphopenia
There is a potential for clinically  significant l ymphopenia in this study .  If clinically 
indicated, anti -infective prophy laxis should be implemented at the investigator's 
discretion, including appropriate proph ylaxis for viral, fungal, bacterial or Pneumocy stis 
carinii pneumonia (PCP) infections.  Potential for drug -drug interact ions should be 
considered.  See Appendix Efor a description of excluded and cautionary medications.
6.7.4 Management of Tumor Ly sis Sy ndrome
There is a potential for tumor lysis in subjects with various tumor ty pes in the presence of 
the following risk factors:  bulky disease, elevated pre -treatment LDH levels, elevated  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
117
leukocy te count and dehy dration.  Adequate hy dration, careful monitoring of laboratory  
values and an agent to reduce the uric acid level should be considered for subjects at high 
risk during the Lead- in and subsequent cy cles.  Please discuss with the AbbVie Medical 
Monitor, as appropriate.
6.7.5 Determination of the MTD
The MTD is defi ned as the dose at which 30% of subjects experience a DLT during the 
first cy cle.  At each dose level, MTD will be estimated based on actual observations from 
subjects to construct a dose and toxicity  rate model using the maximum likelihood 
method.  As dat a accumulate and the reassessment continues, the MTD will be determined 
based on the convergence criteria described in Section 5.6.4.  The recommended Phase 2 
dose (RPTD) will be defined by  observed DLTs and/or determination of MTD.
7.0 Protocol Deviations
AbbVie does not allow intentional/prospective deviations from the protocol except when 
necessary  to eliminate an immediate hazard to study  subjects.  The investigator is 
responsible for comply ing with all protocol requirements, written instructions, and 
applicable laws regarding protocol deviations.  If a protocol deviation occurs (or is 
identified, including those that may  be due to the COVID -19 pandemic), the investig ator 
is responsible for notifying independent ethics committee (I EC)/independent review board 
(IRB), regulatory  authorities (as applicable), and AbbVie. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
119
8.0 Statistical Methods and Determination of Sample 
Size
8.1 Statistical and A nalytical Plans
Unless otherwise noted, for all statistical anal yses, statistical significance will be 
determined b y a two -sided p-value < 0.05.
8.1.1 Demographics and Treatment A llocation
Demographics
Descriptive statistics will be provided for baseline demographic variables for the Phase 1 
and the Phase 2a portion of the study separatel y.  Age, height and weight will be 
summarized with means, medians, standard errors, standard deviations and ranges.  
Frequencies and percentages will be provided for gender and race.
Treatment Allocation
One of the objectives of the Phase 1 portion of this study  is to determine the MTD, and 
the dose allocation process will be conducted according to a continual reassessment 
method (CRM).35,36,37  A two -parameter logistic regression model will be employ ed to 
characterize dose and toxi city rate relationship.  A prior model based on preclinical and 
clinical data will be employ ed to estimate doses with approximately  30% and 90% 
probability  of inducing a DL T.  The MTD is the dose that reflects a 30% rate of DLT.  
The dose associated with 9 0% DLT rate will be incorporated for future model fitting to 
stabilize the high dose -toxicity  portion of the model.  For each subject, the response will 
be defined as 0 (no DLT event) or 1 (DLT).  Along with the actual observed data, 
10imputed subjects wi ll be added with 9 subjects having DLT and 1 without DL T at the 
dose associated with 90% DLT rate.  A small weight of 0.025 will be assigned to these 
imputed data to reflect a small degree of certainty, and at the same time to stabilize the 
model fitting process as shown in the simulations.  To estimate the dose corresponding to 
approximately 30% probability  of inducing DLT, one out of the three subjects in the 
160mg dosing cohort from the M06- 814 study  will be utilized with a small weight of  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
120
0.083 assigne d to these prior data.  For the actual observations, a unity  weight will be 
assigned.  The maximum likelihood method will be employed to estimate the parameters 
and probability  of DLT within the framework of the logistic regression analy sis.  The 
fitted model will be inverted to estimate the target dose associated with 30% chance of 
DLT, or the MTD.  The next cohort of subjects will then be assigned to the projected 
MTD and evaluated.  The outcome will be incorporated to update the logistic regression 
model using all the cumulative information.  The design will continue to adapt data from 
current results and assign subjects to the projected MTD until the target dose changes by 
less than 10%, or a sample size of 40 subjects is reached.  Simulations to compare the 
conventional fixed 3+3 design and the CRM based design are provided in Appendix F.
8.1.2 Pharmacokinetics
8.1.2.1 Tabulations and Summary  Statistics
Plasma concentrations of ABT -263 and pharmacokinetic parameter values will be 
tabulated for each subject and each dose level, and summary statistics will be computed 
for each sampling time and each parameter.
8.1.2.2 Model and Tests
Dose Proportionality
For subjects who participate in the Phase 1 14/21 day  dosing portion of the study , an 
analysis will be performed on pharmacokinetic variables for C1D1 dose to simultaneously  
explore for demographic variables that explain some of the variability  in 
pharmacokinetics and to address questions of dose proportionality  and linear kinetics.  An 
analysis will be performed for dose -normalized C max, Tmax, and dose -normalized AUC t 
(AUC 0-24), provided that they can be adequately determined from the data.  The model 
used for the statistical analyses will include dose level.  This may be done by classify ing 
subjects by  dose level or, if appropriate, using dose level as a continuous variable.  
Covariates such as age, body  weight, bod y surface area, gender, and potentially 
formulation (if applicable), as well as others that might explain some of the variability in  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
121
the population will be included in the model initially.  However, a covariate may b e 
dropped from the model if the regression coefficient is not significant at level 0.10.  The 
natural logarithmic transformation will be employed for C maxand AUC tunless the data 
clearl y indicate that other transformation or the untransformed variable pro vides more 
nearl y symmetric probability  distributions and/or more nearly  homogenous variances 
across dose levels.  Within the framework of the model, tests that have good power for a 
trend with dose will be performed on the effect of dose level.
A correspo nding anal ysis will also be performed on pharmacokinetic variables of the dose 
on C1D14 for both the Phase 1 14/21 and 21/21 day  dosing schedules.  The variables will 
include dose -normalized C max, Tmax, and dose -normalized AUC t(AUC 0-8).
Additional analy ses will be performed if useful and appropriate.
8.1.2.3 Missing Values and Model Violations
The possibility  of bias from missing data of subjects who prematurely  discontinue will be 
addressed.  Normall y values of pharmacokinetic variables (C max, AUC, etc.) will be 
determined without replacing missing individual concentration values, simply using the 
available data, and if necessary  doing the analy sis with some missing values for a 
pharmacokinetic variable.  However, missing concentration values for isolated individual 
blood samples may  be replaced (imputed) if such might affect stud y conclusions or 
meaningfully  affect point estimates.
8.1.3 Exploratory  Efficacy
The following exploratory efficacy  anal yses will be performed on the data collected from 
the Phase 2a portion of the study .
8.1.3.1 Progression- Free Survival
The distribution of PFS will be estimated using Kaplan- Meier methodology .  Median time 
to PFS and the corresponding 95% confidence interval will be estimated. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
122
For a given subject, PFS will be defined as the number of da ys from the date the subject 
started study  drug to the date the subject experiences an event of disease progression, as 
defined in Section 5.3.3, or to the date of death if disease progression is not reached.  
Allevents of disease progression will be included, regardless of whether the event 
occurred while the subject was still taking study drug or had previously discontinued 
study  drug.  Events of death will be inc luded for subjects who had not experienced disease 
progression provided the death occurred within 2 cycles (42 days) of the date of the last 
available tumor evaluation.  If a subject has not experienced an event of disease 
progression or death as defined a bove, then the subject's data will be censored at the date 
of the last available evaluation for disease progression.  The date of the last available 
evaluation will be the date of the last study visit at which a tumor assessment was 
performed.
8.1.3.2 Objective Re sponse Rate
The proportion of subjects with a complete remission (CR), complete remission with 
incomplete bone marrow recovery  (CRi) or partial remission (PR) based on the NCI -WG 
criteria in Section 5.3.3.1 will be estimated and the corresponding 95% confidence 
interval for the proportion will be constructed.  The exact binomial distribution will be 
used to construct this confidence interval.
Asubject will be classi fied as a complete remission (CR), complete remission with 
incomplete bone marrow recovery  (CRi), partial remission (PR) or as having PD based on 
the definition in Section 5.3.3.1 .  The objective response rate (CR, CRi, PR ) will be 
computed for all subjects with active disease at baseline (in the opinion of the 
investigator).
8.1.3.3 Time to Tumor Progression
Time to tumor progression for a given subject will be defined as the number of day s from 
the date the subject started study  drug to the date of the subject's tumor progression .  Time 
to tumor progression may be collected up to 2 cy cles (42 day s) following the date of the 
last available tumor evaluation.  All events of tumor progression will be included,  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
123
regardless of whether the event occurred while the subject was still taking study  drug, or 
after the subject discontinued study drug.  Ifa subject has not progressed, then the data 
will be censored at the date of the last study  visit at which a tumor assessment was 
performed.
The distribution of the time to tumor progression will be estimated using Kaplan -Meier 
methodology .  Median time to tumor progression and the corresponding 95% confidence 
interval will be estimated.
8.1.3.4 Overall Survival
Time to death for a given subject will be defined as the number of day s from the date the 
subject started study drug to the date of the subject's death.  All events of death will be 
included, regardless of whether the event occu rred while the subject was still taking study  
drug, or after the subject discontinued study  drug.  If a subject has not died, then the data 
will be censored at the date of the last study visit, the last contact date, or the date the 
subject was last known to be alive, whichever is last.  The date of the last study  visit will 
be determined b y selecting the last available date of the following stud y procedures for a 
subject:  phy sical examination, vital signs assessment, blood chemistry , hematology , and 
urina lysis collection.
The distribution of the time to death will be estimated using Kaplan- Meier methodology .  
Median survival time and the corresponding 95% confidence interval will be estimated.
8.1.3.5 Duration of Overall Response
The duration of overall response f or a given subject will be defined as the number of day s 
from the day  the criteria are met for CR, CRi or PR(whichever is recorded first) to the 
date that PD is objectively documented.  The reference for PD will be the smallest 
measurements recorded since the treatment started.  Ifa subject is still responding then the 
subject's data will be censored at the last stud y visit at which a tumor assessment was 
performed. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
124
The distribution of the duration of overall response will be estimated using Kaplan- Meier 
Methodology .
8.1.3.6 ECOG Performance Status
For the ECOG performance scale, descriptive statistics will be summarized for each 
assessment.  In addition, a mean change from baseline to each assessment will be 
summarized.
8.1.3.7 Reporting of Results
All subjects enrolled will be assessed for response to treatment based on the NCI -WG 
criteria in Section 5.3.3.1 .  Each subject will be assigned to one of the follo wing 
categories:  1) complete remission, 2) complete remission with incomplete bone marrow 
recovery , 3) partial remission, 4) stable disease, 5) progressive disease, 6) early death 
from malignant disease, 7) earl y death from toxicity , 8) earl y death becaus e of other 
cause, or 9) unknown (not assessable, insufficient data).
Subjects in response categories 5 -8 will be considered as failing to respond to treatment 
(disease progression).  Thus, an incorrect treatment schedule or drug administration will 
not res ult in exclusion from the anal ysis of a response.
Sub-analyses may  be performed on the subset of subjects for whom major protocol 
deviations have not been reported (e.g., earl y discontinuation of treatment, major protocol 
violations, etc.).  The reasons fo r excluding subjects from the anal ysis will be clearly  
reported.
8.1.4 Safety
Safety  summaries will include all subjects participating in the stud y unless otherwise 
indicated.  A safet y anal ysis will be performed for all subjects in the Phase 1 portion of 
the st udy once the MTD is reached and/or RPTD is determined, after the last enrolled 
subject completes one cycle of drug, and prior to enrollment of subjects into the Phase 2a 
portion of the study .  A second safet y anal ysis will be performed for all subjects in the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
125
Phase 1 and Phase 2a portions of the study  upon completion of the study .  The following 
will be included in these anal yses:
Adverse Events
The number and percentage of subjects having treatment -emergent adverse events will be 
tabulated b y MedDRA system organ class and preferred term.38  The tabulations will also 
be provided with further breakdowns b y NC I CTCAE toxicity  grade and relationship to 
study  drug.  Serious adverse events, events leading to discontinuation of treatm ent, and 
events leading to death, will be summarized.  For subjects who participate in Cycle 1 of 
Phase 1 of the stud y, all summaries will be done by dose.  For the stud y as a whole, 
summaries will be provided with a breakdown as appropriate.
Platelet Coun ts
Platelet counts will be explored for trends with dose and time and summarized as 
appropriate.  The baseline value (last measurement before the beginning of study  drug 
administration) will be included in the statistical analy sis and changes from baseline will 
be addressed.
A repeated measures model with dose level as a classification variable will be performed 
for values in C ycle 1 of the platelet counts for which multiple measurements will be 
taken.  A transformation of a variable will be used if it clea rly provides more nearl y 
symmetric probability  distribution and/or more nearly  homogenous variances across dose 
levels.
The relationship between drug concentration variables and platelet counts will be 
explored.  The dependence of observations from the same subject will be appropriatel y 
taken into account in all of the above anal yses.
Other Safety Measurements
Laboratory test results, lymphocy te enumeration results, vital signs, echocardiogram 
results, and ECG interval measurements results will be explored for trends with dose and  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
126
time and summarized as appropriate.  The baseline values (Screening values) will be 
included in the statistical anal ysis and changes from baseline will be addressed.  Changes 
from baseline at the recommended Phase 2a dose will be a nalyzed with a t-test at each 
scheduled visit.  Where applicable, blood chemistry and hematology  determinations will 
be categorized according to NCI  CTCAE (Version 3.0) grades, and shifts from baseline 
NCI CTCAE grades to maximum and final post -baseline gr ades for each treatment group 
will be assessed.  Vital signs values will be evaluated for possible clinical significance 
using criteria developed at AbbVie.  Additional analy ses will be performed if useful and 
appropriate.
8.2 Determination of Sample Size
The sample size was based on simulations for CRM, clinical justification and subject 
enrollment numbers historically used for the testing of new oncology compounds.
During the dose -toxicity  modeling process, a minimum of three subjects per cohort will 
be inclu ded to warrant reasonable accuracy  for the estimates.  The total number of 
subjects required for the Phase 1 portion of this study will depend upon the toxicities 
observed as the trial progresses.  The total number of subjects for Phase 1 is not likely to 
exceed 40 based on operational considerations.  For the Phase 2a portion of the study, 
approximately  32 subjects with relapsed disease was chosen to further characterize safet y 
and assess preliminary  evidence of efficacy  with the RPTD in this population.
9.0 Ethics
9.1 Independent Ethics Committee (IEC) or Institutional Review 
Board (IRB)
Good Clinical Practice (GCP) requires that the clinical protocol, an y protocol 
amendments, the Investigator's Brochure, the informed consent and all other forms of 
subject informa tion related to the study  (e.g., advertisements used to recruit subjects) and 
any other necessary  documents be reviewed by an IEC/IRB.  IEC/I RB approval of the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
127
protocol, informed consent and subject information and/or advertising, as relevant, will be 
obtained prior to the authorization of drug shipment to a study  site.
Any amendments to the protocol will require IEC/I RB approval prior to implementation 
of an y changes made to the study design.  A list of the documents required prior to 
initiation of the stu dy can be found in Appendix C.
During the conduct of the study , the investigator should promptly  provide written reports 
(e.g.,ICH Expedited Reports or an y additi onal reports required b y local regulations) to 
the IEC/I RB of an y changes that affect the conduct of the study  and/or increase the risk to 
subjects.  Written documentation of the submission to the I EC/IRB should also be 
provided to AbbVie.
In the event of a state of emergency  due to the COVID -19 pandemic leading to difficulties 
in performing protocol -specified procedures, AbbVie will engage with study  site 
personnel in efforts to ensure the safet y of subjects, maintain protocol compliance, and 
minimize risks to the integrit y of the stud y while trying to best manage subject continuity 
of care.  This may  include alternative methods for assessments (e.g., phone contacts or 
virtual site visits), alternative locations for data collection (e.g., use of a local lab instead 
of a central lab), and shipping investigational product and/or supplies direct to subjects to 
ensure continuit y of treatment where allowed.
In all cases, these alternative measures must be allowed b y local regulations and permitted 
by IRB/IEC.  In vestigators should notify  AbbVie if an y urgent safet y measures are taken 
to protect the subjects against any immediate hazard.
9.2 Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, International Conference on 
Harmonization (I CH) GCP guidelines, applicable regulations and guidelines governing 
clinical study  conduct and ethical principles that have their origin in the Declara tion of 
Helsinki.  The investigator must ensure that the study  is conducted in accordance with the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
128
provisions as stated in the FDA regulations and complies with prevailing local laws and 
customs.  Responsibilities of the clinical investigator are specified in Appendix D.
9.3 Subject Information and Consent
Prior to the initiation of any  screening or study- specific procedures, the investigator or 
his/her representative wil l explain the nature of the study to the subject and answer all 
questions regarding this study .  Subjects who provide blood or tissue samples for 
pharmacogenetic or pharmacod ynamic anal yses will also sign an informed consent 
regarding the collection of the se samples.  Each informed consent will be reviewed, 
signed and dated b y the subject or his/her legal representative and the person who 
administered the informed consent.  A cop y of each informed consent will be given to the 
subject and each original will be placed in the subject's medical record.  An entry must 
also be made in the subject's dated source documents to confirm that informed consent 
was obtained prior to an y study -related procedures and that the subject received a signed 
copy .
10.0 Source Documents and Case Report Form 
Completion
10.1 Source Documents
Source documents are defined as original documents, data and records.  This may include 
hospital records, clinical and office charts, laboratory data/information, subjects' diaries or 
evaluation checklists, pharmacy  dispensing and other records, recorded data from 
automated instruments, microfiches, photographic negatives, microfilm or magnetic 
media, and/or x -rays.  Data collected during this study  must be recorded on the 
appropriate source documents.
The i nvestigator(s)/institution(s) will permit study -related monitoring, audits, I EC/IRB 
review, and regulatory  inspection(s), providing direct access to source data documents.
During the COVID- 19 pandemic, remote monitoring of data may  be employed if allowed 
by the local regulatory  authority , IRB/IEC, and the study  site. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
129
10.2 Case Report Forms
Case report forms must be completed for each subject enrolled in this study.  These forms 
will be used to transmit information collected during the stud y to AbbVie and regula tory 
authorities, as applicable.  The CRF data for this study will be collected with an Electronic 
Data Capture (EDC) tool called InForm provided by  the technology  vendor Phase 
Forward of Waltham, MA, USA.  In addition, this study  will use the Central Codi ng tool 
provided b y Phase Forward to code event and medication terms.  The EDC system and the 
study -specific eCRFs will be in compliance with Title 21 CFR Part 11.  The 
documentation related to the validation of the EDC tool is available through the vendor , 
Phase Forward, while the validation of the study -specific eCRFs will be conducted by  
AbbVie and be maintained in the Trial Master File at AbbVie.
The investigator will document subject data in his/her own patient files.  These patient 
files will serve as source data for the trial.  eCRF data required b y this protocol will be 
recorded b y investigative site personnel in the EDC tool.  Data entered into the eCRF 
should be supported b y source documentation.
If eCRF corrections are necessary  they  will be made by the investigator or by  an 
authorized member of the investigator's staff to the eCRFs.  All change information, 
including the date and person performing the corrections, will be available via the audit 
trail, which is part of the EDC sy stem.  For an y correction, a reason for the alteration will 
be provided.  The CRFs will be reviewed periodically for completeness, legibility, and 
acceptability  by AbbVie personnel (or their representatives).  AbbVie (or their 
representatives) will also be allowed access to all source documents pertinent to the study  
in order to verify  eCRF entries.  The principal investigator will review the eCRFs for 
completeness and accuracy  and provide his/her electronic signature and date to eCRFs as 
evidence thereof.
Access to the EDC system will be provided by  Phase Forward for the duration of the trial 
through a password -protected method of Internet access.  Such access will be removed 
from investigator sites at the end of the site's participation in the study .  Data from the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
130
EDC tool will be archived on appropriate data media (CD -ROM, etc.) and provided to the 
investigator at that time as a durable record of his eCRF entries.  It will be possible for the 
investigator to make paper printouts from that media.
10.3 Extension Study  Case Report Forms
Case report forms must be completed for each subject enrolled in this study.  These forms 
will be used to transmit information collected during the stud y to AbbVie and regulatory 
authorities, as applicable.  Each CRF will be printed on 2 -part NCR pa per: the white cop y 
will be retrieved b y AbbVie or its designee, and the pink cop y will be retained by the site.
All information written on the CRFs must also be reflected in the subject source 
documents.  All CRFs must be legible and completed in indelibl e ballpoint ink.  Any 
necessary  corrections are to be made b y drawing a single line through the incorrect entry 
and writing in the revision, which must be initialed and dated b y the investigator or 
designee.  Data are not to be obliterated b y blacking out, correction fluid, or by  erasing the 
original entry .  If the reason for the correction is not obvious, a brief explanation 
(e.g., "transcription error") should accompany the change.  Once a CRF has been 
separated, all changes must be made via addenda.  All addenda must be signed and dated 
by the investigator.
The principal investigator will review the case report forms for completeness and 
accuracy  and sign and date the set of case report forms where indicated.
Case report forms will be reviewed periodicall y against source documents for 
completeness, legibility , and acceptability  by AbbVie Laboratories personnel or its 
designee.
11.0 Data Quality  Assurance
Prior to enrolling an y subject in the study, an initiation meeting will be held with AbbVie 
personnel, the i nvestigator(s), and the stud y coordinators/project manager(s).  This 
meeting will include a detailed discussion and review of the protocol and essential  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
131
documents, performance of study  procedures, case report form completion and specimen 
collection methods.  The personnel at the study site will be trained on the study 
procedures, when applicable, by  AbbVie (or designee).
The AbbVie designated monitor will monitor the study  site throughout the study .  A 
100% source document review will be made against entrie s on the case report forms and a 
quality  assurance check will be performed to ensure that the investigator is comply ing 
with the protocol and regulations.  I n addition, continuous review of the data will be 
conducted b y a ph ysician or representative at Abb Vie.
Computer logic checks will be run to identify such items as inconsistent study dates.  An y 
necessary  corrections will be made to the electronic CRF.
Routine hematology, serum chemistry  and urinaly sis tests will be conducted using a 
certified clinical laboratory .  Laboratory  reference ranges will be obtained prior to the 
initiation of the study .  The AbbVie designated monitor, the investigator and other 
appropriate personnel from AbbVie will conduct a review of all laboratory results.
12.0 Use of Information
All information concerning ABT -263 and AbbVie operations, such as AbbVie patent 
applications, formulas, manufacturing processes, basic scientific data, or formulation 
information, supplied by  AbbVie and not previously  published is considered confidential 
information.
The information developed during the conduct of this clinical study  is also considered 
confidential and will be used by  AbbVie in connection with the development of ABT -263.  
This information may  be disclosed as deemed necessary  by AbbVie to o ther clinical 
investigators, other pharmaceutical companies, to the FDA and to other governmental 
agencies.  To allow for the use of the information derived from this clinical study and to 
ensure complete and thorough anal ysis, the investigator is obligate d to provide AbbVie 
with complete test results and all data developed in this study  and to provide direct access  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
132
to source data/documents for study -related monitoring, audits, IEC/IRB review, and 
regulatory  inspection.
This confidential information shall r emain the sole propert y of AbbVie, shall not be 
disclosed to others without the written consent of AbbVie, and shall not be used except in 
the performance of this study .
The investigator will maintain a confidential subject identification code list of all subjects 
enrolled in the study , including each subject's name, subject number, address, phone 
number and emergency  contact information.  This list will be maintained at the study  site 
with other study  records under adequate securit y and restricted access, and will not be 
retrieved b y AbbVie.
Any pharmacogenetic research that may  be done using DNA samples from this study  will 
be experimental in nature.  Hence, neither the investigator, the subject nor the subject's 
physician (if different than the investigat or) will be informed of individual subject 
pharmacogenetic results, should analyses be performed, nor will anyone not directly 
involved in this research.  Correspondingl y, genetic researchers will have no access to 
subject identifiers.  Individual results will not be reported to an yone not directly involved 
in this research other than for regulatory  purposes.  Aggregate pharmacogenetic 
information from this study  may  also be used in scientific publications or presented at 
medical conventions.  Pharmacogenetic information will be published or presented onl y in 
a way  that does not identify  any individual subject.
AbbVie agrees that before it publishes any  results of this study , it shall provide the 
investigator a pre -publication manuscript for review prior to the submission of the 
manuscript to the publisher.
13.0 Completion of the Study
The investigator will conduct the study  in compliance with the protocol and complete the 
study  within the timeframe specified in the contract between the investigator and AbbVie.  
Continuation of this study beyond this date must be mutually agreed upon in writing b y  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
133
both the investigator and AbbVie.  The investigator will provide a final report to the 
IEC/IRB following conclusion of the study , and will forward a copy  of this report t o 
AbbVie or their representative.
AbbVie may  terminate this study either in its entirety  or at a study  site provided that 
written notice is submitted at a reasonable time in advance of the intended termination.  
The investigator may  also terminate the stud y at his/her study site after providing written 
notice to AbbVie at a reasonable time in advance of the intended termination.  Advance 
notice is not required b y either part y if the stud y is stopped due to safet y concerns.  If 
AbbVie terminates the study  for safety  reasons, it will immediately  notify  the investigator 
by telephone and subsequently  provide written instructions for study  termination .
AbbVie will select the signatory coordinating investigator from the investigators who 
participate in each multi -center stud y.  Selection criteria for this signatory investigator 
will be based on level of participation, and significant knowledge of the clinical research, 
investigational drug, and study  protocol.  The signatory  investigator for the study  will 
review and sign the final study  report in accordance with the European Agency  for the 
Evaluation of Medicinal Products (EMEA) Guidance on Investigator's Signature for Stud y 
Reports.
The end of stud y is defined as the date of the last subject's last scheduled visi t or the 
actual date of follow -up contact, whichever is longer. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
134
14.0 Investigator's A greement
1. I have received and reviewed the Investigator Brochure for ABT- 263.
2. I have read this protocol and agree that the stud y is ethical.
3. I agree to conduct the study  as outl ined and in accordance with all applicable 
regulations and guidelines.
4. I agree to maintain the confidentiality  of all information received or developed in 
connection with this protocol.
Protocol Title: A Phase 1/2a Study  Evaluating the Safet y, Pharmacokinetics, and 
Efficacy  of ABT -263 in Subjects with Relapsed or Refractory  Chronic 
Lym phocy tic Leukemia
Protocol Date: 03September 2020
Signature of Principal Investigator Date
Name of Principal Investigator (printed or typed) 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
135
15.0 Reference List
1. Korsmey er SJ.  BCL -2 gene famil y and the regulation of programmed cell death.  
Cancer Res.  1999;59:1693s- 1700s.
2. Cory  S, Adams JM.  The Bcl -2 family :  regulators of the cellular life -or-death 
switch.  Nature Reviews.  Cancer 2002;2:647- 656.
3. Borner C.  The Bcl -2 protein family :  sensors and checkpoints for life -or-death 
decisions.  Molecular Immunology .  2003;39:615 -647.
4. Cory  S, Huang DCS, Adam JM.  The Bcl -2 family :  roles in cell survival and 
oncogenesis.  Oncogene.  2003;22: 8590- 8607.
5. Willis S, Day  CL, Hinds MG, et al.  The Bcl -2 regulated apoptotic pathway.  
Journal of Cell Science.  2003;116:4053 -4056.
6. Wei MC, Zong WX Cheng EHY, et al.  Proapoptotic BAX and BAK:  a requisite 
gateway  to mitochondrial dy sfunction and death.  Science.  2001;292:727 -730.
7. Lindsten T, Ross AJ, King A, et al.  The combined functions of proapoptotic Bcl -2 
family  members Bak and Bax are essential for normal development of multiple 
tissues.  Molecular Cell.  2000;6:1389- 1399.
8. Degenhardt K, Sundararaja n R, L indsten T, et al.  Bax and Bak independently  
promote cy tochrome c release from mitochondria.  Journal of Biological 
Chemistry .  2002;277:14127 -14134.
9. Adams JM, Cory  S.  Life or death decisions by  the Bcl -2 protein famil y [Review].  
Trends in Biochemi cal Sciences.  2001;26:61
-66.
10. Fadeel B, Zhivotovsk y B, Orrenius S.  All along the watchtower:  on the regulation 
of apoptosis regulators [Review].  FASEB Journal.  1999;13:1647 -1657.
11. Tsujimoto Y, Shimizu S.  Bcl -2 family :  life -or-death switch [Review].  FEBS 
Letters.  2000;466:6 -10.
12. Yang E, Korsmey er SJ.  Molecular thanatopsis:  a discourse on the Bcl -2 family  
and cell death.  Blood.  1996;88:386- 401. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
136
13. Cordy namics.  R&D/08/1639.  Cardiovascular assessment of sy stemic and 
pulmonary  hemody namic parameters in dogs after 28 day s of dosing with 
A-855071 (ABT- 263).  2008.
14. AbbVie.  ABT- 263 (A -855071) Investigator's Brochure Edition 1 5.  
29August 2019.
15. Diehl LF, Karnell LH, Menck HR, the American College of Surge ons Commission 
on Cancer and The American Cancer Societ y.  The National Cancer Data Base 
report on age, gender, treatment, and outcomes of patients with chronic 
lymphocy tic leukemia.  Cancer.  1999;86:2684 -2692.
16. Zwiebel JA, Cheson BD.  Chronic ly mphocy tic leukemia:  staging and prognostic 
factors.  Seminars in Oncology .  1998;25:42 -59.
17. Ries L AG, Harkins D, Krapcho M, et al.  SEER Cancer Statistics Review, 
1975- 2003, National Cancer Institute.  Bethesda, MD 
http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data 
submission, posted to the SEER web site 2006.
18. Jemal A, Clegg LX, Ward E, et al.  Annual report to the nation on the status of 
cancer, 1975- 2001, with a special feature regarding survival.  Cancer.   
2004;101:3- 27.
19. Francis S, Karanth M, Pratt G, et al.  The effect of immunoglobulin V H gene 
mutation status and other prognostic factors on the incidence of major infections in 
patients with chronic l ymphocy tic leukemia.  Cancer.  2006;107:1023 -1033.
20. Lamanna N, Weiss MA, Maslak PG, et al.  Sequential therap y with fludarabine, 
high dose cy clophosphamide, and rituxamib induces a high incidence of complete 
response in patients with chronic l ymphocy tic leukemia (CLL).  Proc Am Soc Clin.  
2003;22:580.
21. Keating MJ, O'Brien S, Albitar M, et al.  Earl y results of a chemoimmunotherapy  
regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for 
chronic l ymphocy tic leukemia.  J Clin Oncol.  2005;23(18):4079 -4088. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
137
22. Yee KWL and O'Brien SM.  Chronic ly mphocy tic leukemia:  diagnosis and 
treatm ent.  May o Clin Proc.  2006;81:1105 -1129.
23. Hallek M, Schmitt B, Wilhelm M, et al.  Fludarabine plus cy clophosphamide is an 
efficient treatment for advanced chronic l ymphocy tic leukaemia (CLL):  results of 
a phase II study  of the German CLL Study  Group.  Br J Haematol.  
2001;114:342- 348.
24. Keating MJ, O'Brien S, Kantarjian H, et al.  Long -term follow -up of patients with 
chronic l ymphocy tic leukemia treated with fludarabine as a single agent.  Blood.  
1993;81:2878- 2884.
25. Byrd JC, Stilgenbauer S, Flinn I W.  Chroni c lymphocy tic leukemia.  Hematology  
2004; 163- 183.
26. Campath [package insert].  Cambridge, MA:  Genzy me Corp; 2005.
27. Fujita, N.  In vivo veritas:  Bcl -2 and Bcl -XL mediate tumor cell resistance to 
chemotherap y Drug Resistance Updates 2000, 3 (149 -154).
28. Schof fski P, Riggert S, Fumoleau P, et al.  Phase 1 trial of intravenous aviscumine 
(rViscumin) in patients with solid tumors:  a study of the European Organization 
for Research and Treatment of Cancer New Drug Development Group.  Annals of 
Oncology  2004;15(12) :1816 -1824.
29. O'Quigley  J, Zohar S.  Experimental designs for phase I and phase I/ II dose -finding 
studies.  British Journal of Cancer 2006;94:609 -613.
30. Cheson BD, Bennett, MG, Kay  N, et al.  National Cancer Institute -Sponsored 
Working Group Guidelines for Chr onic Ly mphocy tic Leukemia:  Revised 
Guidelines for Diagnosis and Treatment.  Blood.  1996;12:4990 -4997.
31. Hallek, M, Cheson BD, Catovsky  D, Caligaris -Cappio F, Dighiero G, 
Dohner H,etal.  Guidelines for the diagnosis and treatment of chronic l ymphocy tic 
leukemia:  a report from the I nternational Workshop on chronic l ymphocy tic 
leukemia (IWCLL) updating the National Cancer Institute -Working Group (NCI -
WG) 1996 guidelines.  Blood.  E pub 2008 Jan 23. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
138
32. Storer BE.  An evaluation of phase I clinical trial designs in the continuous 
dose-response setting.  Stats Med 2001;20:2399 -2408.
33. Potter DM.  Adaptive dose finding for phase I clinical trials of drugs used for 
chemotherap y of cancer.  Stats Med 2002;21:1805 -1823.
34. Common Terminology  Criteria for Adverse Events, Ve rsion 3.0, DCTD, NCI , 
NIH, DHHS.  August 9, 2006.  Available at:  
http://ctep.cancer.gov/reporting/ctc_v30.html.  Accessed November 2006.
35. O'Quigley  J, Shen LZ.  Continual reassessment method:  a likelihood approach.  
Biometrics 1996 Jun;52(2):673- 84.
36. Piant adosi S, Fisher JD, Grossman S.  Practical implementation of a modified 
continual reassessment method for dose -finding trials.  Cancer Chemother 
Pharmacol 1998;41(6):429 -36.
37. Goodman SN, Zahurak ML , Piantadosi S.  Some practical improvements in the 
continual reassessment method for phase 1 studies.  Stat Med 1995 June 
15;14(11):1149- 61.
38. Coding Guidelines for MedDRA Term Selection, AbbVie Global Pharmaceutical 
Research and Development (GPRD), Global Pharmacovigilance and Clinical 
Project Team.
39. Oken M, Creech R, Tormey  D, et al.  Toxicity  and response criteria of the Eastern 
Cooperative Oncology  Group.  Am J Clin Oncol.  1982;5:649 -655. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
139
Appendix A. List of Abbreviations and Definitions of Terms
Abbreviations
ACD Acid Citrate Dextrose
AE Adverse Event
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Count
AST Aspartate Aminotransferase
aPTT Activated Partial Thromboplastin Time
Bcl B-Cell Lymphoma
BH Bcl-2 Hom ology
BSA Body  Surface Area
BUN Blood Urea Nitrogen
14C Carbon -14 (Radiocarbon)
CGH Com parative Genomic Hybridization
CLL Chronic Lymphocytic Leukemia
CNS Central Nervous System
COVID -19 Coronavirus Disease -2019
CR Com plete Remission
CRi Com plete Remission with Incomplete Bone Marrow  Recovery
CRM Continual Reassessment Method
CRF Case Report Form or Electronic Case Report Form
CT Com puted Tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP2C8 Cytochrome P450 2C8
CYP2C9 Cytochrome P450 2C9
CYP3A Cytochrome P450 3A
DLT Dose Limiting Toxicity
DNA Deoxyribonucleic acid
DTP Direct To Patient
EC50 50% Effective Concentration
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic Case Report Form 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
140
EDC Electronic Data Capture
EDTA Edetic Acid (ethylenediaminetetraacetic acid)
EMEA European Agency for the Evaluation of Medical Products
ERT Estrogen Replacement Therapy
FCR Fludarabine, cyclophosphamide, rituximab
FDA U.S. Food and Drug Administration
FISH Fluorescence in situ Hybridization
GCP Good Clinical Practice
G-CSF Granulocyte -Colony Stimulating Factor
GM-CSF Granulocyte Macrophage -Colony Stimulating Factor
HDPE High Density Polyethylene
HIV Human Immunodeficiency Virus
hr Hour
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IQR Interquartile Range
IRB Institutional Review Board
ITP Immune Thrombocytopenia Purpura
IWCLL International Workshop for Chronic Lymphocytic Leukemia
JP Japanese Pharmacopoeia
K/L Thousand per Microliter
kg kilogram
Ki Inhibition Constant
LDH Lactate Dehydrogenase
MCH Mean Corpuscular Hemoglobin
MCHC Mean Corpuscular Hemoglobin Concentration
mcl microliter
MCT Medium Chain Triglyceride
MCV Mean Corpuscular Volume
MedDRA Medical Dictionary for Regulatory Activities
g Microgram
mg Milligram
min Minute
mL Milliliter 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
141
M Micromolar
MPV Mean Platelet Volume
MRI Magnetic Resonance Imaging
MTD Maximum Tolerated Dose
NCI National Cancer Institute
NCI-WG National Cancer Institute -Working Group
nM Nanomolar
NOAEL No Observed Adverse Effect Level
nPR Nodular Partial Remission
ORR Objective Response Rate
OS Overall Survival
PCP Pneumocystis Pneumonia
PD Pharmacodynamic or Progressive Disease
PFS Progression -free Survival
PG Pharmacogenetic
Ph. Eur. European Pharmacopoeia
PK Pharmacokinetic
PLL Prolymphocytic Leukemia
PR Partial Remission
PT Prothrombin Time
QD Once daily
QTc QT interval corrected for heart rate
RBC Red Blood Cell
RPTD Recommended Phase Tw o Dose
SAE Serious Adverse Event
SCLC Small Cell Lung Cancer
SD Stable Disease
SGOT Serum Glutamic Oxaloacetic Transaminase
SGPT Serum Glutamic- Pyruvic Transaminase
SSRI Selective Serotonin Reuptake Inhibitor
STAT statim (immediately)
TLS Tumor Lysis Syndrome
TTP Time-to-Tum or Progression
ULN Upper Limit of Normal 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
142
US Ultrasound
USP United States Pharmacopoeia
WBC White Blood Cell
Pharmacokinetic and Statistical Abbreviations
AUC Area under the plasma concentration -time curve
AUC t Area under the plasma concentration -time curve from time zero to time of 
last measurable concentration
AUC  Area under the plasma concentration -time curve from time zero to infinity
Cmax Maximum observed plasma concentration
Cmin Minimum observed plasma concentration
t1/2 Term inal phase elimination half -life
Tmax Time to maximum observed plasma concentration 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
143
Appendix B. List of Protocol Signatories
Nam e Title Functional Area
Sr. Scientist II Biomarkers
 Program Lead II Clinical Program Development
 Study Project Manager II Clinical Program Development
Director Statistics
 Executive Medical Director, TA MD Clinical Program Development 

ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
144
Appendix C. Documents Required Prior to Initiation of the Study
As sponsor of a clinical study , AbbVie has an obligation to ensure that the study  will be 
conducted b y a qualified investigator with sufficient resources (of time, personnel, and 
physical facilities) to conduct the study  and to ensure that the investigator understands and 
agrees to comply  with Good Clinical Practic es and applicable regulations, policies, and 
procedures.  Prior to the beginning of an y clinical study, the investigator will be asked to 
provide the following documentation.
1. A signed and dated Investigator's agreement page for the stud y.
2. A signed and date d Form FDA 1572 certify ing the investigator's agreement to 
comply  with the appropriate regulations governing the conduct of the stud y.  A 
signed and dated Investigator Information and Agreement Form certifying the 
investigator's agreement to comply  with th e appropriate (e.g., I CH GCP) 
regulations governing the conduct of the stud y.
3. Current curriculum vitae for the investigator.  If subinvestigators will participate in 
the study , curriculum vitae for each.
4. Requirements for the Independent Ethics Committee (I EC)/ Institutional Review 
Board (IRB).
●A cop y of the signed and dated letter of approval of the IEC/I RB.  The letter 
must specify  that both the protocol and informed consent form were approved 
(unless separate documentation that the informed consent was app roved is 
provided).
●A dated list containing the names and affiliations of the members of the 
IEC/IRB, or the institution's General Assurance Number.
●If the investigator and/or subinvestigator is a member of the IEC/IRB, a letter 
stating that he/she did not participate in the review or approval of the protocol 
or informed consent form.
5. A specimen cop y of the IEC/I RB-approved informed consent document to be used 
in the study . 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
145
6. A list of reference ranges of values for all laboratory tests specified b y the proto col 
for all laboratories utilized.
7. A cop y of the laboratory(ies) certification(s) or the authorization number of the 
certification(s), the name of the certifying authority, and the period of certification.
8. Financial Disclosure Certification forms must be c ompleted by  each investigator 
and all subinvestigators identified on the Form FDA 1572 or Investigator 
Information and Agreement Form.  A Financial Disclosure, EU Consent, is 
required to be completed for each investigator and/or subinvestigator who is a 
resident of the European Union. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
146
Appendix D. Responsibilities of the Clinical Investigator
Clinical research studies sponsored b y AbbVie are subject to the Good Clinical Practices 
(GCP) and local regulations and guidelines governing the stud y at the site location.  I n 
signing the Investigator Agreement in Section 14.0 of this protocol the investigator is 
agreeing to the following:  
1. Conducting the stud y in accordance with the rel evant, current protocol(s) and only  
make changes in a protocol after notify ing AbbVie, except when necessary  to 
protect the safet y, rights, or welfare of subjects.
2. Personally  conducting or supervising the described investigation(s).
3. Inform all subjects, or any persons used as controls, that the drugs are being used 
for investigational purposes and compl ying with the requirements relating to 
informed consent and ethics committees  (e.g., independent ethics committees 
[IEC] or institutional review board [IRB] ) review and approval of the protocol 
amendments.
4. Reporting adverse experiences that occur in the course of the investigation(s) to 
AbbVie and the site director.
5. Reading the information in the I nvestigator's Brochure/safet y material provided, 
including the instructions for use and the potential risks and side effects of the 
investigational product.
6. Informing all associates, colleagues, and employees assisting in the conduct of the 
study  about their obligations in meeting the above commitments.
7. Maintaining a dequate and accurate records of the conduct of the study  and make 
those records available for inspection by  representatives of AbbVie, and/or the 
appropriate regulatory  agency , and retaining all study -related documents until 
notification from AbbVie.
8. Maint aining records demonstrating that an ethics committee reviewed and 
approved the initial clinical investigation and all amendments. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
147
9. Reporting promptl y all changes in the research activity  and all unanticipated 
problems involving risks to human subjects or o thers to the appropriate individuals, 
coordinating investigator, institutional director and/or directl y to the ethics 
committees and AbbVie.
10. Following the protocol and not make an y changes in the research without ethics 
committee approval, except where nec essary  to eliminate apparent immediate 
hazards to human subjects. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
148
Appendix E. Sample List of Excluded and Cautionary Medications
SSRI's (Cautionary) CYP3A Inhibitors (Excluded)
citralopram (Celexa) atanazavir
escitalopram (Lexapro) clarithromycin
fluoxetine (Prozac) fluconazole
paroxetine (Paxil) fluvoxamine (Luvox)
sertraline (Zoloft) indinavir
itraconazole
Anticoagulation Therapy (Excluded) ketoconazole
coumadin (Warfarin)+ nefazodone
dalteparin (Fragmin) nelfinavir
enoxaparin (Lovenox) ritonavir
fondaparinux (Arixtra) saquinavir
heparin++ telithromycin
melagatran/ximelagatran voriconazole
tinzaparin (Innohep)
CYP3A Inducers (Cautionary)
Anti -platelet (Excluded) barbiturates
acetylsalicylic acid (Aspirin) carbamazepine (Tegretol®)
aspirin/extended -release dipyridamole (Aggrenox) efavirenz
clopidogrel (Plavix) nevirapine
dipyridamole (Persantine) oxcarbazepine
ticlopidine (Ticlid) phenobarbital
Tirofiban (Aggrastat) phenytoin (Dilantin®)
rifampin (Rifadin®)
NSAIDS+ (Excluded) rifapentine
aspirin St. John's wort
celecoxib
diclofenac CYP2C9 Substrates (Cautionary)
diflunisal fluvastatin
etodolac glipizide
ibuprofen irbesarten
indomethacin losartan
ketoprofen phenytoin 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
149
nabumetone sulfamethoxazole
naproxen sulfinpyrazone
oxaprozin tolbutamide
salsalate tosomide
sulindac
tolmetin CYP2C8 Substrates#(Cautionary)
aminodarone
Ethanol (Excluded)** amodiaquine
cerivastatin
Aldehyde Dehydrogenase Inhibitor (Excluded)** chloroquine
disulfiram (Antabuse) lovastatin*
paclitaxel (Taxol)
pioglitazone
repaglinide
rosiglitazone
simvastatin (Zocor)*
troglitazone
+ Warfarin and many NSAIDS are also CYP2C9 substrates.
++ Heparin may be used for patency of a central venous catheter.
* Significant increase in AUC by co -administration of gemfibrozile, a potent CYP2C8 inhibitor.  However, the 
involvement of CYP2C8 is unclear.
** This does not apply if the subject is taking Meltrex tablets.
# Only certain statins qualify as CYP2C8 substrates. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
150
Appendix F. Simulations Comparing Fixed 3+3 Design Versus CRM- based 
Design
Introduction
Simulations were conducted to compare a fixed 3+3 design to a design based on a specific 
continual reassessment method (CRM).  Designs were compared with respect to total 
sample size required, closeness of the design -determined MTD to the true MTD, and 
number of subjects treated at doses that are potentially 'too high' (e.g. ,doses with a > 90% 
chance of resulting in a DL T).  Two families of dose -toxic ity curves were considered, 
onerepresenting a "steep" dose -toxicity  response curve and another representing a 
"shallow" dose -toxicity  curve.
The CRM -based method provided essentially uniformly better results than the fixed 
3+3design.  That is, for each s imulated dose -toxicity  relationship, the CRM design 
generall y required fewer total subjects, resulted in an estimated MTD closer to the true 
MTD, and treated fewer subjects at potentially toxic doses, compared to the fixed 
3+3design.
The following section s describe the stud y designs, the simulations, and the performance 
of each design in the simulations.
Methods
Abbreviations
CRM continual reassessment method
D30 dose w ith a 30% probability of a DLT
D90 dose w ith a 90% probability of a DLT
DLT dose-limiting toxicity
MTD maximum tolerated dose (defined as D30 for this protocol) 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
151
Fixed 3+3 Design
The following steps describe the dose allocation scheme for the simulated fixed 
3+3designs.
●Three simulated subjects treated at the initial dose (10 m g).
●If no DLTs, double the dose.
●Proceed similarly until the first DLT is observed.
●If 1/3 DLT, enroll 3 more subjects at the same dose.
●If 1/6 DLT, increase dose by 33%.
●If > 1/6 DLTs decrease dose by 25%.
●If 2/3 or 3/3 DLTs, decrease dose b y 25%.
●Upon dose decrease:
●If 0/3 or 1/6 DLTs, this is the MTD
●If > 1 DLT, dose decrease by  25% and repeat.
●If 0/3 or 1/6 DLTs, this is the MTD.
●If > 1 DLT, the MTD is the next highest dose with 0/3 or 1/6 DL Ts
CRM Design
Three simulated subjects are treated at a dos e of 10 mg.  Data from these 3 subjects (for 
each subject, DLT or no DLT) are combined with 13 imputed values.  Ten values are 
imputed at a very  high dose (2000 mg):  9 observations with a DL T and 1 observation 
without a DL T.  These 10 values represent a d ose with a probability  of a DLT of at least 
90%, and they  were assigned a weight of 0.025, so that they collectivel y represent 
one-fourth of one subject.  Three values are imputed at a dose of 160 mg: 1 observation 
with a DLT and two observations without a DLT.  These 3 values represent data borrowed 
from Study  M06 -814, in which 1/3 subjects who received a dose of 160 mg experienced a 
DLT.  The 3 imputed values are assigned a weight of 0.083, so that they  collectively  
represent one -fourth of one subject.  The use of the imputed data is essential to allow the 
model fit to converge.  Without the imputed data, the logistic regression model fit is  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
152
essentially  a step function, which generally  does not allow the CRM to converge to the 
MTD.
A 2-parameter logistic r egression model is fitted to the data as described above, and the 
next dose is chosen to be at the model -estimated MTD (the dose predicted to result in a 
30% probability  of DLT, "D30").  If the predicted dose is more than 100 mg above the 
current dose, the new dose is escalated b y 100 mg or less.
When the next predicted D30 value is within 5% of the current dose, the model is 
considered to have converged and the MTD is declared.
Simulation Details
Two families of dose -toxicity  relationships were considered:   one with a steep slope 
Figure 1) and one with a shallow slope (Figure 2).  Parameters were chosen so that a total 
of 7 dose -toxicity  curves for each famil y were assessed, spanning the expected dynamic 
range of ABT -263 doses.  Thus, the fixed 3+3 design w as compared to the CRM -based 
design in 14 different scenarios.  In each scenario, 1000 simulations of each design were 
conducted and the following characteristics were summarized:
●Estimated MTD (median, IQR)
●True DLT probabilities associated with the estimated MTD (median, IQR)
●Sample size (median, interquartile range [IQR])
●Subjects dosed above D90 (median) 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
153
Figure 1. Steep Dose -toxicity Relationships
0%20%40%60%80%100%
0 100 20 0 300 400 500 600 700 800 900 1000
Dose (mg)Probability of DLTIntercept:
–5 – 10 –15 –20 –25 –30 –35 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
154
Figure 2. Shallow Dose -toxicity Relationships
Results
Results for simulations of the steep dose -toxicity  relationships are summarized in Table 1.  
The CRM design consistently  resulted in better estimates of the MTD.  The median 
estimated MTD ranged from D12 to D35, whereas the fixed design consistently  
underestimated the true MTD (median estimated MT D values ranged from < D01 to 
D25).  The CRM design also had an advantage in total number of subjects required, 
especiall y for dose -toxicity  relationships with a lower true MTD.  For higher true MTDs, 
the sample size advantage disappeared due to the restriction on the maximum dose 
increase (100 mg, see Methods).  Finall y, the CRM design generally dosed a smaller 
number of subjects above the D90.0%20%40%60%80%100%
0 100 20 0 300 400 500 600 700 800 900 1000
Dose (mg)Probability of DLTIntercept:
–2 –3 –4 –5 –6 –7 –8 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
155
Table 1. Simulation Results for Steep Dose -toxicity Curves (Slope = 0.04)
InterceptTrue 
MTD
(mg) DesignEstimated MTD
(median, IQR)True DLT 
probabilities 
assoc. with est. 
MTD
(median, IQR)Sample size
(median, IQR)No. 
dosed 
above 
D90
(median)
–5 104Fixed 90 (80, 90) .20 (.14, .20) 27 (21, 27) 0
CRM 99 (93, 117) .26 (.22, .42) 15 (12, 21) 0
–10 229Fixed 181 (181, 213) .06 (.06, .19) 30 (30, 30) 3
CRM 234 (212, 240) .35 (.18, .40) 18 (15, 21) 0
–15 354Fixed 320 (320, 320) .10 (.10, .10) 30 (30, 30) 6
CRM 364 (332, 359) .30 (.15, .35) 21 (18, 24) 0
–20 479Fixed 362 (362, 481) .00 (.00, .32) 33 (27, 33) 3
CRM 461 (452, 485) .17 (.13, .35) 24 (24, 24) 0
–25 604Fixed 481 (481, 481) .00 (.00, .00) 27 (27, 30) 0
CRM 592 (574, 628) .21 (.12, .53) 27 (27, 27) 0
–30 729Fixed 723 (640, 723) .25 (.01, .25) 33 (33, 33) 6
CRM 726 (699, 726) .28 (.12, .28) 30 (30, 30) 0
–35 854Fixed 723 (723, 723) .02 (.02, .02) 33 (33, 33) 6
CRM 825 (825, 862) .12 (.12, .37) 33 (33, 36) 0
Both designs performed better for shallow dose -toxicity  curves (Table 2) than they  did for 
steep curves, but the CRM design retained advantages over the fixed design, both in the 
accuracy  of the estimates (median estimated MTDs ranged from D26 to D30, versus D10 
to D23 for the fixed design) and in total sample size (median of 3 to 11 fewer subjects). 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
156
Table 2. Simulat ion Results for Shallow Dose -toxicity Curves (Slope = 0.01)
InterceptTrue 
MTD
(mg) DesignEstimated MTD
(median, IQR)True DLT 
probabilities 
assoc. with est. 
MTD
(median, IQR)Sample size
(median, IQR)No. 
dosed 
above 
D90
(median)
–2 115Fixed 40 (15, 80) .17 (.14, .23) 21 (15, 30) 0
CRM 116 (88, 149) .30 (.24, .38) 18 (15, 24) 0
–3 215Fixed 159 (90, 199) .20 (.11, .27) 30 (24, 36) 0
CRM 213 (177, 252) .30 (.23, .38) 18 (15, 24) 0
–4 315Fixed 241 (213, 320) .17 (.13, .31) 33 (27, 36) 0
CRM 314 (262, 346) .30 (.30, .37) 21 (15, 24) 0
–5 415Fixed 325 (319, 462) .15 (.14, .20) 33 (30, 33) 0
CRM 404 (354, 448) .28 (.19, .37) 21 (18, 24) 0
–6 515Fixed 481 (362, 481) .23 (.08, .23) 33 (27, 33) 0
CRM 495 (450, 556) .26 (.18, .39) 24 (21, 27) 0
–7 615Fixed 481 (481, 640) .10 (.10, .35) 30 (30, 33) 0
CRM 596 (556, 660) .26 (.19, .40) 27 (24, 30) 0
–8 715Fixed 640 (481, 641) .17 (.04, .17) 36 (33, 36) 3
CRM 699 (662, 762) .27 (.20, .41) 27 (27, 33) 0
Example Simulations
Figure 3 and Figure 4 show ty pical simulation runs for a steep dose -toxicity  curve 
(slope = 0.04, intercept = –10) for the fixed 3+3 design and the CRM design, respectivel y.  
The true MTD for this example is 229 mg. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
161
Appendix G. Extension Study - Assessments
Table 1. Extension Study:  Schedule of Assessments
Procedures Day 1#Every 
4Cycles#Final Visit#30 Day 
Safety 
Follow -up 
Visit#
Informed Consent X
Physical Exam (including weight) XaXaX X
Vital Signs X X X X
12-lead ECG X
2D Echocardiogram with Doppler X
Platelet Countb,#X X X X
Lymphocyte Enumerationc,#X
Chemistryd,#X X X X
Hem atologyd,#X X X X
Urinalysisd,#X X
Performance Status (ECOG)#X X
Tumor Assessmentse,#X
Disease Progression Assessment X X X
Adverse Event/Concomitant Medications 
AssessmentX X X Xf
Dispense/Collect ABT -263gX X X
Dispense/Collect Subject Dosing Log X X X
# Visits and activities may be conducted in the subject's home residence or by phone/virtually.
a. Symptom directed.
b. Platelet Counts will be performed and assessed by the investigator or subinvestigator prior to study drug 
administration.  Any platelet count less than 25,000/mm3should be confirmed the same day by manual reading and 
separate peripheral draw.  Additional platelet counts will be obtained if ABT -263 is held or interrupted.  If a 
platelet count is less than or equal to 50,000/mm3, additional platelet counts will be p erformed every day at the 
discretion of the investigator.  Platelet counts should be obtained 10 to 60 minutes after the completion of any 
platelet transfusion.  
c. Perform Lymphocyte Enumeration at the Final Visit and as needed for subjects if deemed nec essary by the 
investigator. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
162
Table 1. Extension Study:  Schedule of Assessments (Continued)
d. The specific laboratory tests required for chemistry, hematology and urinalysis are listed in Table 7.  Triglycerides, 
amylase and lipase will only be collected at the Final Visit.  For any subjects who are at high risk for tumor lysis 
syndrome (TLS), additional samples for hematology and chemistry may be coll ected as per the management 
guidelines in Section 6.7.4 .  ANC ≥ 500/µL and < 1,000/µL should be monitored at an increased frequency at the 
discretion of the invest igator.  Grade 2 chemistry labs should be monitored at an increased frequency at the 
discretion of the investigator.
e. If additional tumor assessments are collected by the site per standard of care, the data should be recorded on the 
appropriate paper CRF .
f. Adverse events will be followed until satisfactory clinical resolution of the adverse event is achieved.
g. A bottle's expiration date and pill count should be taken into account when dispensing 4 cycles of drug. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
163
Appendix H. Protocol Amendment:  List of Changes
The summary  of changes is listed in Section 1.1.
Specific Protocol Changes
Section 1.0  Title Page
"Sponsor/Emergency Contact:," "Title" previously read:
Group Med ical Director
Has been changed to read:
Executive Medical Director
Section 3.0  Introduction
Subsection ABT -263 Clinical Data
Add:  new fourth paragraph
Considering the coronavirus (COVID -19) pandemic, the benefit and risk to subjects 
participating in this study has been re -evaluated.  Subjects receiving ABT -263may be at 
an increased risk for COVID- 19 infection or experience serious illness if infected.  
Management of these adverse events will be made on a case -by-case basis with 
consideration of benefit/r isk.  However, based on the population and disease being 
studied, and the anticipation that COVI D-19 related risks are not expected to differ 
substantially  between study  subjects and the broader population of subjects receiving 
treatment for CLL ,no change to the benefit/risk balance for subjects in this study  is 
expected.
Section 5.3.1.1   Study Procedures
Add:  new last paragraph
Study  visits may  be impacted due to the COVID -19 pandemic. This may  include changes 
such as phone or virtual visits, visits at alternative locations, or changes in the visit 
frequency  and timing of study  procedures, among others. Additional details are provided 
in the subsequent section. Every  effort should be made to ensure the safety of subjects  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
164
and site staff, while maintaini ng the integrit y of the study. If visits cannot be conducted 
onsite due to travel restrictions or other pandemic -related reasons, follow the updates 
below how to proceed.
Section 5.3.1.1   Study Procedures
Subsection COVID -19 Pandemic -Related Acceptable Pr otocol Modifications
Add:  new subsection title and text
COVID -19 Pandemic -Related Acceptable Protocol Modifications
During the COVID- 19 pandemic, if it is not possible for all study  procedures to be 
performed as specified due to travel restrictions or other reasons, the following 
modifications are allowed:
●If permitted b y local regulations, the I RB/IEC and the subject, the subject 
visitsmay be conducted in the subject's home residence.
●Some study  visits and/or activities may  be performed by  phone/virtually .  
These are indicated b y a hashtag (#) in the activity table ( Appendix G)
○During a virtual v isit, activities that do not need to be performed are 
indicated b y a (#) in the activity table ( Appendix G).
● S tudy visits and/or activities may  be performed b y a lo cal 
clinic/hospital/laboratory. All procedures performed at local facilities must be 
performed b y appropriately  qualified personnel.
●Study  Visits and/or activities should be performed as scheduled whenever 
possible. If it is not possible to do so due to the pandemic, perform the activity  
at the earliest feasible opportunity . Laboratory  draws must be obtained within 
24 hours from the scheduled visit.
Section 5.3.1.1   Study Procedures
Subsection Informed Consent
Add:  new last paragraph
Due to the COVID -19 pandemic, it is possible that additional protocol modifications not 
outlined in this protocol may become necessary . If this situation arises, in addition to the  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
165
study  informed consent, additional verbal consent may  be obtained prior to these 
adaptations or substantial changes in stud y conduct in accordance with local regulations.
Section 5.3.1.1   Study Procedures
Subsection Vital Signs
Heading " COVID -19 Pandemic -Related Acceptable Protocol Modifications"
Add:  new heading title and text
COVID -19 Pandemic -Related Acceptable Protocol Modifications 
Due to the COVID -19 pandemic, subject visits may  be conducted via phone or video 
conference.  In these situations, weight, and vital signs measurements may be performed 
by the subject or caregiver as needed.
Section 5.3.1.1   Study Procedures
Subsection Platelet Count
Heading " COVID -19 Pandemic -Related Acceptable Protocol Modifications"
Add:  new heading title and text
COVID -19 Pandemic -Related Acceptable Protocol Modifications 
If travel restrictions or other chan ges in local regulations in light of the COVID -19 
pandemic prevent the subject from having blood drawn for laboratory  testing at the stud y 
site, if possible, arrange for subjects to have laboratory work done at a local lab, hospital, 
or other facility .Local lab results should be obtained along with reference ranges and 
kept within the subjects' source documentation. Local lab results should be reviewed b y 
the investigator as soon as possible. If laboratory  samples cannot be obtained, study  drug 
administration may  be continued provided the investigator has reviewed all prior 
laboratory  results and confirms and discusses with the subject that there is no safet y 
concern for the subject to continue use of the study drug in the absence of current labs. 
The subject should be scheduled for laboratory draws as soon as feasible within 14 day s 
from the scheduled visit. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
166
Section 5.4.1  Discontinuation of Individual Subjects
Add:  new fourth and fifth paragraph
During the COVID- 19 pandemic, it has been necessary  to employ  mitigation strategies to 
enable the investigator to ensure subject safet y and continuity of care.
The investigator should contact the sponsor medical contact before discontinuing a subject 
from the study  for a reason other than "planned per protoc ol," to ensure all acceptable 
mitigation steps have been explored.
Section 5.5.1  Treatments Administered
Add:  new third and fourth paragraph
During the Study  Drug Dosing Period, a subject with confirmed (viral test positive) or 
suspected COVID- 19 infecti on can onl y be dosed with study  drug if the following 
COVID- 19 viral clearance criteria are met:
●Symptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours apart 
after at least 10 days have passed since recovery , defined as resolution of f ever 
without use of antipy retics and improvement in respiratory  symptoms (e.g., 
cough, shortness of breath)
●Asymptomatic subjects:  At least 2 negative viral tests in a row, ≥ 24 hours 
apart after at least 10 days have passed since prior positive result (note:  
subjects who develop s ymptoms will follow guidance above for symptomatic 
subjects)
Delay s in study  drug dosing due to the above COVID -19 testing guidance for subjects 
must be discussed with the AbbVie medical contact, along with the possibility  of 
premature discontinuation from the study  drug dosing period.  Frequency  or timing of 
COVID- 19 testing and intervals between testing for the above viral clearance criteria may  
be adjusted to account for epidemiologic trends, updated information regarding 
infectivity , and local/institutional guidelines. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
167
Section 5.5.4  Selection and Timing of Dose for Each Subject
Subsection COVID -19 Pandemic -Related Acceptable Protocol Modifications
Add:  new subsection title and text
COVID -19 Pandemic -Related Acceptable Protocol Modifications
Study  drug may  be shipped from the stud y site directly to the stud y subject's home if all 
the following criteria are met:
●Direct -to-patient (DTP) shipment of study  drug is allowed by  local regulations 
and the relevant ethics committe e
●Study  drug can be administered by  the subject (or subject's caregiver) at home
●Subject agrees to have the study  drug shipped directly  to their home
●Shipments may  also include other study  supplies (e.g., drug dosing diaries).  
Instructions will be provide d by AbbVie as to how a study  site can initiate a 
DTP shipment using Marken, a global vendor selected b y AbbVie to provide 
this service when necessary .  Shipments of study  drugs from the study  site to a 
subject's home will be appropriatel y temperature cont rolled (qualified shipper 
or temperature monitoring) within the labeled storage conditions. Signature is 
required upon delivery ; due to COVID -19 related social distancing, this may  
be provided b y the courier after delivery.  Documentation of the shipment is to 
be retained b y the clinical site.
●AbbVie will not receive subject identify ing information related to these 
shipments, as the site will work directl y with the courier.
The study  site is responsible for meeting IRB/IEC reporting requirements related t o DTP 
shipments of study  drug, and for obtaining consent to provide delivery  information to the 
courier and documenting this consent in source documents.
Section 6.5  Adverse Event Reporting
"AbbVie Medical Monitor," "Title" previously read:
Group Medical Director 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
168
Has been changed to read:
Executive Medical Director
Section 6.5  Adverse Event Reporting
Subsection COVID -19 Pandemic -Related Acceptable Protocol Modifications
Add:  new subsection title and text
COVID -19 Pandemic -Related Acceptable Protocol Modi fications 
Supplemental study  case report forms should be completed in the event of COVID -19 
related missed/virtual visits, study  drug interruptions or discontinuations, or adverse 
events (including capture of specific signs/s ymptoms of infection and testi ng results).
COVID- 19 infections should be captured as adverse events.  If the event meets the criteria 
for a serious adverse event (SAE), then follow the SAE reporting directions per the 
protocol and above.  The following COVID -19 related supplemental eCR Fs should be 
completed:
● COVID- 19 Supplemental Signs/sy mptoms
● COVID- 19 Status Form
Section 7.0  Protocol Deviations
First paragraph previously read:
Protocol deviations should be avoided.  When a deviation from the protocol is deemed 
necessary  for an indiv idual subject, the investigator or other ph ysician in attendance must 
contact one of the following AbbVie representatives prior to implementation:
Has been changed to read:
AbbVie does not allow intentional/prospective deviations from the protocol except when 
necessary  to eliminate an immediate hazard to study  subjects.  The investigator is 
responsible for comply ing with all protocol requirements, written instructions, and 
applicable laws regarding protocol deviations.  If a protocol deviation occurs (or i s 
identified, including those that may  be due to the COVID -19 pandemic), the investigator  
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
171
of a central lab), and shipping investigational product and/or supplie s direct to subjects to 
ensure continuit y of treatment where allowed.
In all cases, these alternative measures must be allowed b y local regulations and permitted 
by IRB/IEC.  Investigators should notify  AbbVie if an y urgent safet y measures are taken 
to protect the subjects against any immediate hazard.
Section 10.1  Source Documents
Add:  new last paragraph
During the COVID- 19 pandemic, remote monitoring of data may  be employed if allowed 
by the local regulatory  authority , IRB/IEC, and the study  site.
Appen dix A.   List of Abbreviations and Definitions of Terms
Subsection Abbreviations
Add:
COVID -19 Coronavirus Disease -2019
DTP Direct To Patient
Appendix B.   List of Protocol Signatories
Previously read:
Nam e Title Functional Area
Sr. Scientist II Biomarkers
 Program Lead II Clinical
 Study Project Manager II Clinical
 Director, Biometrics Statistics
 Group Medical Director Clinical 

ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
172
Has been changed to read:
Nam e Title Functional Area
Sr. Scientist II Biomarkers
 Program Lead II Clinical Program Development
 Study Project Manager II Clinical Program Development
  Director Statistics
 Executive Medical Director, TA MD Clinical Program Development
Appendix G.  Extension Study -Assessments
Table 1.  Extension Study:  Schedule of Assessments
Previously read:
Procedures Day 1Every 
4Cycles Final Visit30 Day 
Safety 
Follow -up 
Visit
Informed Consent X
Physical Exam (including weight) XaXaX X
Vital Signs X X X X
12-lead ECG X
2D Echocardiogram with Doppler X
Platelet CountbX X X X
Lymphocyte EnumerationcX
ChemistrydX X X X
Hem atologydX X X X
UrinalysisdX X
Performance Status (ECOG) X X
Tumor AssessmentseX
Disease Progression Assessment X X X
Adverse Event/Concomitant Medications 
AssessmentX X X Xf
Dispense/Collect ABT -263gX X X
Dispense/Collect Subject Dosing Log X X X
a. Symptom directed. 

ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
173
b. Platelet Counts will be performed and assessed by the investigator or subinvestigator prior to study drug 
administration.  Any platelet count less than 25,000/mm3should be confirmed the same day by manual reading and 
separate peripheral draw.  Additio nal platelet counts will be obtained if ABT -263 is held or interrupted.  If a 
platelet count is less than or equal to 50,000/mm3, additional platelet counts will be performed every day at the 
discretion of the investigator.  Platelet counts should be obtai ned 10 to 60 minutes after the completion of any 
platelet transfusion.  
c. Perform Lymphocyte Enumeration at the Final Visit and as needed for subjects if deemed necessary by the 
investigator.
d. The specific laboratory tests required for chemistry, hematology and urinalysis are listed in Table 7.  Triglycerides, 
amylase and lipase will only be collected at the Final Visit.  For any subjects who are at high risk for tumor lysis 
syndrome (TLS), additional samples for hematology and chemistry may be col lected as per the management 
guidelines in Section 6.7.4.  ANC ≥ 500/µL and < 1,000/µL should be monitored at an increased frequency at the 
discretion of the investigator.  Grade 2 chemistry labs should be monitored at an increased frequency at the 
discretion of the investigator.
e. If additional tumor assessments are collected by the site per standard of care, the data should be recorded on the 
appropriate paper CRF.
f. Adverse events will be followed until satisfactory clinical resolution of the adverse e vent is achieved.
g. A bottle's expiration date and pill count should be taken into account when dispensing 4 cycles of drug. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
174
Has been changed to read:
Procedures Day 1#Every 
4Cycles#Final Visit#30 Day 
Safety 
Follow -up 
Visit#
Informed Consent X
Physical Exam (including weight) XaXaX X
Vital Signs X X X X
12-lead ECG X
2D Echocardiogram with Doppler X
Platelet Countb,#X X X X
Lymphocyte Enumerationc,#X
Chemistryd,#X X X X
Hem atologyd,#X X X X
Urinalysisd,#X X
Performance Status (ECOG)#X X
Tumor Assessmentse,#X
Disease Progression Assessment X X X
Adverse Event/Concomitant Medications 
AssessmentX X X Xf
Dispense/Collect ABT -263gX X X
Dispense/Collect Subject Dosing Log X X X
# Visits and activities may be conducted in the subject's home residence or by phone/virtually.
a. Symptom directed.
b. Platelet Counts will be performed and assessed by the investigator or subinvestigator prior to study drug 
administration.  Any platelet count less than 25,000/mm3should be confirmed the same day by manual reading and 
separate peripheral draw.  Additional platelet counts will be obtained if ABT -263 is held or interrupted.  If a 
platelet count is less than or equal to 50,000/mm3, additional platelet counts will be p erformed every day at the 
discretion of the investigator.  Platelet counts should be obtained 10 to 60 minutes after the completion of any 
platelet transfusion.  
c. Perform Lymphocyte Enumeration at the Final Visit and as needed for subjects if deemed nec essary by the 
investigator.
d. The specific laboratory tests required for chemistry, hematology and urinalysis are listed in Table 7.  Triglycerides, 
amylase and lipase will only be collected at the Final Visit.  For any subjects who are at high risk for tumor lysis 
syndrome (TLS), additional samples for hematology and chemistry may be collected as per the management 
guidelines in Section 6.7.4 .  ANC ≥ 500/µL and < 1,000/µL should be monitored at an increased frequency at the 
discretion of the investigator.  Grade 2 chemistry labs should be monitored at an increa sed frequency at the 
discretion of the investigator. 
ABT -263
M06 -873 Protocol Amendment 14
EudraCT 2007 -002143 -25
175
e. If additional tumor assessments are collected by the site per standard of care, the data should be recorded on the 
appropriate paper CRF.
f. Adverse events will be followed until satisfactory clinical resolution of the adverse event is achieved.
g. A bottle's expiration date and pill count should be taken into account when dispensing 4 cycles of drug. 